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Abstract 
The JAK/STAT signalling pathway plays a central role in numerous biological processes 
contributing to development and maintenance of homeostasis. Drosophila melanogaster offers a 
conserved JAK/STAT pathway with much lower redundancy. For this reason, the fruit fly was 
used as a model organism to investigate genetic interactions and functions of the JAK/STAT 
pathway in the context of the whole organism. However, very little is known regarding the 
molecular mechanisms governing the Drosophila JAK/STAT pathway.  
 
Here, we present a molecular analysis of the sole receptor of the JAK/STAT pathway in 
Drosophila, Dome. We show that Dome shares characteristics with different sub-families of 
mammalian cytokine receptors. Specifically, the identified JAK binding site in Dome is 
reminiscent of that found in IFNγ receptor, while constitutive endocytosis leading to lysosomal 
degradation shares similarities with the Leptin receptor. An increase in tyrosine phosphorylation 
and a shift in the ubiquitination pattern of the receptor in response to ligand binding are also 
described.  
 
Furthermore, the structure-function analysis of socs36E, the only SOCS-like protein in the 
Drosophila genome that can potently suppress the JAK/STAT pathway, revealed two 
independent mechanisms of action. Firstly, SOCS36E affects stability of the receptor, most likely 
by forming ubiquitin ligase via the SOCS box domian, a mechanism well described for all 
mammalian SOCS proteins. Secondly, regulation of Dome phosphorylation by the N-terminal 
domain of SOCS36E contributes to suppression of the JAK/STAT pathway in a SOCS box 
independent manner. 
 
Finally, two alleles of the Drosophila JAK that give rise to a phenotype reminiscent of human 
leukaemia, hopTuml and hopT42, are shown to increase transcriptional activity of the pathway 
reporter without increasing phosphorylation of STAT. Both mutations cause constitutive 
activation of the kinase independently of the receptor. Moreover, autophosphorylation kinetics of 
both mutants are unaltered, compared to the wild-type Hop, suggesting non-canonical signalling 
to be the underlying cause of oncogenicity. 
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Chapter I Introduction 
I.1. Signalling pathways 
Development and maintenance of homeostasis of multicellular organisms requires 
precise cell-to-cell communication, a process which orchestrates numerous cellular 
processes in the context of a tissue or a whole organism. Signalling pathways provide 
means of communication that allow for a temporal and spatial regulation at the level of a 
single cell. Numerous signal transduction pathways have been characterised, although the 
exact number depends on the categorization criteria. However, the high number of 
signalling pathways seems numerically insignificant when considered in the context of 
the complexity of development and the subsequent maintenance of multicellular 
organisms. This means that individual signalling pathways must contribute towards 
numerous processes by cross-modulation and complementation. Not surprisingly, 
mutations arising in the components of the signalling pathways during development can 
have a profound impact on the whole organism. While many examples have been 
described, one of the common diseases contracted due to mutations in the signalling 
pathways is cancer.  
 
I.2. The JAK/STAT signalling pathway  
I.2.1 Function 
The JAK/STAT pathway was first identified as mediating response to Interferon 
following Influenza virus infection (LINDENMANN et al., 1957). Numerous studies 
focusing on the JAK/STAT pathway showed its importance in inflammation and immune 
response. Indeed that JAK/STAT pathway mediates cytokine and growth factor 
signalling, which play central role in development and functioning of the haematopoietic 
and immune systems (Levy and Darnell, 2002).  Other processes regulated by the 
JAK/STAT pathway involve reproduction, embryonic development, sexually dimorphic 
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growth, wound healing, mammary gland development and lactation as well as 
adipogenesis, evidence for which comes from numerous studies including murine 
knockout models (Table.I.1) (reviewed in, O'Shea et al., 2002).  
Table.I.1	  Murine	  knockout	  models	  
Gene Phenotype 
jak1 Prenatally lethal, small 
jak2 Embryonic lethal, no erythropoiesis 
jak3 SCID 
tyk2 Immunodeficient 
stat1 and stat2 Immunodeficient 
stat3 Early fetal death 
stat4 Unresponsive to IL-12, immunodeficient 
stat5a Lactation defective, impaired PRL signalling 
stat5b Loss of dimorphic growth, defective GH signalling 
stat5a/stat5b Female infertility, immuodefficient 
stat6 Immunideficient 
Adapted from Igaz et al., 2001. 
I.2.2 General structure of the pathway 
The canonical JAK/STAT signalling pathway comprises a linear cascade 
responsible for the transduction of extracellular signals into transcriptional responses 
(Fig.I.1). Binding of a diffusible ligand to the extracellular portion of the trans-membrane 
receptor is considered to be the activating step. Receptors for the JAK/STAT pathway 
exist as preformed dimers that are stabilized and undergo conformational change 
following ligand binding. Consequently, receptor pre-associated Janus kinases (JAKs) 
come into close proximity with each other allowing for trans-phosphorylation and 
activation. JAKs phoshorylate the receptors on tyrosines, creating docking sites for Signal 
Transducers and Activators of Transcription (STATs). During transient interactions with 
the receptor, STATs become tyrosine phosphorylated, dissociate from the receptor 
complex and dimerize in the cytoplasm. Following nuclear translocation STAT dimers 
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bind to the palindromic consensus DNA motifs found in the promoters of pathway target 
genes and induce their transcription.  
Figure.I.1	  Conceptual	  JAK/STAT	  pathway	  
 
Figure.I.1 Conceptual JAK/STAT pathway. Schematic representation of linearity of 
simplified core JAK/STAT pathway. 
 
I.2.3 Ligands 
The common generalization that cytokines activate the JAK/STAT pathway is not 
entirely accurate as the superfamily of cytokines comprises hundreds small soluble 
molecules capable of stimulating the immune system. Not all of them act through the 
JAK/STAT pathway, with prime examples being TGF-β and TNFs, the structures of 
which are mainly characterized by β-sheets. Only a subset of cytokines, described as 
helical cytokines, due to the dominance of α-helices in their structure, have the ability to 
activate the JAK/STAT pathway (Grotzinger et al., 1999). This group includes all 
interferons (IFN) and interleukins (IL), with exception of IL-1, IL-17 and IL-8 families, 
and haematopoietins.  Additionally, the JAK/STAT pathway mediates signalling of a 
subset of growth factors and hormones that share structural similarities with helical 
cytokines, including prolactin, leptin, granulocyte colony-stimulating factor (G-CSF) and 
growth hormone (GH) (reviewed in Mohr et al., 2012). A list containing selected ligands 
of the JAK/STAT pathway and associated receptors is presented in Table.I.2. 
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Table.I.2	  Interaction	  partners	  
Ligand Receptor JAK STAT SOCS 
IL-6 IL-6R, gp130 JAK1, JAK2, 
Tyk2 
STAT1, 
STAT3 
SOCS3 
SOCS1 
OSM OSMR, gp130 JAK1, JAK2, 
Tyk2 
STAT3, 
STAT1 
SOCS3 
LIF LIFR, Gp130 JAK1, JAK2, 
Tyk2 
STAT3, 
STAT1 
SOCS3 
G-CSF G-CSFR 
 
JAK2, JAK3 STAT3 SOCS3 
Leptin Ob-R JAK1 STAT3 SOCS3, CIS, 
SOCS2 
IFNα IFNAR1 
IFNAR2 
JAK1, Tyk2 STAT1, 
STAT2 
STAT5a 
STAT5b 
SOCS1 
IFNγ IFNGR1 
IFNGR2 
JAK1, JAK2 STAT1 SOCS1 
Epo EpoR JAK2 STAT5a, 
STAT5b 
SOCS3, 
SOCS2, CIS 
Tpo TpoR JAK2, Tyk2 STAT5a, 
STAT5b 
SOCS1, 
SOCS3 
PRL PRLR JAK2 STAT5a, 
STAT5b 
SOCS2, CIS 
GH GHR JAK2 STAT3, 
STAT5a, 
STAT5b 
SOCS2 
Adapted from Linossi et al., 2013; Baker et al.,2007; Schindler and Plumee, 2008; 
Crocker et al., 2008. 
 
 20 
I.2.4 Receptors of the JAK/STAT pathway  
Receptors activating the JAK/STAT pathway include not only selected cytokine 
receptors, but also receptors of growth factors and hormones reported to activate the 
JAK/STAT pathway described previously (listed in Table.I.2). However, the literature 
does not make such distinction, therefore the term ‘cytokine receptor’ will be used here to 
describe general population of over thirty JAK/STAT receptors described to date. As the 
majority of JAK/STAT pathway ligands share α-helical structure, their receptors 
predominantly contain β-sheets at the sites of ligand interaction, often referred to as 
cytokine binding module (CBM) (Fig.I.2). The CBM subdivides the cytokine receptor 
family into the type I subfamily characterised by the presence of four conserved 
disulfide-linked cysteins in the N-terminal portion of CBM and at least a semi-conserved 
WSxWS motif in the C-terminal portion, while receptors of the type II subfamily lack the 
WSxWS motif entirely (x represents any amino acid) (Bazan, 1990a, 1990b; Thoreau et 
al., 1991). The type I cytokine receptors represent the large majority of the receptor 
superfamily with the exception of the interferon receptors. In addition, the 
immunoglobulin-like domain present in several type I cytokine receptors has been 
reported to perform many functions, including stabilization of protein trafficking in the 
case of IL-6R and contributes towards ligand:receptor complex assembly as reported for 
PDGF:PDGFR interactions (Miyazawa et al., 1998; Vollmer et al., 1999).  
Figure.I.2	  Structure	  of	  cytokine	  receptor	  
 
Figure.I.2 Structure of cytokine receptor. Structure of a prototype cytokine receptor 
gp130. CBM – cytokine binding motif, FNIII – fibronectin type III domain; 4C’s – four 
conserved cysteins. Numbers at extremities represent protein size. 
Adapted from Brown et al., 2001. 
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More membrane proximal are fibronectin type-III domains (FNIII), characterised 
as mediators of interactions with heparins as well as other constituents of the cell surface 
environment. The exact number of FNIII domains varies between different receptors, 
ranging between two and four. Moreover, position-specific residues in the FNIII domains 
have been implicated in receptor dimerization as reported for the shared gp130 receptor 
(Timmermann et al., 2002). Conversely, erythropoietin receptor (EpoR) has been shown 
to homodimerize in a transmembrane domain-dependent manner (Constantinescu et al., 
2001). Interestingly, juxtamembrane domains of cytokine receptors have been deemed 
necessary for receptor activation following ligand binding via phenomenon commonly 
referred to as conformational change (Kurth et al., 2000; Constantinescu et al., 2001; 
Greiser et al., 2002; Couturier and Jockers, 2003; Seubert et al., 2003; Staerk et al., 
2011).  
The cytokine receptors exist as stable or transient preformed complexes on the 
cell surface. Composition of those complexes varies between cytokine receptors - EpoR 
and IFNγR form homodimers, while gp130 forms hetero-dimers/oligomers with OSMR, 
IL6R and LIFR  (Liu et al., 1994; Modrell et al., 1994; Livnah et al., 1999; Giese et al., 
2005; Krause et al., 2006; Tenhumberg et al., 2006, reviewed in Mohr et al., 2012). The 
transient heterodimers/oligomers of gp130 as well as homodimers of TpoR are stabilized 
by ligand binding which also triggers conformational change thought to alter the relative 
orientation of their cytoplasmic domains (Staerk et al., 2011; Dagil et al., 2012). 
The intracellular domain of cytokine receptors generally contains classical Box 
domains common amongst JAK/STAT pathway receptors, which have been shown to 
mediate receptor:JAK and receptor:STAT interactions (Fig.I.2) (Hackett et al., 1997; 
Hirano et al., 1997; Taga and Kishimoto, 1997; Grant and Begley, 1999). Located 
proximally to the plasma membrane, the Box 1 has been described to specifically mediate 
interactions with JAK kinases via PxP motif (x represents any amino acid) (Stahl et al., 
1994). However, only a semi-conserved PxP motif has been reported sufficient to 
mediated interaction between IFNγR1 and JAK1 (Kaplan et al., 1996). Box 2 domain of 
several cytokine receptors has been characterized as essential for JAK binding (Witthuhn 
et al., 1993; Lebrun et al., 1995; Zhu et al., 1998; Haan et al., 2000). 
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I.2.5 Janus kinases  
Despite the large number of cytokines and their receptors present, only four JAKs 
are encoded by human genome, jak1-3 and tyk2 (Wilks et al., 1991; Firmbach-Kraft et 
al., 1990; Takahashi and Shirasawa, 1994). JAKs are characterized as non-receptor 
protein tyrosine kinases that associate with cytokine receptors via Box1/2 in receptors as 
described previously and band 4.1, Ezrin, radixin and moiesin (FERM) domain in JAKs 
(Chishti et al., 1998; Hilkens et al., 2001; Huang et al., 2001; Radtke et al., 2002; He et 
al., 2003). Differences in the structures of FERM domains provide the selectivity in 
interactions with the receptors (Table.I.2). Situated in the N-terminal portion of JAKs, 
FERM domains are composed of Jak homology (JH) domains 7 through 4 (Fig.I.3) 
(Wilks et al., 1991). FERM domains have been shown to interact directly with and 
regulate the catalytic activity of the kinase (Funakoshi-Tago et al., 2008). 
 
Figure.I.3	  Structure	  of	  JAK	  kinase	  
 
Figure.I.3 Structure of JAK kinase. Schematic representation of JAK2 kinase. JH – JAK 
homology domains, as described originally, shown below. JH1 and JH2 are kinase 
domains. Selected phosphorylated regulatory residues are shown above, negative 
regulators are italicised and in gray. The numbers at extremities represent size of the 
protein, 0 represents N-terminus. 
 
Centrally located JH3-4 domains are reminiscent of Src homology 2-like (SH2-
like) domain, however, they have not been shown to mediate interactions with 
phosphorylated tyrosine residues (Kampa and Burnside, 2000; Radtke et al., 2005; Haan 
et al., 2006). The C-terminal portion of JAKs contain the JH1 and JH2 domains, with 
JH1 situated at the proteins extreme (Fig.I.3). JH1 constitutes a classical tyrosine kinase 
domain that is required for substrate phosphorylation and contains a double tyrosine 
motif (YY), phosphorylation of which is crucial for activation of JAK1 and 2 (Feng et al., 
1997; Liu et al., 1997; Zhou et al., 1997). Conversely, the JH2 domain was considered to 
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be a pseudo-kinase domain, with kinase-like structure missing some key residues 
required for catalytic activity (Wilks et al., 1991). More recently, it has been shown that 
the JH2 domain of JAK2 is actually a double-specificity functional kinase domain 
(Ungureanu et al., 2011). The role of JH2 domain is to inhibit JH1 domain from 
functioning, with two models of action proposed: steric inhibition and 
autophosphorylation (Saharinen et al., 2000; Saharinen and Silvennoinen, 2002; 
Saharinen et al., 2003; Shuai and Liu, 2003). Autophosphorylation of JAK kinases can 
have different outcomes, depending on the residue modified - S523 and Y570 
downregulate JAK2 kinase activity, while Y201, Y221, Y813 and other tyrosines up-
regulate it (Fig.I.3) (Argetsinger et al., 2004; Kurzer et al., 2004; Matsuda et al., 2004; 
Yan et al., 2012). This intrinsic auto-regulation does not require an external kinase for 
activation. Instead, it is thought that ligand binding and conformational change of the 
receptors cause JAKs to come into close proximity allowing for trans-phosphorylation 
(Matsuda et al., 2004).  
Besides catalytic activity, JAK kinases play important role in regulation of 
receptor stability. Numerous reports indicate the receptors of the pathway to be stabilised 
by JAK binding (Radtke et al., 2002; He et al., 2005; Royer et al., 2005; Haan et al., 
2006). Indeed, the receptor:JAK complex has been proposed to behave similarly to the 
receptor tyrosine kinases, and dissociation of JAK2 from EpoR following ligand-
mediated simulation has been described to destabilize the receptor (Funakoshi-Tago et 
al., 2006; Haan et al., 2006). Interestingly, association of JAK2 with EpoR has been 
suggested to occur in the endoplasmic reticulum, where the kinase is hypothesised to 
assist in correct folding of the receptor (Huang et al., 2001). Regulation of receptor 
stability on the plasma membrane by JAKs often involves physical masking or 
phosphorylation of the internalization motifs present on the receptors (Ragimbeau et al., 
2003; Radtke et al., 2006). 
 
I.2.6 Signal Transducers and Activators of Transcription 
The human genome encodes seven STATs, stat1-4, stat5a and 5b and stat6 
(Shuai et al., 1993; Improta et al., 1994; Yamamoto et al., 1994; Zhong et al., 1994a, 
1994b; Azam et al., 1995; Quelle et al., 1995). In canonical JAK/STAT signalling STAT 
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proteins bind to the tyrosine phosphorylated receptors via SH2 domains and become 
phosphorylated by JAKs (Fig.I.1). Upon phosphorylation, STATs dissociate from the 
receptor complex and dimerize in the cytoplasm via their SH2 domains (Shuai et al., 
1993). Dimerization allows for nuclear translocation to modulate transcription of pathway 
target genes (Koster and Hauser, 1999, reviewed in Igaz et al., 2001; Kisseleva et al., 
2002). Despite sharing conserved SH2 domain, structural differences between STATs 
result in selectivity towards receptor:JAK complexes, with the phospho tyrosine sites on 
the receptor being the direct sites of interaction (Table.I.2) (Kotenko et al., 1996; 
Kohlhuber et al., 1997, reviewed in Lim and Cao, 2006). Tertiary structure of STATs is 
well conserved across species, indicating common ancestry (Fig.I.4) (reviewed in Jatiani 
et al., 2010). The N-terminal domain of STATs is critical for function as it is implicated 
in nuclear import and export, receptor interaction, modulation of DNA binding and the 
formation of inactive dimers. Downstream of the N-terminal domain is the coiled-coil 
region involved in receptor and regulator interaction, followed by a highly conserved 
DNA-binding domain required for binding to conserved recognition sequences in 
promoters of target genes (Xu et al., 1996; O'Shea et al., 2002). The next domain is the 
linker domain required for structural integrity, followed by SH2 domain necessary for 
interaction with tyrosine phosphorylated substrates, formation of homo- and 
heterodimers, nuclear translocation and DNA binding. The C-terminally located 
transactivation domain is the most variable element of STAT proteins but it is crucial for 
transcriptional activation of target genes (reviewed in Schindler and Strehlow, 2000).  
 
Figure.I.4	  Structure	  of	  STAT	  
 
Figure.I.4 Structure of STAT. Schematic representation of STAT1 with indication of 
recognised domains.  
Adapted from Jatiani et al., 2001. 
 
Besides canonical signalling, STATs have received a lot of attention due to their 
emerging roles in non-canonical signalling. Evidence for microtubule binding affecting 
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migration, regulation of oxidative phosphorylation, activation of Akt pathway and 
modulation of the epigenetic landscape have been reported (reviewed in Mohr et al., 
2012).  
 
I.3. Regulation of the JAK/STAT pathway 
Roles of the JAK/STAT pathway in the regulation of numerous vital processes 
requires tight regulation of pathway activity. Multiple levels of regulation have evolved, 
including proteins acting in trans-, interactions with other signalling pathways as well as 
processes such as endocytosis, transcriptional editing, epigenetic regulation and 
polarization of the pathway components. A selection of these regulatory processes 
relevant to this thesis are described below. 
 
I.3.1 Suppressors of Cytokine Signalling  
The family of Suppressors of Cytokine Signalling (SOCS) proteins has been 
described, as the name suggests, as negative regulators of the JAK/STAT pathway which 
act in a negative feedback loop. The family consists of eight members, SOCS1-7 and CIS 
(Endo et al., 1997; Masuhara et al., 1997; Minamoto et al., 1997; Naka et al., 1997; 
Hilton et al., 1998; Starr and Hilton, 1998, 1999, reviewed in Croker et al., 2008). All of 
the SOCS proteins share a centrally located SH2 domain that mediates interaction with 
tyrosine phosphorylated substrates and a C-terminally located SOCS box domain 
(Fig.I.5). The SH2 domain is immediately flanked by N- and C-extended SH2 domain 
regions, which help to orientate interaction with phosphorylated tyrosines (Sasaki et al., 
1999; Yasukawa et al., 1999; Babon et al., 2006). SOCS proteins appear to differ in their 
affinities for substrates, which include JAKs, receptors and JAK:receptor complexes 
(Yasukawa et al., 1999; Piganis et al., 2011; Kershaw et al., 2013). The SOCS box 
domain has been shown to mediate interaction with Elongins B/C and Cullin 5, which in 
turn recruits Rbx2 thereby forming an active E3 ubiquitin ligase (Kamura et al., 1998; 
Zhang et al., 1999; Kamura et al., 2004). The Elongin-Cullin-SOCS (ECS) complex 
mediates transfer of ubiquitin moieties from E2 ubiquitin conjugating enzymes onto 
substrates, targeting them for degradation. SOCS proteins perform substrate recognition 
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role in the ECS complexes, however the affinity of each SOCS protein towards Elongins 
B/C and Cullin 5 differs (Kile et al., 2002; Babon et al., 2009).  
Figure.I.5	  SOCS	  family	  of	  proteins	  
 
Figure.I.5 SOCS family of proteins. Schematic representation of SOCS family of proteins 
with indication of recognised domains, SB – SOCS box, KIR – kinase inhibitory region. 
Numbers at extremities indicate protein sizes. 
Adapted from Yoshimura, 2001. 
 
The N-terminal domain of SOCS proteins display low conservation among family 
members and no easily distinguishable structures are present within this domain. 
Exception to this are SOCS 1 and 3, which contain a kinase inhibitory region (KIR) 
located immediately upstream of the SH2 domain (Nicholson et al., 1999; Sasaki et al., 
1999; Piganis et al., 2011; Doti et al., 2012). Recently, the crystallographic structure of 
SOCS3 bound to JAK2 has been resolved, showing that the KIR directly blocks substrate 
association with the catalytic groove of the kinase (Kershaw et al., 2013). Function of the 
 27 
long N-terminal domains of SOCS4-7 remains enigmatic, with only handful of reports 
providing insight into their roles. Structural analysis of the N-terminal domains of 
SOCS4-7 revealed them to be largely disordered (Feng et al., 2011). A cryptic but more 
organised region in the N-terminal domains of SOCS4 and 5 has been determined, with 
indication of a role in protein interactions (Feng et al., 2011). Indeed, the N-terminal of 
SOCS5 is sufficient for interaction with IL-4 in a phosphotyrosine independent fashion, 
and was reported to be required for interaction with EGFR (Seki et al., 2002; Kario et al., 
2005; Nicholson et al., 2005, reviewed in Croker et al., 2008). 
The three domains – SH2, SOCS box and N-terminal KIR – correspond to the 
mechanisms utilized by SOCS proteins to regulate the JAK/STAT pathway. SH2 domain 
mediates interactions with substrates, which might lead to competitive inhibition in case 
of phosphotyrosines used for biding of STATs (Endo et al., 2003; Lavens et al., 2006). 
As described previously, the SOCS box domain mediates the formation of a ubiquitin 
ligase resulting in ubiquitination and subsequent degradation of SOCS substrates. JAKs 
can undergo such modification, however evidence suggests that the ubiquitination of 
cytokine receptors is the most common of the three mechanisms (Nicholson et al., 2000; 
Kapuria et al., 2011; Linossi and Nicholson, 2012). Direct interference with JAK:STAT 
interaction via KIR has been suggested for SOCS1 and 3 only, however it constitutes a 
major mechanism for both of those proteins (Linossi et al., 2013). 
 
I.3.2 Protein tyrosine phosphatases 
With tyrosine phosphorylation at the core of JAK/STAT pathway activity, protein 
tyrosine phosphatases represent an important regulatory element. Five protein tyrosine 
phosphatases belonging to three divergent families have been implicated in the regulation 
of the JAK/STAT pathway. SH2-containing phosphatases (SHP) 1 and 2 are cytoplasmic 
proteins that recognise their substrates via SH2 domains present in their structures (Yi et 
al., 1993; Jiao et al., 1997). Expression of SHP1 is restricted predominantly to the 
haematopoietic system and mice knockouts have been reported to have elevated 
phosphorylation levels of JAK1 and 2, IFNαR1, GHR and EpoR (Klingmuller, 1997; 
Migone et al., 1998; Alicea-Velázquez et al., 2013, reviewed in Valentino and Pierre, 
2006). Expression of SHP2 is more ubiquitous, with its knockout resulting in lethality in 
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mouse models. SHP2 has been associated with inhibition of IL6 and gp130 containing 
receptors (Lehmann et al., 2003). Interestingly, SHP2 becomes phosphorylated by JAKs 
resulting in dissociation from receptor complex, suggesting a transient interaction or a 
regulatory loop (Lu et al., 2001, 2003).   
Second pair of phosphatases involved in regulation of the JAK/STAT pathway are 
protein tyrosine phosphatase 1B (PTP1B) and T cell protein tyrosine phosphatase (TC-
PTP) (Tonks et al., 1988, reviewed in Stuible et al., 2008). Both of those proteins 
selectively recognise the double tyrosine motif present in JAKs, however they display 
different specificity with PTP1B preferentially binding to JAK2 and Tyk2 and TC-PTP 
associating with JAK1 and JAK3 (Carbone et al., 2012, reviewed in Levine and Wernig, 
2006). A splice variant of TC-PTP has been shown to dephosphorylate nuclear STATs, 
contributing to their nuclear export and termination of signalling (ten Hoeve et al., 2002). 
The final phosphatase reported to act on the JAK/STAT pathway is CD45, a 
transmembrane tyrosine phosphatase expressed specifically in haematopoietic cells (Irie-
Sasaki et al., 2001). CD45 mice knockouts displayed elevated phosphorylation levels of 
JAK1 and 3, however direct association with JAKs has not been shown. 
 
I.3.3 Protein Inhibitors of Activated STATs 
Four proteins constitute the family of Protein Inhibitors of Activated STATs 
(PIAS), PIAS1 and 3, PIASx and PIASy (reviewed in Shuai and Liu, 2005). STAT 
proteins have been shown to undergo SUMOylation, which affects their transcriptional 
activity, however the enzymes responsible remain unknown (Begitt et al., 2011). PIAS 
proteins are SUMO-E3-ligases, making them prime suspects for such activity (Schmidt 
and Muller, 2002). At the same time, PIAS1 and 3 have been shown to interact directly 
with STAT1 and 3, blocking their DNA binding activity (Chung et al., 1997; Liu et al., 
1998). Conversely, PIASx and PIASy recruit co-repressors, such as histone deacetylases 
to inhibit transcriptional activity of STAT1 and 4 (Liu et al., 2001). 
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I.3.4 Src family of kinases 
A significant number of signalling pathways have been shown to affect 
JAK/STAT pathway in a process commonly called cross-talk. The Src family of non-
receptor tyrosine kinases has been shown to positively regulate the JAK/STAT pathway 
via more than one way (for a review on Src kinases, see Thomas and Brugge, 1997). 
Firstly, Src kinases can activate STATs by direct phosphorylation, leading to a model of 
Src kinases being positive regulators of the JAK/STAT pathway (Silva and Shupnik, 
2007). This model is supported by recent findings in Drosophila, which indicate that Src 
kinases polarize STAT subcellular localization via a non-catalytic activity, thereby 
sensitizing the pathway (Sotillos et al., 2013). Finally, Src kinases were shown to directly 
phosphorylate SOCS proteins, leading to their inactivation, thereby leading to an increase 
in JAK/STAT pathway activity (Sommer et al., 2005).  
 
I.3.5 Endocytosis 
The majority of cytokine receptors undergo clathrin-mediated endocytosis (CME) 
either in response to ligand binding or as a constitutive process (Fig.I.6) (Doherty and 
McMahon, 2009). In either case, endocytosis plays a three-fold role. Internalization of 
receptors from cell surface regulates cell’s sensitivity to ligands, which most often 
represents desensitization. Secondly, the endocytic pathway has been shown to modulate 
the quality of the signalling output by enriching endosomal compartments with distinct 
signalling/accessory molecules, a concept described as signalling endosomes (Howe and 
Mobley, 2004). Modulation of the JAK/STAT pathway signalling output by endocytosis 
is however poorly understood (reviewed in Mohr et al., 2012). Finally, endocytosis leads 
to termination of signalling via degradation of the receptor complex or its recycling to the 
plasma membrane following ligand decoupling and receptor dephosphorylation (Grant 
and Donaldson, 2009; Raiborg and Stenmark, 2009).  
Endocytosis is a dynamic and fluid process, with several stages that can be 
distinguished. CME is initiated by a process of cargo selection followed by 
internalization into the intracellular endocytic vesicles, at which stage the affected 
receptor loses contact with extracellular environment but can still signal through its  
 30 
Figure.I.6	  Schematic	  endocytic	  pathway	  
 
Figure.I.6 Schematic endocytic pathway. Schematic representation of clathrin-mediated 
endocytosis of cytokine receptors. 1. Ligand-induced internalization of the receptor into 
clathrin coated vesicles concludes with fusion of the vesicles with the Sorting Endosome. 
At this point receptors intracellular domain remains in the cytoplasm allowing for 
activation of cytoplasmic STATs. Fate of receptor is determined in the Sorting 
Endosome and either of the four routs can take place. 2-4 Following uncoupling of the 
ligand and dephosphorylation, receptor can be recycled to the plasma membrane 
directly (2.) or through the Recycling Endosome (3. and 4.). 5. Following maturation of 
the Sorting Endosome, receptor in vesicles is transported and incorporated into Multi-
vesicular Bodies, while remaining in Intraluminal Vesicles. Contact with cytoplasm is lost 
and no signalling can occur. 6. Fusion with lysosome destroys the receptor. 7. Receptor 
is transported to the Trans Golgi Network from where it can undergo several processes. 
Proteosomal degradation and maturation of the Sorting Endosome into Late Endosome 
is not shown. 
Adapted from Platta and Stenmark, 2011.  
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cytoplasmic domain (reviewed in Traub, 2009). Internalization of cytokine receptors has 
been shown to require binding of a tertrameric AP-2 adaptor protein, which mediates 
interaction with Clathrin (Bonifacino and Traub, 2003). However, the process leading to 
AP-2 binding differs between cytokine receptors. As AP-2 requires non-phosphorylated 
tyrosine residues for binding, IFNαR has to be dephosphorylated on Y466 by PTP1B to 
allow for interaction (Carbone et al., 2012). Intriguingly, the dileucine motif (an 
alternative AP-2 binding motif) of OSMR is masked by bound JAK1 which has to 
dissociate for internalization to occur (Radtke et al., 2002). Similar process has been 
reported for internalization of IFNαR1 and Tyk2 (Ragimbeau et al., 2003). Finally, 
ubiquitination has been reported to be strongly associated with regulation of cytokine 
receptor stability, including receptor internalization. Both, internalization and endocytic 
shuttling of G-CSFR and Prolactin receptor, among others, is regulated by site specific 
ubiquitination (Swaminathan et al., 2008; Varghese et al., 2008; Wölfler et al., 2009). All 
of the aforementioned processes are not mutually exclusive and different combinations of 
these processes might be required for receptor internalization, as has been shown for 
EGFR (Goh et al., 2010).  
Following internalization of the receptor and arrival at the sorting endosome, 
receptors can be recycled directly or indirectly to the plasma membrane or Golgi or, 
alternatively they can be targeted for lysosomal or proteosomal degradation (Fig.I.6) 
(reviewed in Pfeffer, 2009). The means by which receptors are sorted are still not fully 
understood, however some evidence suggest motifs in the cytoplasmic domains of the 
receptors may be determining factors (Hitchcock et al., 2008). In addition, a further 
signal controlling receptor fate determination is ubiquitination, as shown in case of PRLR 
and G-CSFR (Thrower et al., 2000; Peng et al., 2003; Pickart and Fushman, 2004; 
Lauwers et al., 2009). 
 
I.4. JAK/STAT pathway in states of disease 
The JAK/STAT pathway plays a central role in the regulation of cellular 
proliferation, survival, apoptosis and differentiation, therefore it is not surprising that 
mutations affecting the function of the JAK/STAT pathway lead to a wide variety of 
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diseases, including erythrocytosis, acromegaly, inflammatory disorders and 
haematopoietic malignancies. Pathogenic mutations affecting the JAK/STAT pathway are 
most prominent in the haematopoietic and immune system, due to the central role of the 
pathway in the relevant tissues (reviewed in Vainchenker and Constantinescu, 2013). A 
brief overview of those diseases and their aetiology is given below. 
 
I.4.1 TEL-JAK2 fusion 
The best described gene fusion involving JAK/STAT pathway components is 
translocation ETS leukemia-JAK2 (TEL-JAK2) fusion which leads to oligomerization of 
the catalytic domains of JAK2 resulting in constitutive activity (Lacronique et al., 1997). 
Besides the aberrant activation of the JAK/STAT pathway, PI3K, RAS/ERK, p38 and 
NF-κB pathways are also activated (Nguyen et al., 2001). The TEL-JAK2 mutations is 
associated with T-cell childhood acute lymphocytic leukaemia (ALL) and atypical 
chronic myeloid leukaemia (CML). 
 
I.4.2 JAK2 mutations 
The JAK2 V617F mutation is found in over 90% of patients with polycythaemia 
vera (PV) and 50% of patients with essential thrombocythemia (ET) and primary 
myelofibrosis (PMF) (Baxter et al., 2005; James et al., 2005a; Kralovics et al., 2005). 
These haematological malignancies represent the classical non-BCR-ABL 
myeloproliferative neoplasias, characterized by production of excess mature blood cells 
(Tefferi, 2006). The V617F mutation resides in the JH2 domain of the kinase, and is 
thought to function by suppressing the autoinhibitory effects of this domain, as described 
previously. This leads to hypersensitivity to cytokines or cytokine-independent pathway 
activation. The molecular mechanism of action has been extensively studied, however 
some controversy exists regarding potential non-canonical aspects of mutant protein 
activity (Dawson et al., 2009; Girodon et al., 2011, reviewed in James et al., 2005b; 
Quintas-Cardama and Verstovsek, 2013).  
A significant proportion of patients suffering from myeloproliferative diseases 
that are both BCR-ABL- and V617F-negative are diagnosed with jak2 exon 12 somatic 
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mutations located in the JH2 domain (Pietra et al., 2008). Resulting hyperactivation of 
the JAK2 leads to phenotypes identical to those caused by V617F mutation. Moreover, a 
deletion of a small region in the JH2 domain (ΔIREED) as well as mutations of R683 in 
this region have been found in patients with B-cell ALL (Malinge et al., 2007). Finally, a 
single point mutation in the FERM domain of JAK2, R340Q, has been associated with 
chronic myeloproliferative neoplasias (Aranaz et al., 2010). 
 
I.4.3 Mutations in the remaining JAKs 
Somatic mutations in FERM and JH1 domains (including a JAK2 V617F 
equivalent, V658F) of JAK1 were found in 10-20% of patients with T-cell ALL and less 
frequently in B-cell ALL (reviewed in Vainchenker and Constantinescu, 2013). Also 
patients with acute myeloid leukaemia were found to carry mutated JAK1 (Xiang et al., 
2008). 
The Y100C mutation in the FERM domain of JAK3 causes a decreased 
interaction with IL-2 receptor in B-cells, resulting in autosomal severe combined 
immunodeficiency (SCID) (Cacalano et al., 1999). The gain of function mutations 
L156P, E183G and R172Q residing in the same domain of JAK3 are associated with 
adult T-cell leukaemia/lymphoma (Elliott et al., 2011).  
 
I.4.4 Mutations in the remaining components of the JAK/STAT pathway 
Although mutations in the cytokine receptors have only rarely been associated 
with human diseases, mutations mimicking the activated state of TpoR are associated 
with ET and PMF (Pikman et al., 2006). Furthermore, T617D mutation in G-CSFR has 
been associated with JAK2 hyperactivation, resulting in familial neutrophilia (Plo et al., 
2009).  
Mutations arising in the exon 21 of stat3 have been found in 40% of patients 
suffering from large granular lymphocytic leukaemia (Jiang et al., 2009; Koskela et al., 
2012). Mutations were localised to the SH2 domain of STAT3 and resulted in increased 
phosphorylation and transcriptional activity of STAT3. Patients carrying these mutations 
are also more susceptible to neutropenia and rheumatoid arthritis. Interestingly, also 
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mutations in stat5b have been reported to produce large granular lymphocytic leukaemia 
in patients that were tested negative for stat3 mutations (Rajala et al., 2013).  
 
I.5. Conservation of the JAK/STAT pathway in Drosophila melanogaster 
I.5.1 Overview of the pathway  
The Drosophila JAK/STAT pathway is conserved on all levels of the cascade, 
however it displays much lower redundancy (reviewed in Arbouzova and Zeidler, 2006). 
The only functional receptor of the pathway, Domeless (Dome), can be activated by any 
of the three ligands of the pathway: Upd, Upd2 or Upd3 (Fig.I.7) (Harrison et al., 1998; 
Brown et al., 2001; Agaisse et al., 2003; Gilbert et al., 2005; Hombría et al., 2005). No 
significant differences in pathway transcriptional output were observed in response to 
stimulation with individual ligands, however, dissociation dynamics as well as in vivo 
temporo-spatial expression is likely to differentiate these ligands (Hombría et al., 2005; 
Bina et al., 2010; Wright et al., 2011). In addition, the tertiary structure of Upd3 has 
recently been shown to be related to mammalian helical cytokines, while human helical 
cytokine leptin was shown to activate the Drosophila JAK/STAT pathway, implying 
strong conservation of signalling mechanisms between human and fly (Rajan and 
Perrimon, 2012; Oldefest et al., 2013).  
Genetic interaction studies as well as RNAi-mediated genome-wide screens 
confirmed existence of only a single JAK kinase, termed Hopscotch (Binari and 
Perrimon, 1994). Initially identified as a regulator of pair-rule and segment-polarity gene 
expression in the Drosophila embryo, Hop was soon after identified as a component of a 
conserved JAK/STAT pathway contributing to numerous biological processes. The 
homology to mammalian JAKs was first determined based on the presence of two kinase 
domains, JH1 and JH2. Loss of hop in vivo leads to under-proliferation of cells 
constituting larval imaginal discs, precursors of organs in the adult fly (Perrimon and 
Mahowald, 1986; Mukherjee et al., 2005).  
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Figure.I.7	  JAK/STAT	  pathway	  in	  Drosophila	  
 
Figure.I.7 JAK/STAT pathway in Drosophila. Schematic representation of the JAK/STAT 
signalling pathway as described in Drosophila. Negative regulators of the pathway are 
indicated on the right. Their position relative to the pathway represents the level of the 
signalling cascade at which the regulator acts. Regulators located in between levels act 
on both levels below and above.  
Adapted from Arbouzova and Zeidler, 2006.  
 
The Drosophila genome encodes a single STAT, called stat92E (Hou et al., 1996; 
Yan et al., 1996b). STAT92E has been shown to be core pathway component, 
transducing signal in the process of canonical signalling, thereby contributing to growth 
of imaginal discs, as described previously. However, once the JAK/STAT pathway 
signalling is suppressed, STAT92E performs an anti-proliferative role (Mukherjee et al., 
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2005). This ability to change proliferative functions has been attributed to the non-
canonical signalling performed by STAT92E (reviewed in Arbouzova and Zeidler, 2006). 
This accounts for activation of STAT92E by receptor tyrosine kinases as well as by Src 
kinases (Li et al., 2003; Read et al., 2004). Moreover, emerging evidence suggests that 
STAT92E can modulate the epigenetic landscape, similarly to the mammalian STATs, by 
affecting heterochromatin stability (Shi et al., 2006; Brown and Zeidler, 2008; Shi et al., 
2008). 
 
I.5.2 Regulation of the Drosophila JAK/STAT pathway 
The Drosophila JAK/STAT pathway has been shown to be regulated already at 
the level of ligand secretion and diffusion. Polarized mRNA expression of Upd, leading 
to polarized secretion pattern has been observed in the Drosophila overy, while Dally and 
Dally-like glypicans have been shown to regulate extracellular distribution pattern of 
Unpaired in the developing eye (Fig.I.7) (van de Bor et al., 2011; Zhang et al., 2013). 
Reception of the ligand is further regulated by Dome homodimerization and its 
heterodimerization with Latran/Eye transformer, a negative regulator of the pathway 
expressed in response to physical insult, such as wasp infestation, in a tissue specific 
manner (Brown et al., 2003; Kallio et al., 2010; Makki et al., 2010) Fisher et al., in prep). 
Cells constituting ectodermal tissues in Drosophila were reported to have STAT92E 
localization to sub-apical regions of the cell, resulting in sensitization of the pathway 
(Sotillos et al., 2008, 2013).  
The major regulators of the mammalian JAK/STAT pathway are also conserved 
in Drosophila. The SOCS family of proteins is represented by three SOCS-like 
molecules, SOCS16D, SOCS36E and SOCS44A, however only SOCS36E acts in a 
negative feedback loop and potently suppresses the JAK/STAT pathway signalling 
(Callus and Mathey-Prevot, 2002; Karsten et al., 2002; Rawlings et al., 2004, reviewed in 
Stec and Zeidler, 2011). SOCS44A has been shown to mainly affect the EGFR signalling 
pathway while function of SOCS16D has not been determined to date.  
So far, only Ptp61F, a homologue of human PTP1B, has been identified as a 
phosphatase regulating the fly pathway while the SHP2 homologue, Corkscrew, has no 
discernable effect on the Drosophila JAK/STAT pathway (Baeg et al., 2005; Müller et 
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al., 2005). Epistasis experiments determined Ptp61F to act on the level of STAT92E and 
Hop (Baeg et al., 2005; Müller et al., 2005), however in vitro experiments put it on the 
level of the receptor complex (Fig.I.7) (Fragiadaki and Fisher et al., in prep). Moreover, a 
single PIAS protein, referred to as dPIAS or Su(var)2-10, has been identified and shown 
to interact with STAT92E and suppress ectopically activated pathway in vivo (Betz et al., 
2001; Hari et al., 2001).  
Finally, the process of endocytosis has been shown to regulate the Drosophila 
JAK/STAT signalling pathway (Müller et al., 2005), however the only two reports on the 
matter suggest different regulatory outcomes (Devergne et al., 2007; Vidal et al., 2010). 
Never-the-less, the core endocytic machinery is well conserved between humans and flies 
and emerging evidence suggests a modulatory role in cell signalling for the Drosophila 
endocytic pathway (Huang et al., 2010; Robinson and Moberg, 2011; Katja Vogt, 
personal communication). 
 
I.5.3 JAK/STAT pathway in Drosophila development and maintenance of homeostasis 
Classically, Drosophila has been used as a developmental model organism. Not 
surprisingly, studies on the Drosophila JAK/STAT pathway are predominantly conducted 
in a developmental context. The JAK/STAT pathway in Drosophila was originally 
identified as necessary for correct segmentation within the embryo as well as for the 
formation of embryonic structures such as the gonads, hindgut, trachea and posterior 
spiracles (Small et al., 1996; Yan et al., 1996a; Brown et al., 2001; Johansen et al., 2003; 
Brown et al., 2006; Sotillos et al., 2010). During larval stages, JAK/STAT pathway 
regulates cell proliferation in the developing eye and wing discs, thereby contributing to 
tissue size and patterning in the adult (Bach et al., 2003; Mukherjee et al., 2005). 
Interestingly, those processes have been shown to depend on both, canonical and non-
canonical signalling by STAT92E (reviewed in Arbouzova and Zeidler, 2006; Brown and 
Zeidler, 2008).  
The reproductive systems in male and female flies also involves the JAK/STAT pathway, 
which plays essential roles in maintenance of the stem cell populations as well as 
specification and correct border cell migration in the ovary (Kiger et al., 2001; Tulina and 
Matunis, 2001; Decotto and Spradling, 2005; Silver et al., 2005). Emerging evidence 
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suggests essential roles for the JAK/STAT pathway in maintenance of the intestinal stem 
cell niche and immune response in this tissue, suggesting strong functional parallels 
between human and fly (Buchon et al., 2009a, 2009b; Jiang et al., 2009). Despite lack of 
conservation of the adaptive immune system in Drosophila and drastic differences in 
“blood” composition, parallels can also be drawn regarding involvement of the 
JAK/STAT pathway in haematopoiesis (Rizki and Rizki, 1992; Sorrentino et al., 2002; 
Meister and Lagueux, 2003; Crozatier et al., 2007; Krzemien et al., 2007). This 
comparison is particularly interesting considering hyperactivation of the Drosophila 
JAK/STAT pathway by pathogenic Hop mutants, HopTuml and HopT42, leads to formation 
of melanotic masses phenotypically reminiscent of human haematopoietic malignancies 
(Harrison et al., 1995; Luo et al., 1997).  
 
I.6. Synopsis 
The aim of this study is to investigate the molecular mechanisms governing the 
Drosophila JAK/STAT signalling pathway. Particular emphasis is put on the dissection 
of the structure-function relationship of core pathway components and pathway 
regulators. Questions regarding interaction sites between Dome and downstream pathway 
components as well as endocytosis of the receptor are addressed in Chapter III. Chapter 
IV focuses on the structure of SOCS36E and how it relates to regulation of the 
JAK/STAT pathway. Finally, the oncogenic Hop mutants, HopTuml and HopTuml, are 
dissected on the molecular level, with particular focus on the hyperactivation of the 
canonical JAK/STAT pathway, in Chapter V. Conclusions of this study in broader 
perspective as well as suggestions regarding future directions are provided in Chapter VI. 
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Chapter II Materials and methods  
II.1. Molecular techniques 
II.1.1 Polymerase Chain Reaction 
All Polymerase Chain Reactions (PCR) used in the generation of protein expression 
plasmids were conducted using Herculase II Fusion DNA Polymerase (Agilent 
Technologies) according to manufacturer instructions on a PTC-200 thermocycler (MJ 
Research). Primers used were obtained from Integrated DNA Technologies (Coralville, 
Iowa, USA) and their sequences are listed in Table.II.1. Previously generated cDNA 
clones were used as templates for amplification: Dome (LD46805; DGRC), SOCS36E 
(SD04308; DGRC), Hop (Binari and Perrimon, 1994). All PCR products were sequenced 
for mutations and correct orientation following sub-cloning into destination vectors at 
Core Genomic Facility (Medical School, University of Sheffield, Sheffield, UK).  
 
II.1.2 Cloning into Gateway vectors 
PCR amplified fragments were inserted into Gateway System Entry vector using pENTR 
Directional TOPO Cloning Kit (Invitrogen) and subsequently cloned into destination 
vectors pAWF or pAWH (Drosophila Gateway Vector Collection) using Gateway LR 
Clonase II Enzyme Mix (Invitrogen), according to manufacturer’s instructions. Gateway 
destination vectors were obtained from Drosophila Genomics Resource Centre (Indiana, 
USA).  
 
II.1.3 Cloning SOCS36E constructs into pRSETA plasmid 
Forward and reverse primers (Table II.1) containing BglII and KpnI restriction enzyme 
sites, respectively, were used to PCR amplify SOCS36E truncations using cDNA 
template (SD4308; DGRC). PCR product was poly-A tailed and sub-cloned into pCR2.1-
TOPO vector using TOPO TA Cloning Kit (Invitrogen). SOCS36E SH2* mutation was 
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introduced at this stage as described in section II.1.4. All vectors were sequenced and 
selected against unwanted mutations. Plasmids were cut with BglII (New England 
BioLabs) or Asp718 (Roche) restriction enzymes according to manufacturer instructions. 
Reactions were resolved on 1% agarose electroporesis gel and required bands were 
extracted using QIAquick Gel Extraction kit (QIAGEN) according to manufacturer 
guidelines. Purified DNA fragment was ligated into pre-cut pRSET A plasmid 
(Invitrogen) using T4 DNA ligase (New England BioLabs). 
 
Table.II.1	  Primers	  used	  for	  cloning	  
Gene Primer Sequence 
 
Gateway cloning 
 
 
Forward caccATGGTGGCCCAGGAGCAGC 
Dome 
Reverse GAGGACGTGCCGATTGTGGGC 
Forward caccATGGCCCTGGCCAACGG 
Hop 
Reverse CTCGGCATCCGTCGGCTGATTCGGC 
Forward caccATGGGTCATCACCTTAGCAAGTTCTCAGCA 
SOCS36E 
Reverse TACATTGCCGTAGTACGGCATCG 
Forward caccATGCACTGCCTGGTTCCCGATCT 
SOCS36EΔN 
Reverse TACATTGCCGTAGTACGGCATCG 
Forward caccATGGGTCATCACCTTAGCAAGTTCTCAGCA 
SOCS36EΔSB 
Reverse GGAGAAGGTCTGCCTTCTGTGCAG 
 
pRSET A cloning 
Forward GCAAGATCTATGGGTCATCACCTTAGCAAGTTCTCAGCA 
SOCS36E 
Reverse ACATTGCCGTAGTACGGCATCGGGTACCTAC 
Forward TCTAGATCTATGCACTGCCTGGTTCCCGATCT 
SOCS36EΔN 
Reverse ACATTGCCGTAGTACGGCATCGGGTACCTAC 
Forward GCAAGATCTATGGGTCATCACCTTAGCAAGTTCTCAGCA 
SOCS36EΔSB 
Reverse GGAGAAGGTCTGCCTTCTGTGCAGGGTACCGGA 
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II.1.4 Generation of single point mutations 
Single point mutations in Dome, Hop and SOCS36E were introduced using QuickChange 
II XL Site-Directed Mutagenesis Kit (Agilent Technologies) and primers listed in 
Table.II.2. Gateway entry vector carrying gene of interest was used as DNA template for 
site directed mutagenesis reaction. Sequencing was undertaken to exclude unintended 
mutations as described previously (Section.II.1.1). Mutated DNA was subsequently 
cloned into pAWH or pAWF expression vectors, as described previously (Section.II.1.2). 
Table.II.2	  Primers	  for	  site-­‐directed	  mutagenesis	  
Gene Mutation Sequence 
P925I–F GATATCGGTCTAGTGCTGATTCAGGGAATCATGGAGACC 
P925I–R GGTCTCCATGATTCCCTGAATCAGCACTAGACCGATATC 
Y914F-F CTACCTCGTGTACAAGAAATTCCGCAAGATGTCCGATATCG 
Y914F-R CGATATCGGACATCTTGCGGAATTTCTTGTACACGAGGTAG 
Y1022F-F GTTGGTCCGCCCACCAGCTTCCTGGCCATGCGGCATGGC 
Y1022F-R  GCCATGCCGCATGGCCAGGAAGCTGGTGGGCGGACCAAC 
Y1070F–F CAGAGTTGCACCAATGGTTTCATCAAGCCCACACAGATG 
Y1070F–R CATCTGTGTGGGCTTGATGAAACCATTGGTGCAACTCTG 
Y1219F–F CAAAATGGCTGACATCGGCTTTACCACCATGGAGCAGTTGC 
Y1219F–R GCAACTGCTCCATGGTGGTAAAGCCGATGTCAGCCATTTTG 
L985R–F GTGAGAGCTCGAAACGGCTGCTGCGCACAGC 
L985R–R GCTGTGCGCAGCAGCCGTTTCGAGCTCTCAC 
Y966F–F GACGACTCGCCGCCATTCACGCCGCAGGATCTG 
Dome 
Y966F–R CAGATCCTGCGGCGTGAATGGCGGCGAGTCGTC 
G341E–F GGATTCCCTGGAGCCTGGACTCAAGGTGGCCAGGG 
G341E-R CCCTGGCCACCTTGAGTCCAGGCTCCAGGGAATCC 
E695K–F GCGGCATGCACTATTTGAAGGACAACAAGATT 
E695K–R AATCTTGTTGTCCTTCAAATAGTGCATGCCGC 
K926Q–F CCGAGCAGGTTGCCATCCAGATGCTGAACACCATG 
Hop 
K926Q–R CATGGTGTTCAGCATCTGGATGGCAACCTGCTCGG 
R499E–F GGCACGTTCCTGCTGGAGGACTCCGCCCAGGAG SOCS36E 
R499E–R CTCCTGGGCGGAGTCCTCCAGCAGGAACGTGCC 
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II.1.5 Plasmid propagation and purification 
NEB-10β cells (New England BioLabs) were transformed according to manufacturer 
instructions, plated on LB-agar plates with appropriate antibiotic selection and grown 
overnight at 37OC according to standard protocols. Individual colonies were picked and 
grown in 5ml of LB medium supplemented with appropriate antibiotic overnight at 37OC. 
DNA was extracted using Plasmid Mini kit (QIAGEN) and restriction digests were 
performed to determine orientation and identity of the insert. If correct, large-scale 
bacterial culture was grown overnight and DNA was extracted using Plasmid Midi or 
Plasmid Maxi kit (QIAGEN) according to manufacturer guidelines.  
 
II.1.6 Extraction of genomic DNA from wild-type flies 
50 wild-type flies (w1118) were frozen at -80OC overnight, homogenized in 400µl of DNA 
extraction buffer (0.1M NaCl, 0.2M Sucrose, 0.1M Tris HCl pH9, 50mM EDTA, 0.5% 
SDS) and incubated at 65OC for 30 minutes. 120µl of 8M of KOAc was added and 
further incubated for 30 minutes on ice. Reaction was centrifuged at 13,000 rpm for 5 
minutes at 4OC and 750µl of the supernatant were aliquoted into a fresh eppendorf. The 
volume was doubled with 100% ethanol and incubated for 5 minutes at room 
temperature. Reaction was centrifuged at 13k rpm for 5 minutes at 4OC, supernatant was 
discarded and the pellet was washed with 70% ethanol and air-dried. Pellet was 
resuspended in 400µl of TE buffer. 2 µg/ml RNase A was added and incubated at 37OC 
for 30min to remove any RNA. 40µl of StratClean (Stratagene) was then used to remove 
remaining protein contaminants for 1 minute and centrifuged at 13,000 rpm  for 5min at 
4OC. Supernatant was transferred into a fresh eppendorf and 1/10th volume of 5M NaCl 
and 2 volumes of 100% ethanol were added. Reaction was incubated overnight at -80OC 
for 2 hours to allow for DNA precipitation and centrifuged at 13,000 rpm for 10 minutes 
at 4OC. Pellet was washed with 70% ethanol and resuspended in 50µl of TE buffer. 
 
II.1.7 Generation of double stranded (ds)RNAs 
Wild-type fly genomic DNA was used as a template for PCR using primers listed in 
Table.II.3. Genomic DNA used for generation of LacZ dsRNA was obtained from flies 
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expressing LacZ and was a kind gift from Victoria M. Wright. PCR products were 
transcribed in vitro using MEGAScript T7 transcription kit (Ambion), according to 
manufacturer instructions. dsRNAs were checked for size by separation on standard 1% 
agarose gel. Efficiency of knockdowns was assessed by qPCR (Fig.II.1). 
 
Table.II.3	  Primers	  to	  make	  dsRNAs	  
Gene Primer Sequence 
Forward TAATACGACTCACTATAGGGAGAGCAGCACCTCTACCTCCAA 
Cullin 5 
Reverse TAATACGACTCACTATAGGGAGCTATCCATCAGGCGGAACAT 
Forward TAATACGACTCACTATAGGGAGCCCACGTCCTACAAAAGGTC 
Elongin C 
Reverse TAATACGACTCACTATAGGGAGTCTCGCAGGGACAATCTTCT 
Forward TAATACGACTCACTATAGGGAGCTGCCGTCTCAACTGCAATA 
Elongin B 
Reverse TAATACGACTCACTATAGGGAGGTTCGCTCAGTTCGCACATA 
Forward TAATACGACTCACTATAGGGGGCAACCACTCCACGCA 
Rab5 
Reverse TAATACGACTCACTATAGGGTCCTGGCCAGCCGTGT 
Forward TAATACGACTCACTATAGGGATCCCTCAAATCCCAGTTCC 
TSG101 
Reverse TAATACGACTCACTATAGGGAAAGTGGCGCTGTGGTG 
Forward TAATACGACTCACTATAGGGGTGTTTAACCTCAGGGTGAC 
Dor 
Reverse TAATACGACTCACTATAGGGGCGTGCTCGGCTATCA 
Forward TAATACGACTCACTATAGGGCCTTGCTTCGTTCTAATCGC 
Hop 
Reverse TAATACGACTCACTATAGGGATGCAGTGTTACATTGGGCA 
Forward TAATACGACTCACTATAGGGGCTCACTGGGCTGATAAAGC 
Dome 
Reverse TAATACGACTCACTATAGGGTACAGGTTCTGGGTTCTGGG 
Forward TAATACGACTCACTATAGGGAAGCTGCTTGCCCAAAACTA 
STAT92E 
Reverse TAATACGACTCACTATAGGGGTCGACGATAAAGGCAGAGC 
Forward TAATACGACTCACTATAGGGGAGCGTCACTCCAACTCCTC 
SOCS36E 
Reverse TAATACGACTCACTATAGGGCCAGCGATTACGAAAAGCTC 
Forward TAATACGACTCACTATAGGGAGACAGTGGCGTCTGGCGGAAA 
LacZ 
Reverse TAATACGACTCACTATAGGGAGATCCGAGCCAGTTTACCCGC 
Forward TAATACGACTCACTATAGGGAGCGAAACCAAAAGCAAAGA 
Ptp61F 
Reverse TAATACGACTCACTATAGGGGAAGGGCAAAAAGAGTGCTG 
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Figure.II.1	  Knockdown	  efficiency	  
 
Figure.II.1 Knockdown efficiency. Results of quantitative RT-PCR on cells treated with 
control dsRNA or targeting gene of interest, as indicated.  
 
II.1.8 Isolation of mRNA from cells 
mRNA that was used for qPCR analysis of dsRNA-mediated knockdown efficiency was 
extracted from cells using Trizol extraction (Chomczynski and Mackey, 1995). Briefly, 
cells grown in monolayer were washed once with ice cold PBS and lysed in the culture 
dish directly, using 1ml of TRIzol Reagent (Invitrogen) per well in 6-well plate and 0.5ml 
per well in 12-well plate. 0.2ml of chloroform per 1ml of Trizol was added, vortexed for 
15s and incubated for 3min. Phase separation was achieved by centrifugation at 12,000g 
for 15min at 4OC. Aqueous phase was transferred intro a fresh tube and mixed with 
isopropanol, volume of which was defined as half the starting volume of Trizol. 
Following 10min incubation at room temperature, samples were centrifuged at 12,000g 
for 10min at 4OC. Pellet was washed twice with 1ml of 75% ethanol, air dried and 
resuspended in DEPC treated water.  
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II.1.9 Reverse transcription 
Concentration of mRNA was determined using a NanoDrop spectrophotometer 
(NanoDrop Technologies). 2µg of mRNA were used for reverse transcription reaction 
using High Capacity RNA-to-cDNA Kit (Applied Biosystems), according to 
manufacturer guidelines. For quantitative Real-Time PCR, 20µl cDNA reaction was 
topped up to 30µl volume with water. 
 
II.1.10 quantitative Real Time-PCR 
qRT-PCR was carried out on C1000 Touch Thermal Cycler (Bio-Rad) in 96-well plates, 
according to manufacturer instructions. The total volume of reaction per well was 10µl, 
consisting of 5µl of SYBR® Green JumpStart Taq ReadyMix for Quantitative PCR 
(Sigma), 1µl of diluted cDNA, 0.1µl per primer and 3.8µl water. Final primer 
concentration of 1µM, was used per reaction. Primer sequences used are provided in 
Table.II.4. Results were analysed using the ΔΔCT method (Livak and Schmittgen, 2001) 
and normalised using the housekeeping gene rpl32 (Dostert et al., 2005). Results of qRT-
PCRs are available in the Fig.II.1. 
 
II.2. Tissue culture techniques 
II.2.1 Maintenance of cell cultures 
Kc167 and S2R+ cells were maintained in Drosophila Schneider’s Medium (Gibco), 
supplemented with 10% Foetal Bovine Serum (FBS) (Sigma) and 5% Penicillin-
Streptomycin (Gibco) at 25OC in a humified incubator at atmospheric levels of CO2. 
Unfortunately, following change to the composition of the media in January 2012, by 
Gibco, Kc167 cells no longer survived, and experiments using S2R+ cells were also 
affected. All protocols were readjusted, and the latest ones are presented here. The Kc167 
cell line was reacquired and cultured in Shields’s and Sang M3 Insect Medium (Caisson 
Labs) supplemented with 1g/L of yeast extract (Sigma), 2.5g/L peptone (Fisher 
Scientific), 10% FBS (Sigma) and 5% Penicillin-Streptomycin (Gibco). However, some 
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experiments with Kc167 cells could never be replicated following media change and are 
not presented in this thesis. 
 
Table.II.4	  qRT-­‐PCR	  primers	  
Gene Primer Sequence 
Forward GACGCTTCAAGGGACAGTATCTG Rpl32 
Reverse AAACGCGGTTCTGCATGAG 
Forward ACTTTCGGTACTCCATCAGC Dome 
Reverse TGGACTCCACCTTGATGAG 
Forward GAGGAGACACAAATAACAAAGTACC Tsg101 
Reverse TGAGTGTCCATCAACCAAATAC 
Forward CACAGCTTAGCTCCCATGTA Rab5 
Reverse TGTTTGACAAATCTGCCTTG 
Forward AGTGCTTTACTGCTGCGACT Socs36E 
Reverse TCGTCGAGTATTGCGAAGT 
Forward GCATTCACGCACAATATAGC Hop 
Reverse TTCATCTCCTACCTGGGTATCT 
Forward CTACGCGGATGTGGGTTA Elongin B 
Reverse GTGCAAGCGAAGTAGGAAAA 
Forward GTATCTCCCGGAAATGCAC Elongin C 
Reverse GCCATGTACGTGAAGCTGAT 
Forward CGTCGTCCCGTCTCATATAC Cullin5 
Reverse GCACACAAGAGGCCATTATC 
 
II.2.2 Transfections 
Transient transfections of cells were performed using Effectene transfection kit (Qiagen). 
For transfections, cells were plated at following concentrations: 1x106 per well in 24-well 
plate, 2x106 per well in 12-well plate, 5x106 per well in 6-well plate, 12.5x106 per T25 
flask, 37.5x106 per T75 flask. All plastic-ware was acquired from Corning. Amount of 
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transfected DNA was always totalled at 2µg per well in 6-well plate and scaled 
accordingly. Amount of individual plasmids used in transfections was determined based 
on comparable amounts of protein expressed, assessed by western blotting. Cells were 
incubated at 25OC for at least 2 days to allow proteins to express, before harvesting for 
western blotting. For RNAi experiments, transfected cells were incubated for 24h before 
treating with dsRNA (section II.2.3).  
 
II.2.3 RNAi-mediated knockdowns 
Cells were plated at the same concentrations as outlined above and allowed to settle for 2 
hours. Media was substituted for serum-free medium (prepared as the media used for 
maintenance, without FBS) containing diluted dsRNAs. For volumes and concentrations 
see Table.II.5. After 1 hour incubation at 25OC, volume was doubled with standard 
maintenance media supplemented with 10% FBS. Knockdown was allowed to occur for 
4-5 days, depending on the experimental requirements. 
Table.II.5	  Concentration	  of	  dsRNAs	  per	  well	  
Plate Volume per well (µ l) Amount of dsRNA (µg) 
6-well plate 1500 12 
12-well plate 600 6 
24-well plate 300 3 
96-well plate 75 1 
 
 
II.2.4 Preparation of Upd2-GFP conditioned media 
Kc167 cells in 6-well plate were transfected with 2µg pAc-Upd2-GFP plasmid, as 
described previously. Cells were incubated until reaching confluence, resuspended and 
moved into a T75 flask. A single well was put into one flask and volume was topped up 
to 15ml with maintenance medium. After 5 days, medium was collected, filtered through 
0.2µM filters (Thermo Scientific) divided into 1ml aliquots and frozen at -80OC. The 
ability of the conditioned media to induce transcriptional response of the pathway in a 
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luminescence reporter assay (Section II.2.5), was used as a determining factor for amount 
of conditioned media used in future experiment with each batch. To generate mock-
conditioned media cells were transfected with pAc5.1C/V5-HisC plasmid (Invitrogen).  
Protocol was adapted from (Vidal et al., 2010). 
 
II.2.5 Luminescence assays 
Cells were co-transfected with required plasmid, 500ng of pAc-6x2xDrafLuc, 250ng of 
pAc-Renilla-Luc and topped up to 2µg with pAc5.1/V5-HisC vector (Invitrogen) per well 
in 6-well plate (Müller et al., 2005). Following 24h incubation, wells were moved into 
96-well plates, seeding 80k cells per well, topped up to 50µl with maintenance media and 
left for 2hour to settle. If required, dsRNAs were applied as described previously, 
however the maintenance media to double the volume was supplemented with mock or 
Upd2-GFP-conditioned media. If no dsRNA was used, volume was topped up to 100µl 
with mock or Upd2-GFP-conditioned media and incubated for 4-5 days. On the day of 
analysis, media was removed and replaced with 40µl of lysis buffer (BL buffer and 0.3% 
Triton-X100) per well and incubated for 10 min at room temperature. 60µl of firefly 
luciferase buffer (BL buffer, B2 buffer and 35.7mM D-Luciferin (Apollo Scientific)) was 
added to each well and the firefly luciferase luminescence recorded using a Mithras LB 
940 plate reader (Berthold Technologies). 60µl of Renilla luciferase buffer (BL buffer, 
B2 buffer and 0.2mM Coelenterazine (Apollo scientific)) was added per well and the 
luminescence measured again using a 500nm short pass emission filter (ie. a filter that 
allows all wavelengths shorter than 500nm to pass through it while blocking light of 
longer wavelengths).  
Schematic representation of reporters is shown in Fig.II.2. 
BL buffer : 50mM Hepes pH 7.6, 0.5mM EDTA, 0.33mM Phenylacetic acid, 0.07mM 
Oxalic acid 
B2 buffer : 415mM DTT, 33mM ATP, 1mM AMP 
Protocol was adapted from (Wright et al., 2011). 
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Figure.II.2	  Transcriptional	  pathway	  activity	  reporters	  
 
Figure.II.2 Transcriptional pathway activity reporters. Schematic representation of 
reporters used to assess transcriptional activity of the JAK/STAT pathway.  
 
II.2.6 Immunohistochemistry 
3 days after transfection as described above, cells were seeded at 3x105 per 10mm glass 
coverslip in a well in 24-well plate. Cells were allowed to settle for 4 hours, washed three 
times with PBS (Sigma) and fixed with 4% formaldehyde in PBS for 20min. Fixed cells 
were washed 3x in PBS, incubated with PBST (PBS with 0.1% TritonX-100) for 20min 
and incubated with blocking media (PBST supplemented with 3% BSA) for 30min. 
Primary antibodies diluted in blocking media, concentrations are provided in Table.II.6, 
were applied onto cells and incubated at 4OC overnight. Primary antibodies were washed 
off with three washes in PBST (each 10min long) and incubated in secondary antibodies 
in blocking media for 2 hours at room temperature (for concentrations, see Table.II.6). 
Alexa Fluor conjugated phalloidin (Invitrogen) at 1:50 concentration was added to the 
secondary antibody mixture. Media was changed to PBST with Hoechst at 2µg/ml final 
concentration and incubated for 10min. Cells were washed with PBST three times for 
10min each time and  dry slide was mounted using Paramount (Thermo Fisher). 
 
II.2.7 Dextran uptake assay 
Cells treated with dsRNAs as described above, were seeded at 3x105 per 10mm glass 
coverslip in a well in 24-well plate and allowed to settle for 4 hours. Cells were washed 
with PBS and incubated with media containing Alexa Fluor conjugated dextran  
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Figure.II.3	  Dextran	  uptake	  analysis	  
 
Figure.II.3 Dextran uptake analysis. The original image input into the MetaXpress 
software (top left), was separated into Red (bottom right) and Blue (bottom left) 
channels, corresponding to dextran and Hoechst, respectively. Those two channels were 
used to generate quantification mask (top right) used for analysis.  
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(MW=10,000) (Invitrogen) at 1µg/µl and mock or ligand-conditioned media. At indicated 
times, cells were washed with ice cold PBS, fixed and prepared as described above. 
II.2.8 Confocal microscopy and image analysis 
All slides were visualised using Zeiss LSM 510 confocal microscope. The standard image 
size is 1024 x 1024 pixels. Cells were visualised using a 63X oil immersion objective. 
Images were prepared using Image J (v1.43) or Adobe Photoshop CS v8.0. Z-stacks were 
obtained when imaging slides for dextran uptake assay, which were than analysed as 
maximal projections using MetaXpress 3.1 software (MDS). Analysis was automated 
using Transfluor protocol, with exemplary images generated by the software shown in 
Fig.II.3. Following parameters were used to determine internalized dextran vesicles, from 
which intensity was determined: vesicle size between 0.5 and 2.5µm with intensity of at 
least 50 grey levels above proximal background. At least 40 cells per condition were 
analysed in a single replicate.  
 
II.2.9 Biotinylation  
Cells transfected with pAc-Dome-FLAG, as described above, were washed three times 
with serum-free maintenance media and three times with ice cold PBS. Ice cold PBS with 
0.25mg/ml of EZ-link NHS-Biotin (Thermo Fisher) was left on cells for one hour at 4OC, 
washed away with three washes in PBS and three washes of maintenance media 
supplemented additionally with 0.2% BSA to sequester any unbound biotin. Cells were 
incubated with maintenance media for required periods of time in maintenance media at 
25OC and lysed in standard lysis buffer: 50mM Tric-HCl pH7.4, 1mM EGTA, 1 mM 
EDTA and 0.5% Triton X-100, freshly supplemented with Complete Mini EDTA-Free 
tablet protease inhibitor cocktail tablet (Roche). Lysates were incubated for 30min on a 
rocking shaker at 4OC, centrifuged at 7,000g for 5min at 4OC and supernatant was 
incubated with Streptavidin Magnetic Beads (New England BioLabs) at 4OC overnight. 
Following incubation, beads were washed three times with lysis buffer, boiled in 3x 
Laemmli buffer and resolved by SDS-PAGE (Section II.3.2).  
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II.2.10 Pharmacological agents 
To block de novo protein synthesis, cells transfected with pAc-Dome-FLAG were 
incubated with maintenance media supplemented with cyclohexamide at 10µg/ml 
(Sigma) for 30min at room temperature prior to experiment.  In experiments utilising 
pharmacological inhibitors of degradation, cells were incubated with maintenance media 
supplemented with cyclohexamide and 10µM MG132 (Tocris Bioscience), 0.1µM 
Bafilomycin A1 (Sigma), 10µM N-ethylmaleimide (NEM) (Sigma) or appropriate carrier 
control (DMSO or ethanol) for 30min prior to the experiment and for the duration of the 
experiment.  
 
II.3 Biochemical techniques 
II.3.1 Immunoprecipitation 
Cells were prepared as described previously and treated as required with mock or ligand-
conditioned media. They were subsequently lysed for 30min at 4OC on horizontal shaker. 
In experiments focusing on protein phosphorylation, Kinase immunoprecipitation lysis 
buffer (Kinase IPLB; 50mM Tris-HCl pH7.4, 1mM EGTA, 1mM EDTA, 5mM β-
Glycerophosphate, 2.5mM Na-Pyrophosphate, 1mM Na-Orthovanadate, 0.5% Triton X-
100 supplemented freshly with a Complete Mini EDTA-Free protease inhibitor cocktail 
tablet (Roche)) was used, otherwise standard lysis buffer was used (Section II.2.9). 
Lysates were cleared by centrifugation at 7,000g for 5min at 4oC and incubated with 
primary antibodies for 4h at 4oC with gentle agitation, followed by incubation with 1:5 
Dynabeads (Novex, Invitrogen) overnight at 4OC with gentle agitation. Proteins were 
eluted into 3x Laemmli Buffer by boiling and stored on ice for analysis by SDS-PAGE 
and western blotting.  
 
II.3.2 SDS-PAGE and western blotting 
Appropriate volumes of samples were loaded on to Mini-PROTEAN TGX 4-15% 
gradient gels (Bio-Rad) and run for 1h 30min at 90V in Running Buffer (25mM Tris, 
19m2M Glycine, 0.04% SDS). Proteins were the transferred onto Nitrocellulose 
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membranes (GE Healthcare) in Transfer Buffer (47mM Tris, 38mM Glycine, 0.037% 
SDS, 20% methanol) for 1h 15min at 70V. Membranes were incubated in blocking 
solution (5% Horse Serum (Sigma) in 0.5% TBS-Tween-20 (TBST)) for 30min at room 
temperature and incubated with primary antibodies diluted in blocking solution. Primary 
antibodies and concentrations are listed in Table.II.6. Following overnight incubation at 
4OC, membranes were washed 3 times with TBST and incubated with secondary 
antibodies (listed in Table.II.6) in blocking solution for 2 hours at room temperature. 
Subsequently, membranes were washed 3 times with TBST and developed using ECL 
Western Blotting Detection Reagents (GE Healthcare) and Hyperfilm ECL (GE 
Healthcare) on Optimax 2012 X-Ray Film Processor (Protec). 
TBS: 135mM NaCl, 25mM Tris, 2.5mM KCl; pH adjusted to 7.4 with HCl. 
 
Table.II.6	  Antibodies	  used	  
Antibody Microscopy Immunoprecipitation Blotting 
Primary antibodies 
Anti-FLAG M2 (Sigma) 1:500 1:200 1:2,500 
Anti-HA (Roche) 1:500 1:200 1:2,500 
Anti-pTyrosine (Calbiochem)   1:400 
Anti-α-Tubulin (Sigma)   1:5,000 
Anti-STAT92E (Santa Cruz)  1:50 1:1,000 
Anti-GFP (Abcam)   1:250 
Anti-Ubiquitin (Cell Signalling)   1:500 
Secondary antibodies 
HRP anti-rabbit (Dako)   1:5,000 
HRP anti-rat (Dako)   1:5,000 
HRP anti-mouse (Dako)   1:5,000 
HRP anti-goat (Dako)   1:5,000 
AF647 anti-mouse (Invitrogen) 1:1,000   
AF647anti-rat (Invitrogen) 1:1,000   
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II.3.3 Isolation of SOCS36E protein 
SOCS36E constructs in pRSET A plasmid were used for in vitro synthesis using  
PURExpress kit (New England BioLabs), according to manufacturer instructions. 
Constructs were labelled with 35S-Methionine (PerkinElmer).  
Alternatively, FLAG-tagged SOCS36E constructs were expressed in cells and pulled 
down with anti-FLAG antibody and bound to beads, as described above (Section II.3.1). 
Following overnight incubation, beads were washed 3x with lysis buffer and incubated 
with 3x FLAG peptides to elute protein of interest (Sigma), according to manufacturer 
guidelines. Eluted proteins  were used for further experiments.  
 
II.3.4 in vitro kinase activity assay 
Cells transfected with HA-tagged Hop or Hop mutants were lysed and 
immunoprecipitated as described previously. Kinases bound to beads were washed three 
times with Kinase IPLB and three times with Kinase activity assay reaction buffer 
(KAAB): 20mM HEPES pH7.4, 10mM NaCl, 20mM MgCl2, 100mM NaF, 0.2mM 
NaOVa, 2mM DTT and 10mM MnCl2, and resuspended in 25µl of 2xKAAB. 20µl of 
water or proteins obtained as described above, was added to the reaction and incubated at 
30OC with agitation for 10min. Enzymatic reaction was initialised by addition of 5µl of 
1mM ATP spiked with 32P γ-ATP (PerkinElmer) to ca. 1x106cpm per µl. Reactions were 
incubated at 30OC for 20min with occasional agitation and terminated by adding 200µl of 
20mM EDTA. Three washes with Kinase IPLB preceded elution into 3xLaemmli buffer 
by boiling. Eluted Hop was resolved by SDS-PAGE and either transferred to 
nitrocellulose membrane (GE Healthcare) or dried and exposed to phospho-screen 
(Kodak) and quantified using Molecular Imager FX (Bio-Rad). Linearity between amount 
of bead bound kinase and 32P radioactivity was checked (Fig.II.4). Analysis was 
performed using Quantity One software (Bio-Rad). Protein levels were determined by 
blotting the nitrocellulose membrane for HA or staining gel with Bio-Safe Coomassie G-
250 Stain (Bio-Rad).  
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Figure.II.4	  Linearity	  of	  32P	  incorporation	  
 
Figure.II.4 Linearity of 32P incorporation. In vitro kinase activity assay was conducted 
with batch of kinases bound to beads that were subsequently split into three samples 
with increasing volume of beads, as indicated. Samples where than resolved on SDS-
PAGE gel and the amount of 32P incorporated assessed by exposure to luminescence 
film. 
 
II.3.5 Preparation of MultiDsk beads  
MultiDsk-GST plasmid was a kind gift of Jesper Svejstrup (Cancer Research UK, 
London Research Institute). BL21 bacteria strain were transformed and grown in 5ml 
media overnight at 37OC. 600ml of media was inoculated with the overnight grown 
culture and grown at 37OC until optical density of 0.6 at OD600 was reached. At this point 
bacteria was induced with IPTG at 1mM final concentration and incubated at 30OC for 4 
hours. Bacteria were centrifuged at 3,500g at 4OC for 20min and the pellet was 
resuspended in 20ml of STE buffer supplemented with 100µg/ml lysozyme (Sigma) and 
incubated for 15min on ice. DTT was added to 5mM final concentration and vortexed 
briefly. N-lauryl sarcosine was added to 1.5% final concentration and vortexed for 5s. 
Suspension was sonicated 4x with probe sonicator  (MSE UK) at amplitude 5 microns in 
periods of 15s, spaced 30s apart. This sample was centrifuged at 10,000g for 10min at 
4OC and filtered through a cheesecloth. TritonX-100 was added to a final concentration 
of 3% and DTT concentration was re-adjusted to 5mM. Mixture was incubated for 5min 
at 4OC and 1ml of 50% slurry of BD BaculoGold Glutathione Agarose Beads was added 
(BD Biosciences) and incubated for 4h at 4OC on a roller. Beads were washed in 20ml of 
wash buffer 1, followed by batch wash in wash buffer 2. Beads were then moved into 
empty polystyrene purification columns (Thermo Fisher) and washed with 10ml of wash 
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buffer 1, followed by 10ml of wash buffer 2, allowing both to filter through by gravity-
flow. Beads where than moved into eppendorf, equilibrated by 3x washes with PBS and 
stored at 4OC in PBS supplemented with 0.1% Sodium Azide. Expression of MultiDsk 
was checked at each stage (Fig.II.5). 
 
Protocol adapted from (Wilson et al., 2012). 
STE Buffer: 10mM Tris pH8, 1mM EDTA, 100mM NaCl, supplemented with proteinase 
inhibitor tablets 
Wash buffer 1: 1xPBS, 450mM NaCl, 10% glycerol, 0.1mM EDTA, 0.1% TritonX-100, 
2mM DTT, supplemented with proteinase inhibitor tablets 
Wash buffer 2: 50mM KPhos buffer pH7.4, 50mM NaCl, 10% glycerol, 1mM β-
Mercaptoethanol, 0.2% TritonX-100, supplemented with proteinase inhibitor tablets 
Figure.II.5	  Generation	  of	  MultiDsk	  bound	  to	  beads	  
 
Figure.II.5 Generation of MultiDsk bound to beads. (A) Effectiveness of BL21 induction 
with IPTG. Molecular weight of MultiDsk-GST is 58kDa. (B) Samples were taken at each 
step in sequence of the protocol on MultiDsk bound beads generation: 1. Suspension in 
STE; 2. Sonication; 3. Centrifugation at 10,000g; 4. Supernatant from incubation with 
GST-beads; 5. Batch wash with wash buffer 1; 6. Batch wash with wash buffer 2; 7. 
Column wash with wash buffer 1; 8. Column wash with wash buffer 2; 9. Eluted from 
beads. 
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II.3.6 Assessment of Dome ubiquitination 
Cells transfected with Dome-FLAG were treated with mock or ligand conditioned media 
for 30min at room temperature and lysed in standard lysis buffer freshly supplemented 
with 2mM iodoacetic acid (Sigma), 10µM MG132 (Sigma) and 10µM NEM (Sigma) and 
protease inhibitor tablets (Roche). Following 30min lysis at 4OC, samples were 
centrifuged at 7,000g for 5min at 4OC. Supernatants were used for immunoprecipitation 
as described previously. Proteins were analysed by western blotting for Ubiquitin, or 
incubated with MultiDsk beads generated as described previously and analysed by 
western blotting for FLAG.  
 
II.4. Statistics and reproducibility 
All experiments were replicated with at least three biologically independent repeats. 
Images of western blots are representative. Quantification and statistical analysis was 
performed using Excel (Microsoft) or Prism 6 (GraphPad) software. Statistical 
significance was tested with paired Student’s t-test or ANOVA followed by Bonferroni’s 
multiple comparisons test, as appropriate. Legend to statistical significance: *** - 
p<0.005; ** - p<0.01; * - p<0.05. 
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Chapter III Molecular analysis of Dome  
III.1. Introduction 
III.1.1 Shared homology between Dome and mammalian cytokine receptors 
Domeless (Dome), also called master of marelle, was the last core component of 
the Drosophila JAK/STAT pathway identified (Brown et al., 2001; Chen et al., 2002). It 
has been characterised as most similar to mammalian IL-6 cytokine receptor family, 
mainly gp130 and LIFR (Fig.III.1A and B) (Brown et al., 2001; Chen et al., 2002). 
Sequence analysis tools show that Dome contains three FNIII domains and a CBM 
(Fig.III.1). The CBM is only partially conserved in Dome, with incomplete WSxWS 
motif, although extensive evidence suggests that it can none-the-less bind Upd ligands 
(Silver et al., 2005; Vidal et al., 2010). Consistent with this, recent report has shown that 
human Leptin can signal via Dome, indicating the level of functional conservation of the 
ligand binding domain, even though the shared identity in amino acid sequence between 
Dome and Leptin receptor, Ob-Rb, is fairly low (Fig.III.1B) (Rajan and Perrimon, 2012).  
Despite conservation of FNIII and CBM domains, an Immunoglobulin-like 
domain common to mammalian type I cytokine receptors is not present in Dome 
(Fig.III.1A). Besides Ig-like domains, Dome also does not contain any classical Box 
domains (Fig.III.1A) (Hirano et al., 1997; Taga and Kishimoto, 1997; Grant and Begley, 
1999; Brown et al., 2001; Chen et al., 2002). This structural difference is interesting as 
genetic interactions between Dome:Hop and Dome:STAT92E have been established in 
vivo as well as in vitro (Brown et al., 2001; Chen et al., 2002; Kallio et al., 2010, 
reviewed in Arbouzova and Zeidler, 2006).  
 
III.1.2 JAK/STAT pathway regulation at the level of the receptor 
Regulation of the JAK/STAT signalling pathway occurs at numerous levels of the 
signalling cascade, as described previously (Section.I.5.2). This includes regulation of 
receptor’s post-translational modifications, its stability and interaction partners, including 
 59 
Figure.III.1	  Homologies	  between	  Dome	  and	  mammalian	  cytokine	  receptors	  
 
 
Figure.III.1 Homologies between Dome and mammalian cytokine receptors. (A) 
Schematic representation of Dome, LIFR and gp130 receptors. Domains are colour-
coded, as described. Numbers indicate the amino acid length of proteins. Adapted from 
Brown et al., 2001. (B) Table representing shared identity between Dome and indicated 
human receptors. Numerical values obtained using ClustalW2 sequence alignment 
analysis tool. (C) Phylogram representing common ancestry of Dome and human 
cytokine receptors. Phylogram generated by ClustalW2 sequence alignment analysis 
tool. 
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oligomerization. Numerous, but certainly not all, mammalian cytokine receptors have 
been investigated for various aspects of regulation, with abundant evidence suggesting a 
link between receptor activation by ligand binding, phosphorylation, ubiquitination and 
receptor endocytosis. In addition, structure-function studies of those receptors have also 
been undertaken. However, no common pattern that could be applied to all receptors has 
been proposed; a testimony to how divergent the mammalian family of cytokine receptors 
truly is, as represented by phylogram (Fig.III.1C).  
The Drosophila JAK/STAT pathway contains only a single positively acting 
receptor and an additional negatively acting regulator that behaves like a constitutively 
inactive receptor termed Eye-transformer or Latran, that can heterodimerize or 
oligomerize with Dome (Brown et al., 2001; Chen et al., 2002; Kallio et al., 2010) 
(Makki et al., 2010). Under homeostatic conditions, Dome has been shown to 
homodimerize in a ligand-independent but tissue-specific manner (Brown et al., 2003). 
The exact mechanisms governing dimer formation as well as its modulators remain to be 
determined, however, in vivo analysis indicates that homodimerization is required for 
JAK/STAT pathway activation, a phenomenon that has also been described for EpoR and 
the Leptin receptor (Ob-R) in mammalian systems (Couturier and Jockers, 2003).  
Endocytosis has been established as a regulator of the JAK/STAT pathway 
activity in mammals as well as in Drosophila (Devergne et al., 2007; Vidal et al., 2010, 
reviewed in Platta and Stenmark, 2011). However, both reports on regulation of the 
JAK/STAT pathway by endocytosis in Drosophila, focused on the general outcomes of 
signalling following manipulation of endocytic machinery. As a tool, endocytosis of 
GFP-fused ligands has previously been visualised in the Zeidler lab and while interaction 
of ligand:Dome has been shown, the fate of the receptor has not been investigated. 
Considering the fact that receptors can potentially be recycled from numerous endocytic 
compartments, it is interesting to see what endocytic process the Drosophila Dome 
receptor undergoes and what governs this process (Grant and Donaldson, 2009; Raiborg 
and Stenmark, 2009; Platta and Stenmark, 2011). 
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III.2. Results  
III.2.1 Over-expression of tagged wild-type Dome does not affect pathway activity 
Of the handful of antibodies against Dome generated by various labs (Ghiglione 
et al., 2002; Stephen Brown, personal communication) all have been used for imaging, 
rather than biochemical techniques. Unfortunately, neither antibody was sufficiently 
specific for my requirements, therefore I used tagged Domeless constructs expressed 
from a constitutive Actin promoter in Kc167 and S2R+ cells. Investigation of the 
expression pattern of Dome-FLAG in S2R+ cells by confocal microscopy shows an even 
distribution of Dome throughout the cell, with enrichment around the plasma membrane  
(Fig.III.2A). Expression of Dome-FLAG in much smaller Kc167 cells appeared 
cytoplasmic with numerous puncta throughout the cell and potentially enriched in the 
epinuclear region (Fig.III.2B). The puncta observed in Kc167 cells appeared bigger 
compared to the ones found in S2R+, however the exact subcellular localization was not 
investigated. This indicates that expression of the constructs used by us is similar to the 
one reported for endogenous protein (Ghiglione et al., 2002). 
Over-expression of proteins in cells can have detrimental effect on physiology of 
cells, often caused by a dominant negative effect. To exclude this possibility, I 
investigated the JAK/STAT pathway activity using a previously established STAT92E 
transcriptional activity reporter termed 6x2xDrafLuc, based on a Firefly luciferase gene 
downstream of a minimal promoter and six multimerised regions from the Drosophila 
Raf promoter each of which contains two potential STAT92E binding sites (activity 
reporter) and Rennila (constitutively expressed viability reporter) luciferase (for detailed 
description see materials and methods) (Müller et al., 2005). Expression of Dome-FLAG 
or Dome-HA did not have any effect on transcriptional pathway activity following ligand 
stimulation (Fig.III.2C). Considering that cytokine receptors become phosphorylated in 
response to ligand stimulation, I also investigated whether Dome constructs were tyrosine 
phosphorylated in response to cytokine stimulation (Fig.III.2D). Immunoprecipitation of 
Dome followed by anti-phosphotyrosine western blotting revealed that Dome is 
phosphorylated under steady state conditions, a modification that increases significantly 
following stimulation. Based on these results, it can be concluded that Kc167 cells 
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Figure.III.2 Expression of Dome constructs does not affect pathway activity. (A, B) 
Confocal images of S2R+ (A) or Kc167 (B) cells transiently transfected with indicated 
plasmid and stained with appropriate antibodies. (A) Transfected Dome has even 
cytoplasmic distribution with enrichment around plasma membrane in large S2R+ cells. 
Blue channel was boosted to show weak DAPI stain. (B) Numerous intracellular puncta 
with perinuclear enrichment observed in Kc167 cells. Arrows indicate transfected cells, 
arrowheads point to not transfected cells. (C) Kc167 cells co-transfected with 6x2xDraf 
luciferase reporters and plasmids carrying HA or FLAG tagged Dome under Actin 
promoter were incubated with mock or Upd2-GFP conditioned media for 4 days. At this 
point luminescence was measured as described in material and methods section (II.2.5). 
Results were normalized to Empty vector transfected cells treated with mock conditioned 
media. Statistical significance was checked with two-way ANOVA followed by 
Bonferroni’s multiple comparisons test. No statistically significant difference was 
observed between Empty vector and Dome-FLAG or Dome-HA transfected cells in mock 
or Upd2-GFP treated group. Error bars represent SEM. (D) Kc167 cells transfected with 
Dome-FLAG were treated with mock or Upd2-GFP conditioned media for 10min and 
lysed. Lysates were subjected to anti-FLAG immunoprecipitation and resolved on SDS-
PAGE gels followed by blotting with anti-phosphotyrosine or anti-FLAG antibody, as 
described in materials and methods (II.3.2). 
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expressing tagged Dome is phosphorylated as expected and does not affect JAK/STAT 
pathway transcriptional activity. 
 
III.2.2 Mutation of Proline925 in Dome weakens the interaction with Hop and acts as a 
dominant negative mutation 
JAK/STAT pathway is a phosphorylation dependent signalling pathway, where 
virtually all components of the pathway, with the exception of the ligand, are 
phosphorylated by the JAK kinase. Dome has been reported to physically associate with 
Hop, however the site of interaction was not determined (Kallio et al., 2010). 
Identification of the interaction site might be of added importance in our studies, 
considering reports on stabilization of the receptor following JAK binding (described in 
Section.I.2.5).  
Lack of Box domains in Dome sequence indicated that Dome might share 
interaction motifs common to class II cytokine receptors, such as interferon receptors. 
Literature searches identified the 266LPKS sequence in IFNγR1 to be required for 
interaction with JAK1 (Kaplan et al., 1996). The proline residue in the sequence has been 
reported to be essential for interaction with JAK. I identified a similar motif in Dome - 
924LPQG, with conserved leucine and proline and very similar structurally remaining two 
residues. Moreover, this motif is located in the same position as the one in IFNγR1, 
precisely 13 amino acids downstream of the trans-membrane domain. I hypothesised that 
mutation of the proline residue might disrupt Dome interaction with Hop, therefore I 
generated a construct in which proline was substituted for isoleucine, generating Dome 
P925I. As a control, pull down of wild-type Dome results in a clear co-
immunoprecipitation of Hop (Fig.III.3A). Introduction of P925I mutation caused a 
significant decrease in Dome:Hop interaction. The remaining weak interaction observed 
might be attributed to Dome P925I dimerizing with endogenous wild-type Dome, 
therefore indirectly associating with Hop. While the change in wild-type Dome 
phosphotyrosine levels in response to ligand stimulation was fairly modest (especially by 
comparison to Fig.III.2D), likely caused by higher level expression of exogenous Hop. 
However, no change in pTyr levels of Dome P925I was observed following stimulation 
with ligand-conditioned media (Fig.III.3A). The decrease in association with Hop was 
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Figure.III.3 Proline925 is required for Dome interaction with Hop. (A) Kc167 cells co-
transfected with FLAG tagged Dome or Dome P925I constructs and Hop-HA were 
stimulated with mock or Upd2-GFP conditioned media as indicated for 10min and lysed 
with Kinase lysis buffer. Lysates were subjected to anti-FLAG immunoprecipitation and 
analysed by SDS-PAGE and western blotting using anti-phosphotyrosine, anti-FLAG or 
anti-HA antibodies, as described in materials and methods section (II.3.2). Top two 
panels represent different film exposure times. (B) Transcriptional activity of Kc167 cells 
transfected with indicated FLAG-tagged constructs and incubated with mock or Upd2-
GFP conditioned media for 4 days was analysed using luminescence assay as 
described in materials and methods section (II.2.5). Results were normalized against 
Empty vector transfected cells treated with mock conditioned media. Statistical 
significance was measured by two-way ANOVA followed by Bonferroni’s multiple 
comparison test. Significance between indicated samples is shown with **, p<0.01. No 
significant difference was observed between the mock treated cells. Error bars represent 
SEM.  
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correlated by a marked decrease in Dome P925I tyrosine phosphorylation at basal levels. 
Moreover, expression of Dome P925I mutant resulted in a significant decrease in 
stimulated pathway activity induced by ligand conditioned media (Fig.III.3B). 
Considering the likely dimerization of Dome (Brown et al., 2003), this decrease in 
pathway activity suggests a dominant negative activity of the Dome P925I mutation. 
These results imply that P925 residue is critical for Dome interaction with Hop and 
indicates that this interaction is required for ligand-mediated pathway activation. 
 
III.2.3 Knockout of tyrosine966 in Dome does not have any effect on pathway activity 
Tyrosine phosphorylation of a receptor by its associated JAK kinase allows for STAT 
binding and therefore is required for pathway activation. Out of 10 tyrosine residues 
present in the cytoplasmic tail of Dome, only one complies with the mammalian STAT3 
consensus binding motif of YxxQ (where x represents any amino acid) – this is the 
tyrosine at position 966 (Y966TPQ) (Fig.III.4A) (Stahl et al., 1995; Gerhartz et al., 1996). 
Another putative STAT92E binding site is Y1022, whose context is similar to the 
mammalian STAT5 consensus motif YLx[VIL] (May et al., 1996). I attempted to 
generate single point mutations substituting aforementioned tyrosines for phenylalanines 
and therefore impair association with STAT92E. Unfortunately, protein containing the 
Y1022F mutation did not express or was not stable and this construct was not pursued 
any further. Expression of Dome Y966F mutant in cells did not affect JAK/STAT 
pathway transcriptional activity as indicated by the 6x2xDrafLuc reporter (Fig.III.4B). I 
further investigated pY levels of this mutant as well as its ability to interact with 
STAT92E (Fig.III.4C). No change in phosphorylation of the receptor was observed upon 
introduction of single-point mutation, which is not surprising considering the number of 
tyrosine residues present in the cytoplasmic tail of Dome. In addition, interaction with 
STAT92E was not affected by ligand stimulation or introduction of the Y966F point 
mutation. Taken together, these results suggest that tyrosine residue at position 966 is not 
essential for JAK/STAT pathway activity.  
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Figure.III.4 Mutation of tyrosine966 residue does not affect pathway activity. (A) 
Schematic representation of the cytoplasmic domain of Dome. Tyrosine at position 966 
was mutated to phenylalanine. Construct that did not express is shown in grey and 
italicised. (B) Transcriptional activity of Kc167 cells transfected with FLAG-tagged 
indicated constructs was measured with the luminescence assay as described in 
materials and methods section (II.2.5) after 4 days of incubation with mock or Upd2-GFP 
conditioned media. Results were normalised to Empty vector transfected cells treated 
with mock conditioned media. No statistically significant difference between samples 
within mock or Upd2-GFP treated group was observed upon analysis with two-way 
ANOVA followed by Bonferroni’s multiple comparisons test. Error bars represent SEM. 
(C) S2R+ cells transfected with Dome-FLAG or Dome P925I-FLAG constructs were 
treated with mock or Upd2-GFP conditioned media as indicated for 10min prior to lysis 
with Kinase IPLB buffer. Lysates were subjected to co-immunoprecipitation of 
endogenous STAT92E following pulldown with anti-FLAG antibody as described in 
materials and methods section (II.3.1). SDS-PAGE with subsequent western blot 
analysis was undertaken using anti-pTyr, anti-FLAG or anti-STAT92E antibodies.  
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Figure.III.5 Dome undergoes constitutive degradation. (A) Kc167 cells batch-transfected 
with Dome-FLAG were treated with cycloheximide at 10µg/ml or its carrier as indicated 
for 30min prior to incubation with Upd2-GFP conditioned media containing CHX at the 
same concentration. Cells were lysed at indicated time points and analysed by SDS-
PAGE followed by western blotting. (B) Dome-FLAG batch-transfected Kc167 cells were 
incubated with CHX at 10µg/ml for 30min prior to as well as during incubation with mock 
(top panel) or Upd2-GFP conditioned media (upper middle panel) for indicated periods of 
time, lysed and analysed with SDS-PAGE and western blotting. (C) Dome-FLAG batch 
transfected Kc167 cells were treated with NHS-biotin to label cell-surface proteins for 1h 
at 4OC. Following wash, cells were incubated with mock or Upd2-GFP conditioned media 
for indicated periods of time at which point they were lysed. Lysates were subjected to 
Streptavidin immunoprecipitation (top two panels) followed by SDS-PAGE and western 
blot analysis. Total protein levels were assessed alongside (middle two panels). 
Experiment was performed in the presence of CHX as described in A. (D and E) 
Quantification of the biotinylated fraction (D) and total protein fraction (E) in C. Results 
were normalised against mock treated biotinylated sample at timepoint 0. “none” 
corresponds to not biotinylated control cells. Two-way ANOVA analysis followed by 
Bonferroni’s multiple comparisons test did not reveal any statistically significant 
differences between mock or Upd2-GFP stimulated cells in the same timepoint. Error 
bars represent SEM.  
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III.2.4 Dome undergoes rapid turnover irrespective of ligand binding 
An integral component of regulation of cytokine signalling is endocytosis of the 
receptor, a process that concludes with receptor degradation or recycling back to the 
plasma membrane following ligand uncoupling (Raiborg and Stenmark, 2009; Platta and 
Stenmark, 2011). Due to the necessity of expressing receptor constructs from the 
exogenous actin promoter, I could not study stability of the receptor without blocking de 
novo protein translation using cyclohexamide (Fig.III.5A). Stimulation of cells with 
ligand conditioned media resulted in a build-up of Dome protein over time in control 
cells. Conversely, in the presence of cyclohexamide I observed a decrease in levels of the 
receptor over time, indicating that Dome is degraded in the presence of ligand 
(Fig.III.5A). Closer investigation of the degradation dynamics of the receptor revealed 
that stimulation with Upd2-GFP resulted in only a mild increase in degradation rate 
compared to the steady state unstimulated conditions (Fig.III.5B). However, the total 
protein fraction investigated might include proteins that are undergoing trafficking to the 
plasma membrane or proteins still undergoing folding in the chaperones. In order to 
obtain better understanding of Dome degradation dynamics, I therefore biotinylated cell 
surface proteins prior to stimulation with mock or ligand-conditioned media (Fig.III.5C). 
Quantification of the biotinylated-receptor levels (ie. that proportion of the receptor pool 
present at the plasma membrane at the beginning of the experiment) indicated that 
plasma-membrane-localised Dome is degraded at a constant rate, with potentially weak 
trend towards enhanced degradation following pathway stimulation (Fig.III.5D). This 
trend was also reflected by quantification of the total receptor levels, which indicates that 
differences between mock and ligand-conditioned media treated cells at all time-points 
are not statistically significant (Fig.III.5E). The degradation time frame is in line with 
previous report by Devergne and colleagues (Devergne et al., 2007). Taken together these 
results indicate that Domeless is degraded at a constant rate that is only modestly 
enhanced by ligand stimulation. 
Endocytosis of the receptor begins with an internalization event, in which the receptor is 
removed from contact with extracellular environment. Hypothesising that degradation 
rate should correlate with internalization rate, I used dextran uptake assay, as a 
measurement tool for the receptor-mediated fluid phase endocytosis, to investigate 
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internalization rate of endogenous Domeless population. Cells were treated with mock or 
ligand conditioned media containing fluorescently labelled dextran for indicated periods 
of time and then washed to remove any extracellular dextran (as described in materials 
and methods). Uptake of dextran appeared not to be homogenous across the cell 
population (Fig.III.6A), therefore I utilized large sample pools and automated analysis 
software to quantify differences between samples. This quantification of dextran intensity 
indicated initially faster uptake by cells treated with mock conditioned media, with 
visible difference at 10min of treatment (Fig.III.6B). Within 30min the difference in 
dextran intensity between control and ligand stimulated cells disappeared, indicating 
potential stabilization of the receptor at the plasma membrane following ligand binding. 
In order to confirm that the dextran internalization observed is mediated by liquid phase 
endocytosis of the receptor, I performed RNAi-mediated knockdown of Dome and 
measured dextran uptake (Fig.III.6C). At 15min of treatment, cells depleted of Dome 
accumulated much less dextran compared to the control cells, indicating that Dome is 
responsible for significant portion of constant plasma membrane turnover in Kc167 cells.  
  
III.2.5 Internalization motifs in Dome remain unknown 
Endocytosis begins with internalization of the receptor that might be triggered by 
different events depending on the context (as described previously in Section.I.3.5).  
Previous reports indicated clathrin mediated endocytosis to act as a regulator of the 
Drosophila JAK/STAT pathway (Devergne et al., 2007; Vidal et al., 2010). Clathrin 
mediated endocytosis of cytokine receptors depends heavily on adaptor molecule AP-2 to 
mediate Clathrin’s interaction with the cargo molecule. The α subunit of AP-2, called α-
adaptin, was identified as a negative regulator of the JAK/STAT pathway in a directed 
RNAi mediated screen (Vidal et al., 2010). Considering the high conservation of the 
molecule across species, I hypothesised that the AP2 binding motif in the receptor will 
also be conserved. Two distinct consensus AP2 binding motifs are commonly accepted:  
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Figure.III.6 Fluid phase endocytosis is affected by Dome but not by ligand presence. (A-
C) Kc167 cells treated with Control or otherwise indicated dsRNA for 4 days were 
incubated with mock or ligand-conditioned media supplemented with fluorescently 
labelled dextran at 1mg/ml, fixed and imaged using Confocal microscope, as described 
in materials and methods section (II.2.7). (A) Representative images of Kc167 cells 
treated with Control dsRNA at 15min of treatment with mock or Upd2-GFP conditioned 
media. (B) Quantification of the intensity of dextran accumulated in cells at indicated 
periods of incubation with mock (black) or Upd2-GFP (grey) conditioned media. At least 
40 cells per condition per timepoint per replicate were analysed using maximal projection 
of Z-stacks obtained, as described in materials and methods section (II.2.8). Student’s T-
test was used for statistical analysis with ***, p<0.05; **. P<0.01; *, p<0.005. Error bars 
represent SEM. (C) Quantification of average dextran intensity per cell at 15min of 
incubation with mock or Upd2-GFP conditioned media in cells treated with Control or 
Dome dsRNA, as described in B.  
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Figure.III.7 Internalization motifs in Dome individually do not play a role in regulation of 
JAK/STAT pathway activity. (A) Schematic representation of cytoplasmic domain of 
Dome with indicated mutated residues. Construct that was not cloned is shown in grey 
and italicised. (B) Transcriptional activity of the pathway in Kc167 cells expressing 
indicated FLAG-tagged constructs was measured after 4 days of incubation with mock or 
Upd2-GFP conditioned media using luminescence assay, as described in materials and 
methods section (II.2.5). Results were normalised to Empty vector transfected cells 
treated with mock conditioned media. Two-way ANOVA followed by Bonferroni’s multiple 
comparisons test analysis did not indicate any statistically significant differences among 
samples treated with mock or Upd2-GFP conditioned media. Error bars represent SEM. 
(C) Kc167 cells transfected with FLAG-tagged indicated constructs were treated with 
mock or Upd2-GFP conditioned media for 15min prior to lysis. To determine stability of 
transfected constructs, lysates were analysed using SDS-PAGE and western blotting, as 
described in materials and methods section (II.3.2)  
,Q
WUD
&
HO
OX
OD
U'
RP
DL
Q
70
7$*
7UDQVPHPEUDQH
GRPDLQ70
)/$*RU+$WDJ7$*
/WR5PXWDWLRQ
/5
$ %
'R
PH

'R
PH
/

5
)/$*
7UDQVIHFWHG
)/$*WDJJHG
7XEXOLQ
8SG*)3   
&
<)
<)
<WR)PXWDWLRQ
<)
'R
PH
<

)
'R
PH
<

)
  
 75 
Yxxφ motif (φ represents bulky hydrophobic amino acid) or acidic dileucine motif 
[E/D]xxxL[L/I] (Ohno et al., 1995; Ehrlich et al., 2001; Bonifacino and Traub, 2003). 
Analysis of Dome intra-cellular domain revealed presence of four tyrosine-based motifs: 
914YRKM, 1022YLAM, 1070YIKP and 1219YTTM; and a single dileucine motif: 981ESSKLL 
(Fig.III.7A). I therefore attempted to generate single point mutations that would impair 
AP2 binding by mutating tyrosine to phenylalanine residues in the putative binding 
motifs. Unfortunately, despite numerous attempts I was unable to generate a molecule 
carrying the Y1070F mutation, which failed due to unknown reasons while the Y1022F 
mutation failed to express, as mentioned previously. However, I was able to generate a 
single point mutation of leucine to arginine at position 985 in the dileucine motif 
(Fig.III.7A). Considering that knockdown of proteins involved in clathrin-mediated 
endocytosis resulted in an increase in 6x2xDrafLuc pathway reporter activity (Müller et 
al., 2005; Vidal et al., 2010), I hypothesised that mutation of sites involved in interaction 
with AP2 would have a similar effect on this reporter. However, none of the mutations 
generated affected reporter activity (Fig.III.7B). Moreover, I did not observe the expected 
increase in stability of the receptor (Fig.III.7C). Although care should be taken when 
interpreting negative results, my data suggests that individual putative AP-2 interaction 
sites do not affect the receptor or signalling output of the pathway, potentially due to the 
redundancy between them, as reported for the EGF receptor (Goh et al., 2010). 
Unfortunately time constraints and focus on other aspects of my project did not allow me 
to generate combinatorial mutations and test this hypothesis for Dome. 
 
III.2.6 Proteins involved in regulation of Dome phosphorylation have no effect on 
Dome stability 
Activation of cytokine receptors by ligand binding is followed by phosphorylation 
events that often lead to receptor endocytosis. Proteins regulating phosphorylation can 
directly or indirectly regulate receptor stability – association with JAKs has been shown 
to stabilize the receptors (Haan et al., 2006; Radtke et al., 2006), while SHP2 has been 
shown to dephosphorylate Y466 of IFNαR therefore allowing AP2 binding (Carbone et 
al., 2012). I showed previously that Dome P925I mutant’s interaction with Hop is  
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Figure.III.8 Hop does not affect stability of the receptor. (A) S2R+ cells transfected with 
Dome-FLAG or Dome P925I-FLAG constructs were treated with mock or Upd2-GFP 
conditioned media for indicated periods of time and lysed. Lysates were analysed by 
SDS-PAGE and western blotting. Experiment was performed in the presence of CHX. 
(B) Quantification of blots as shown in C, n=3. Results were normalised to value 
obtained from cells transfected with the same construct at timepoint 0. Student’s T-test 
revealed no statistical differences between Dome and Dome P925I transfected samples 
at matching timepoints. Error bars represent SEM. (C) S2R+ Cells transfected with 
Dome-HA alone or co-transfected with Hop-HA and stimulated with mock or ligand-
conditioned media for indicated periods of time and lysed. Lysates were analysed with 
SDS-PAGE and western blotting. Experiment was performed in the presence of CHX. 
(D) Quantification of blots as shown in C, n=3. Results were normalised to value 
obtained from cells transfected with the same construct combination at timepoint 0. 
Student’s T-test revealed no statistical differences between Dome and Dome with Hop 
co-transfected samples at matching timepoints. Error bars represent SEM. 
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impaired, therefore it is a suitable model to study whether Hop regulates Dome stability. 
To investigate this aspect, cells expressing wild-type Dome or Dome P925I were 
stimulated with mock or ligand-conditioned media and stability of the transfected 
constructs was assessed (Fig.III.8A). Quantification of the blot revealed no statistically 
significant differences between the two constructs, although Dome P925I was trending 
towards increased stability compared to wild-type Dome under steady state conditions, 
but not following stimulation with ligand (Fig.III.8C and D). In the converse experiment, 
I expressed Dome on its own or together with exogenous Hop. Again, I observed no 
difference in receptor stability (Fig.III.8E and F). Taken together, these results indicate 
that Dome stability is not regulated by Hop.  
 
III.2.7 Genes involved in endocytosis affect Dome stability and JAK/STAT pathway 
activity 
Previous reports on the role of endocytosis in regulating JAK/STAT pathway in 
Drosophila sugested that endocytic processing of ligands was delayed following the 
silencing of genes involved in the process (Vidal et al., 2010). To confirm that the 
receptor follows the same endocytic path as ligands do, I knocked down proteins that play 
key roles in endocytosis - Rab5 is essential for early endosome formation, Deep orange is 
involved in multivesicular body biogenesis and TSG101 is a component of the ESCRT-I 
complex required for sorting of ubiquitinated cargo in the endocytic pathway (Raiborg 
and Stenmark, 2009; Platta and Stenmark, 2011). RNAi-mediated knockdown of those 
proteins resulted in stabilisation of the receptor (Fig.III.9A). Moreover, stimulated but not 
basal JAK/STAT pathway activity was increased in cells treated with dsRNAs against 
endocytic genes, as reported previously (Fig.III.9B) (Müller et al., 2005; Vidal et al., 
2010). Interestingly, knockdown of SOCS36E resulted in stabilisation of the receptor and 
increased pathway activity following treatment with mock or ligand-conditioned media. 
This result will be expanded on in the following chapter. Taken together, this data 
suggests the same route of endocytosis for the receptor and the ligand. 
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Figure.III.9 Genes involved in endocytosis affect Dome stability and pathway activity. (A) 
Kc167 cells batch transfected with Dome-FLAG were split and treated with indicated 
dsRNAs for 4 days prior to lysis. Levels of Dome were assessed by SDS-PAGE and 
western blotting. (B) Transcriptional activity of the pathway in Kc167 cells treated with 
indicated dsRNAs and stimulated with mock or Upd2-GFP conditioned media was 
assessed using luminescence assay, as described in materials and methods section 
(II.2.5). Results were normalised against Control cells treated with mock conditioned 
media. Statistical significance was determined using two-way ANOVA analysis followed 
by Bonferroni’s multiple comparisons test. Stars indicate statistically significant 
difference between dsRNA treatments and Control cells within mock or Upd2-GFP 
stimulated groups, with ***, p<0.005; **, p<0.01.  Error bars represent SEM. 
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III.2.8 Endocytosis of Dome terminates in the lysosome 
Previous reports showed internalised Upd2-GFP localises to lysosomes (Vidal et 
al., 2010). This data coupled with the role of genes central to multivesicular body 
biogenesis in the regulation of Dome stability suggests that the lysosome is likely to be 
the site of receptor degradation. To assess this possibility, I utilised a pharmacological 
approach. Cells expressing Dome-FLAG were stimulated with ligand conditioned media 
in presence of cyclohexamide and either Bafilomycin A1, MG132 or DMSO 
(Fig.III.10A). Addition of the lysosomal inhibitor Bafilomycin A1 very potently inhibited 
Dome degradation in comparison to DMSO, a carrier control. Treatment with MG132, 
widely used as an inhibitor of proteosomal degredation, caused a slight increase in 
protein stability, that was not statistically significant upon quantification (Fig.III.10B). 
These results provide a clear indication that Dome is degraded in the lysosome following 
ligand binding.  
Similar Dome degradation dynamics between the steady state and ligand 
stimulated conditions indicate similar degradation route under both conditions. To 
confirm this, I compared degradation of Dome with and without ligand stimulation in the 
presence of Bafilomycin (Fig.III.10B). Again, I observed efficient inhibition of 
degradation that was irrespective of ligand presence. Moreover, Bafilomycin efficiency 
remained unchanged even at half the recommended concentration (50nM). This suggests 
that Dome undergoes lysosomal degradation irrespective of ligand binding. 
 
III.2.9 Dome undergoes dynamic ubiquitination 
While testing pharmacological agents during my investigation I observed that 
addition of N-Ethylmaleimide (NEM), a known deubiquitinase inhibitor, to ligand 
conditioned media resulted in increased stability of a prominent high molecular weight 
band (arrowhead), not visible in stimulated control cells, but present in cells prior to 
stimulation (Fig.III.11A). Unfortunately, NEM interferes with tubulin assembly (Phelps 
and Walker, 2000), therefore no loading control is available and no conclusion can be 
made regarding overall Dome stability. Increased stability of the top band in the presence 
of deubiquitinase inhibitor implies that Dome is not only ubiquitinated, but also  
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Figure.III.10 Dome undergoes degradation in the lysosome. (A) Kc167 cells batch-
transfected with Dome-FLAG were incubated with 0.2µM Bafilomycin A1, 10µM MG132 
or DMSO and stimulated with Upd2-GFP conditioned media for 2 hours. Control sample 
was not treated with any chemical agent, “pre-stimulation” sample was lysed at the start 
of stimulation with Upd2-GFP conditioned media. Lysates were analysed by SDS-PAGE 
and western blotting. Experiment was performed in the presence of CHX. (B) 
Quantification of data in A, n=3. Quantified values were normalised against Pre-
stimulated sample. Stars above columns reflect statistical significance towards Pre-
stimulated sample, stars above bars reflect statistical significance between indicated 
samples. Statistical significance was determined using ANOVA analysis followed by 
Bonferroni’s multiple comparisons test, with **, p<0.01; *, p<0.05; ns, not significant. 
Error bars represent SEM. (C) Kc167 cells batch-transfected with Dome-FLAG were 
treated with increasing concentrations of Bafilomycin A1, as indicated, and stimulated 
with mock or ligand-conditioned media for two hours prior to lysis. Lysates were 
analysed by SDS-PAGE and western blotting. Control refers to cells not treated with 
pharmacological agent or carrier. Experiment was performed in the presence of CHX. 
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deubiquitinated. To directly assess ubiquitination of Dome, I immunoprecipitated Dome 
followed by blot with anti-ubiquitin antibody (Fig.III.11B). Anti-ubiquitin blot revealed 
double band pattern, suggesting that Dome must exist as two differentially ubiquitinated 
forms. I have not however determined whether the bottom band represents mono-
ubiquitinated fraction or which ubiquitin chains are prevalent, although the presence of 
nine lysine residues in the cytoplasmic domain of Dome implies numerous possibilities 
regarding ubiquitination pattern and ubiquitin chain species. However, the lack of 
difference in the band size or pattern between ligand stimulated and non-stimulated 
samples prompted me to investigate further. I therefore employed a more sensitive 
method, based on pull-down of all ubiquitinated intracellular proteins using an Ubiquitin-
specific high affinity resin termed MultiDsk (Fig.III.11C) (Wilson et al., 2012). 
Surprisingly, a stable poly-ubiquitinated Dome population, represented by top band, was 
observed in both stimulated and non-stimulated samples. However, the lower weight 
band was present only in the stimulated fraction. This implies that ligand mediated 
pathway stimulation causes a distinct change in pattern of Dome ubiquitination, while 
poly-ubiquitination is a common feature of Dome, that is independent of ligand 
treatment.  
 
III.3. Discussion 
This study provides molecular characterization of the only functional receptor of 
the Drosophila JAK/STAT signalling pathway. I showed that despite the lack of Box 
motifs characteristic for type I cytokine receptors, Dome associates with Hop via P952. 
This interaction is crucial for pathway activity as mutation of this residue results in a loss-
of-function phenotype that is dominant in the presence of endogenous Dome. Mutation of 
Hop binding site did not have any effect on receptor stability or its degradation rate, 
indicating that Dome stability is not regulated by phosphorylation. Furthermore, I showed 
that Dome undergoes constitutive lysosomal degradation that is not affected by ligand 
presence. Unfortunately, I was not able to pinpoint the AP-2 or STAT92E binding sites in 
Dome. 
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Figure.III.11 Dome ubiquitination status changes following stimulation. (A) Kc167 cells 
batch transfected with Dome-FLAG were treated with N-Ethylmaleimide (NEM) at 10µM 
or EtOH and stimulated with Upd2-GFP conditioned media for two hours and lysed. 
Lysates were analysed by SDS-PAGE and western blotting. Control refers to non-
treated cells, pre-stimulation refers to cells lysed at the start of incubation with 
conditioned media. Experiment was performed in the presence of CHX. (B) Kc167 cells 
transfected with Dome-FLAG were treated with mock or Upd2-GFP conditioned media 
for 30min prior to lysis in modified lysis buffer, as described in materials and methods 
section (II.3.6). Lysates were subjected to immunoprecipitation with anti-FLAG and 
analysed by SDS-PAGE and western blotting. (C) Kc167 cells were prepared and treated 
as in B. Lysates were subjected to immunoprecipitation using MultiDsk - ubiquitin high 
affinity resin followed by SDS-PAGE and western blotting with anti-FLAG antibody.  
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III.3.1 Interactions with Hop  
Dome has been described as most homologous to mammalian gp130 family of 
cytokine receptors, which share a common Box motifs mediating interaction with JAKs  
(Hackett et al., 1997; Taga and Kishimoto, 1997; Grant and Begley, 1999). I have shown 
that Dome:Hop interaction occurs via a motif that has been characterized for type II 
cytokine receptors. However, position of the Hop interaction site remains in close 
proximity to the membrane, a similarity which might be of particular importance for 
activation of the kinase in response to ligand binding. The juxtamembrane region of 
numerous mammalian receptors that form homodimers has been shown to be essential for 
activity as it mediates conformational change resulting in a shift in orientation of 
cytoplasmic domain, bringing JAKs in close proximity (Kurth et al., 2000; 
Constantinescu et al., 2001; Greiser et al., 2002; Seubert et al., 2003; Staerk et al., 2011). 
Proximity of JAKs is required for their trans-phosphorylation and activation (Matsuda et 
al., 2004). This concept is particularly relevant considering the dominant negative nature 
of P925I mutation in Dome, which suppresses stimulated pathway activity when 
expressed in the presence of endogenous Dome (Fig.III.3B). In a situation where wild-
type Dome:Dome P925I dimers form, conformational changes likely bring the 
cytoplasmic domains of Dome constructs in close proximity, however only one Hop is 
present, therefore no trans-phosphorylation can occur.  
The SH2 domain present in the STAT family of proteins provides specificity 
towards cytokine receptors (Lim and Cao, 2006). STAT92E was characterised as a 
homologue of mammalian STAT5, however, the SH2 domains of mammalian STATs are 
relatively well conserved among family members (Pawson and Schlessingert, 1993; Hou 
et al., 1996). I have identified a single tyrosine residue in the cytoplasmic tail of Dome 
that was reminiscent of STAT5 consensus motif. Unfortunately, mutation of this residue 
produced a construct that did not express. Conversely, mutation of a tyrosine in the 
conserved STAT3 consensus sequence did not have any effects on interaction with 
STAT92E. This implies that STAT92E does not share the same consensus motif with 
STAT3 or there is more than one tyrosine residue able to mediate such interaction. The 
physical association of Dome with STAT92E under steady state conditions and the lack 
of observed increase in this interaction following ligand-mediated pathway stimulation 
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suggests that biochemical techniques are inadequate for such studies, possibly because of 
the transient nature of the interaction. 
 
III.3.2 Constitutive degradation of Domeless 
Modulation of a cell’s competence to receive signals as well as termination of 
signalling from numerous cytokine receptors is frequently achieved by receptor 
endocytosis, which also plays a role in the modulation of signalling output quality 
(reviewed in Raiborg and Stenmark, 2009; Platta and Stenmark, 2011). For this reason it 
is important to understand how receptor endocytosis is initiated and regulated. Numerous 
interlinked processes, such as post-translational modifications, structural changes or 
association partners, can regulate cytokine receptor stability and serve as internalization 
triggers. In contrast to a large majority of cytokine receptors that become endocytosed in 
response to ligand binding, Dome undergoes constitutive endocytosis, even in the 
absence of ligand (Fig.III.5). However, trends indicate that stimulation with ligand-
conditioned media does increase degradation kinetics. Even though quantification of this 
process seems to be statistically insignificant, implications for cell physiology and 
signalling output might be very relevant. The observed delay in internalization in cells 
treated with ligand-conditioned media (Fig.III.6B) might indicate a lag on the plasma 
membrane which, in the context of signalling endosomes, might have implications on the 
quality of the signal. Therefore, a more detailed analysis, including sub-cellular 
localization and kinetics of degradation, will be required for detailed characterization of 
the process.  
Some mammalian cytokine receptors are stabilized by JAK kinase binding. 
However, Dome P925I mutant as well as expression of exogenous Hop did not affect 
degradation rate of the receptor. Moreover, degradation of Dome appeared to be higher 
compared to that of Hop, when co-expressing both proteins together (Fig. III.8C). This 
observation is contrary to the suggestion that receptor:JAK complexes behave like RTKs, 
as this result suggests that Hop is likely to dissociate from the receptor prior to 
degradation in Drosophila cells (Haan et al., 2006).  
Unfortunately, my attempts at identifying the motifs responsible for the initiation 
of endocytosis, which most likely involve AP-2 binding sites, were unsuccessful. First of 
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all, I was unable to generate mutations of all putative sites, with Dome Y1022F and 
Dome Y1070F constructs not expressing. Therefore, it is possible that either of those 
residues is required for AP-2 interaction. Another possibility is that AP-2 interaction sites 
are redundant, as demonstrated for EGFR and OSMR (Radtke et al., 2006; Goh et al., 
2010). It would be interesting to generate constructs with all putative AP-2 interaction 
sites mutated and investigate its impact on pathway activity.  
Finally, ubiquitination of the receptor might modulate receptor stability. My data 
indicates that Dome is constitutively poly-ubiquitinated, a finding which correlates with 
constitutive degradation of the receptor (Fig.III.11B and C). As ubiquitination of the 
cytokine receptors has been shown to regulate not only stability but also determine the 
degradation route and kinetics, it is very likely that the same process takes place for 
Dome (Haglund et al., 2003; Belouzard and Rouillé, 2006; Shabek et al., 2009). 
Interestingly, I observed a change in Dome ubiquitination pattern in response to pathway 
stimulation, with a lower molecular weight band appearing in response to ligand 
treatment. Whether this modification is causative for the delay in receptor-mediated fluid 
phase endocytosis (Fig. III.6) and the trend of increased degradation kinetics following 
pathway stimulation (Fig.III.5), remains to be determined. Further evidence for how 
dynamic the relationship between ubiquitination and degradation is, comes from 
stabilization of the higher molecular weight band (corresponding to the polyubiquitinated 
Dome) following treatment with deubiquitinase inhibitors. The process of dynamic 
ubiquitination, where deubiquitinases play important roles was previously described for 
mammalian cytokine receptors, further support the similarity between Dome and 
mammalian cytokine receptors (reviewed in Clague and Urbé, 2010). 
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Chapter IV Drosophila SOCS36E regulates the JAK/STAT 
pathway via two independent mechanisms 
 
IV.1. Introduction 
JAK/STAT signalling pathway plays numerous essential roles in development 
and maintenance of homeostasis (Arbouzova and Zeidler, 2006; Vainchenker and 
Constantinescu, 2013). Not surprisingly, numerous regulators of the pathway activity 
exist. One of the best characterised families of negative regulators is SOCS family of 
proteins. Similarly to the core pathway components, SOCS proteins have been conserved 
in Drosophila at lower redundancy with the Drosophila genome encoding three SOCS-
like proteins (Callus and Mathey-Prevot, 2002; Karsten et al., 2002; Rawlings et al., 
2004), however only SOCS36E can potently suppress the JAK/STAT pathway (reviewed 
in Stec and Zeidler, 2011).  
 
IV.1.1 Drosophila JAK/STAT pathway activity induces socs36E expression 
 Previous studies have characterised socs36E mRNA expression profile to be 
similar to the one observed for Upd expression and in line with the JAK/STAT pathway 
activity in vivo (Karsten et al., 2002; Stec and Zeidler, 2011). Indeed, socs36E promoter 
region contains 19 putative STAT92E binding sites (Karsten et al., 2002) and cell culture 
experiments confirmed socs36E to be a strong transcriptional target for STAT92E (Bina 
et al., 2010). Flies mutant for JAK/STAT pathway ligands or Hop kinase display much 
lower socs36E mRNA expression (Karsten et al., 2002; Rawlings et al., 2004), while 
ectopic-activation of the pathway with HopTuml kinase or ectopic ligand expression causes 
an increase in socs36E transcription (Karsten et al., 2002). This indicates that SOCS36E 
acts in a classical negative feedback loop, similar to the mammalian SOCS proteins (Starr 
et al., 1997). 
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IV.1.2 SOCS36E regulates the JAK/STAT pathway activity 
Role of SOCS36E as the negative regulator of the JAK/STAT pathway has been 
established both in vivo and in vitro (reviewed in Stec and Zeidler, 2011). Indeed, 
numerous cell culture assays, including genome wide RNAi screens, used SOCS36E as a 
control (Baeg et al., 2005; Müller et al., 2005; Vidal et al., 2010; Wright et al., 2011). 
However, the function of SOCS36E in vivo remains cryptic, as null mutants are 
homozygous viable and fertile (Bellen et al., 2004; Almudi et al., 2009). At the same 
time, over-expression of Hop leads to lethality that can be rescued by SOCS36E 
expression (Callus and Mathey-Prevot, 2002). Detailed analysis of JAK/STAT pathway 
reveals that ectopic expression of SOCS36E has been reported to cause wing venation 
and wing posture defects characteristic for upd, hop or stat92E mutants (H.J.Muller, 
1930; Yan et al., 1996a; Callus and Mathey-Prevot, 2002). Moreover, SOCS36E has 
been shown to regulate stem cell maintenance and niche integrity in the testis as well as 
specification and migration of border cells in the ovary, processes that require JAK/STAT 
pathway activity (Silver et al., 2005; Singh et al., 2010; Monahan and Starz-Gaiano, 
2013). Also the size and number of melanotic tumours in flies heterozygous for the 
constitutively active HopTuml allele can be reduced by ectopic expression of SOCS36E, 
while the converse situation, mediated by silencing of socs36E mRNA, is also true (Luo et 
al., 1997; Heinrich et al., 1998; Rane and Reddy, 2000; De Celis and Diaz-Benjumea, 
2003; Bina et al., 2010).   
 
IV.1.3 SOCS36E plays a role in regulation of the EGFR pathway 
The JAK/STAT and EGFR signalling pathways have been found to cross-talk in 
numerous model systems (Shilo, 2003; Rawlings et al., 2004). Not surprisingly, the 
regulatory mechanisms are shared by the two pathways, with mammalian SOCS4 and 5 
proteins involved in regulation of the stability of EGF receptor (Kario et al., 2005; 
Nicholson et al., 2005; Bullock et al., 2007). Studies on photoreceptor cell specification 
in the developing Drosophila eye and wing venation implicate SOCS36E to be involved 
in regulation of the EGFR pathway in a JAK/STAT independent manner (Callus and 
Mathey-Prevot, 2002; Almudi et al., 2009). Moreover, interaction between Sevenless and 
SOCS36E has been found to be direct and dependent on the SH2 domain  
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Figure.IV.1 Homology of SOCS36E. (A) Schematic representation of human SOCS4 and 
5 and Drosophila SOCS36E and homology shared between the proteins. Numbers 
between dashed lines indicate shared identity in the region indicated. SB indicates 
SOCS box domain. (B) Shared identity in the indicated regions between human SOCS 
molecules and dSOCS36E. Numbers in brackets represent amino acid sequence length. 
Domains determined by NCBI Conserved Domains Search tool. (C) Phylogram 
representing common ancestry of human and Drosophila SOCS proteins. Phylogram 
generated by ClustalW2 sequence alignment analysis tool. 
 89 
(Almudi et al., 2010). While regulation of the EGFR pathway is of tremendous 
importance for physiology, this aspect of SOCS36E activity has not been investigated in 
this study.  
 
IV.1.4 Structure of SOCS36E resembles mammalian SOCS4 and 5 
Sequence alignment tools clearly indicate SOCS36E to be most homologous to 
mammalian SOCS4 and 5 (Fig.IV.1A and B) (Callus and Mathey-Prevot, 2002). Most of 
the homology between proteins is located in the SH2 and SOCS box domains, while the 
N-terminal is not conserved. (Fig.IV.1B). Regions of homology are not surprising, 
considering the same regions are the most conserved within the members of the 
mammalian SOCS family (Larsen and Röpke, 2002). The N-terminal domain of 
SOCS36E is larger than that of mammalian SOCS proteins, even the long N-terminal 
domains of SOCS4-7. Computational analysis has not revealed presence of kinase 
inhibitory region in SOCS36E, characteristic for SOCS1 and 3.  
 Phylogenic analysis suggests that mammalian short N-terminal SOCS proteins 
emerged after the divergence of mammalian and insect SOCS proteins, suggesting a 
common ancestry for SOCS36E and SOCS4 and 5 (Fig.IV.1C). Interestingly, SOCS-like 
molecules with long N-terminals have been described in other invertebrate model 
organisms, including Manduca sexta and Tribolium (Elliott and Zeidler, 2008; Bäumer et 
al., 2011). 
 
IV.1.5 SOCS36E might play a role in endocytic regulation of the JAK/STAT pathway 
 Despite being used in numerous cell culture based assays, the mechanism of 
function of SOCS36E remains unknown. During investigation of the roles of endocytic 
machinery in regulation of the JAK/STAT pathway activity, a previous PhD student in 
the Zeidler lab, Oscar Vidal, observed a delay in clearing of the internalised Upd2-GFP 
from cells deprived of SOCS36E, a phenotype similar to that observed upon knockdown 
of genes involved in endocytosis (Fig.IV.2) (Vidal, 2010). Considering that Upd and 
Upd2 bind to the only Drosophila cytokine receptor Domeless, it is therefore possible 
that SOCS36E might be involved in endocytic processing of the ligand-receptor complex  
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Figure.IV.2 SOCS36E is involved in degradation of internalized Upd2-GFP. Kc167 cells 
treated with indicated dsRNAs for 4 days were pulsed with Upd2-GFP conditioned media 
at 4OC and shifter to room temperature. At indicated time points cells were washed with 
acidic buffer to remove any ligand remaining on the plasma membrane. At this point, 
cells were fixed and imaged on Confocal microscope.  
Image adapted from Vidal, 2010. 
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Figure.IV.3 SOCS36E co-localizes with Dome in the follicle cells in Drosophila ovary. (A-
D) Ovaries from the wildtype fly were dissected  and stained with antibodies against 
Dome and SOCS36E. (A) Dome has cytoplasmic distribution with occasional puncta. (B) 
SOCS36E is dispersed in the cytoplasm and accumulates in the puncta. (C) Merge of A 
and B, Dome shown in red, SOCS36E shown in green. Yellow box marks the region 
zoomed on in D. White arrows point to overlapping puncta.  
Images obtained by Nina Bausek, unpublished data. 
 92 
(Devergne et al., 2007; Vidal et al., 2010). This hypothesis is supported by co-
localization of SOCS36E with Dome in follicle cells in the ovary (Nina Bausek, 
unpublished data). Interestingly, co-localization of Dome with SOCS36E is observed in 
the intracellular puncta, which might represent endocytic vesicles or endosomes, 
internalised structures which have been shown previously to be the destination organelle 
for internalized ligands (Devergne et al., 2007; Vidal et al., 2010). Based on the current 
understanding of the function of mammalian SOCS molecules and the data obtained by 
Nina Bausek and Oscar Vidal, I hypothesised that SOCS36E might regulate the 
JAK/STAT pathway activity by affecting stability of the receptor.  
 
IV.2. Results 
IV.2.1 Elongins B/C and Cullin 5 are negative regulators of the activated JAK/STAT 
pathway 
Given the similarly to mammalian SOCS proteins, I hypothesised that SOCS36E 
might be involved in formation of E3 ubiquitin ligase complexes, as described previously 
(Section I.3.1). ElonginB, ElonginC and Cullin 5 are well conserved between human and 
fly, sharing 55%, 90% and 65% identity, repectively. I therefore assessed transcriptional 
activity of the pathway in cells deprived of the putative ubiquitin ligase complex 
components, Elongins B/C and Cullin 5. RNAi-mediated knockdown of Elongins B/C, 
Cullin 5 and SOCS36E caused an increase in pathway activity following stimulation with 
Upd2-GFP conditioned media (Fig.IV.4A), suggesting that components of the ECS 
complex act as negative regulators of the activated pathway. The increase caused by 
knockdown of Elongins B/C and Cullin 5 was quantitatively similar to that observed 
upon ablation of proteins involved in endocytosis - Rab5, TSG101 and Dor. Knockdown 
of SOCS36E increased pathway activity to higher degree than knockdown of Elongins 
B/C and Cullin 5 following stimulation (Fig.IV.4A). Investigation of the pathway activity 
under steady state conditions in the same RNAi backgrounds indicated that Elongins B/C 
and Cullin 5 do not regulate the basal activity of the pathway, similarly to genes involved 
in endocytosis (Fig.IV.4B). Only knockdown of SOCS36E caused an increase in basal 
pathway activity. Taken together these results indicate that Elongins B/C and Cullin 5 
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Figure.IV.4 Components of the ECS complex negatively regulate the activated 
JAK/STAT pathway. Transcriptional pathway activity was measured by 6x2xDrafLuc 
reporter in Kc167 cells treated with indicated dsRNAs and incubated with Upd2-GFP (A) 
or mock conditioned media (B), as described in materials and methods section (II.2.5). 
Dome and STAT92E knockdowns act as controls. Results were normalised to Control 
cells in both conditions. To represent lower pathway activity in mock treated cells 
compared to Upd2-GFP treated cells, normalisation was performed to 0.1. Stars above 
columns represent statistical significance between the column and Control sample. Stars 
above bars indicate statistical significance between indicated samples. Statistical 
significance was analysed by ANOVA followed by Boferroni’s multiple comparisons test, 
with ***, p<0.005; **, p<0.01; *, p<0.05. Error bars represent SEM.  
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regulate the activity of the pathway only following stimulation, while SOCS36E is 
involved in regulation of both basal and activated pathway signalling.  
 
IV.2.2 Elongins B/C and Cullin 5 affect Dome stability 
Having established that components of the ECS complex negatively regulate the 
pathway, I next investigated whether they affect stability of the receptor. RNAi-mediated 
knockdown of ECS components resulted in increased stability of the receptor, however 
the increase was not as potent as in the case of Dor knockdown (Fig.IV.5A). This 
indicates that ECS complex is involved in regulation of Dome stability under steady state 
conditions, however it is not necessary for the process.  
Similar conclusion was made upon investigation of Dome degradation in 
SOCS36E or Elongin B RNAi background upon ligand-mediated pathway stimulation 
(Fig.IV.5B). Knockdown of SOCS36E or Elongin B caused mild stabilization of the 
receptor at 5 hours post treatment with mock or ligand conditioned media, compared to 
control cells. Again, lack of complete inhibition of degradation implies that ECS complex 
is not the only mechanism implicated in Dome degradation, but rather ECS is accessory 
to the process.  
 
IV.2.3 SOCS36E negatively regulates the JAK/STAT pathway not only via ECS 
complex formation 
Pathway activity following individual knockdown of SOCS36E and Elongins B/C 
and Cullin 5 suggested that SOCS36E is more potent negative regulator than other 
components of the ECS complex (Fig.IV.4). This result was in line with the original 
report characterising SOCS36E in vivo that indicated negative regulatory activity of the 
protein even after SOCS box truncation (Callus and Mathey-Prevot, 2002). 
Hypothesising that SOCS36E can utilise mechanism separate from ECS, I ablated 
different combinations of ECS components in cells and investigated pathway activity. 
Cells treated with three dsRNAs targetting Elongins B/C and Cullin 5 did not display 
additive effect of knockdown under ligand-stimulated conditions (Fig.IV.6A). 
Considering that formation of the ECS complex requires presence of all components, this  
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Figure.IV.5 ECS complex components regulate stability of Domeless. (A) Dome-FLAG 
batch-transfected Kc167 cells were treated with indicated dsRNAs for 4 days. At this point 
cells were lysed and lysates analysed with SDS-PAGE and western blotting. (B) Dome-
FLAG batch-transfected S2R+ cells were treated with indicated dsRNAs for 4 days and 
treated with mock or Upd2-GFP conditioned media. After 5 hours of treatment, cells 
were lysed and lysates were analysed with SDS-PAGE and western blotting. Sample 
indicated as “0” was lysate at the start of stimulation.  
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Figure.IV.6 SOCS36E regulates the JAK/STAT pathway via mechanism additional to 
and independent of ubiquitin ligase formation. (A, B) Transcriptional activity in Kc167 cells 
treated for 4 days with indicated dsRNAs was measured with 6x2xDraf luminescence 
assay, as described in materials and methods section (II.2.5). Individual genes were 
targeted by the same quantity of dsRNA with the total amount of dsRNA kept constant 
by the addition of control dsRNA. Along with the dsRNA treatment cells were incubated 
with Upd2-GFP (A) or mock conditioned media (B). (C) Transcriptional pathway activity 
in Kc167 cells transfected with Empty vector or SOCS36E and treated with Control or 
Dome dsRNA for 4 days prior to measurement with 6x2xDraf luminescence assay. 
During dsRNA treatment, cells were stimulated with Upd2-GFP. Stars above columns 
indicate statistical significance relative to Control cells within the experimental conditions 
(A and B) or Empty vector transfected cells treated with Control dsRNA (C). Results 
were normalised to the same samples. In B normalisation was performed to 0.1 to 
symbolise lower pathway activity relative to A. Statistical analysis was performed using 
two-way ANOVA followed by Bonferroni’s multiple comparisons test, with ***, p<0.005; 
**, p<0.01; *. P<0.05.  
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result is not surprising (Babon et al., 2009). However, knockdown of SOCS36E on its 
own or in combination with Elongins B/C or Cullin 5 resulted in a more dramatic 
increase in pathway activity compared to knockdowns of ECS components alone 
(Fig.IV.6A). This indicates that SOCS36E can suppress the JAK/STAT pathway via 
mechanism additional to ubiquitin ligase formation.  
 I previously observed that knockdown of Elongins B/C and Cullin 5 had no effect 
on basal pathway activity under steady state conditions (Fig.IV.4B). In addition, 
combinatorial knockdowns did not produce additive effect on the basal pathway activity 
either (Fig.IV.6B).  In contrast, knockdown of SOCS36E by itself, or simultaneously 
with the remaining components of ECS complex resulted in increased accumulation of 
the luciferase reporter under steady state conditions.  This indicates that SOCS36E 
suppresses the basal JAK/STAT pathway activity even in the absence of other ECS 
components via mechanism that must therefore be independent of ECS complex 
formation.  
Over-expression of SOCS36E causes suppression of the JAK/STAT pathway 
activity in vivo (Callus and Mathey-Prevot, 2002; Rawlings et al., 2004; Bina et al., 
2010; Singh et al., 2010). I observed similar effect in tissue culture cells (Fig.IV.6C). 
Suppression of the pathway caused by SOCS36E over-expression was quantitatively 
similar to the one observed following RNAi-mediated knockdown of Dome. However, 
those two conditions were additive as simultaneous over-expression of SOCS36E and 
ablation of Dome resulted in further suppression of the pathway (Fig.IV.6C). This 
suggests that SOCS36E can suppress the pathway not only by regulating receptor 
stability. 
 
IV.2.4 Truncation of the N- or C-terminal of SOCS36E does not change the sub-
cellular localization 
To investigate the additional mechanism utilised by SOCS36E, I undertook a 
structure-function analysis of the molecule. I generated N- and C-terminal truncations, 
referred to as ΔN and ΔSB respectively (Fig.IV.7A). Based on reports indicating 
positional requirements for arginine residue in the SH2 domain for interaction with pY, I  
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generated a single point mutation in the SH2 domain, substituting arginine residue for 
glutamine acid (R499E) – construct referred to as SH2* (Fig.IV.7A) (Marengere and 
Pawson, 1992; Kamura et al., 1998).  This mutation should prevent binding to tyrosine 
phosphorylated substrates and previous report indicated this mutation to render protein 
unable to suppress the JAK/STAT pathway when over-expressed in vivo (Callus and 
Mathey-Prevot, 2002). As a first step in assessing generated constructs, I adjusted the 
amount of DNA transfected so as to express equivalent protein levels as assessed by 
western blotting (Fig.IV.7B). Sub-cellular localization was investigated by 
immunofluorescence with all constructs localizing predominantly to the cytoplasm with 
epinuclear enrichment in case of the full-length, ΔN and ΔSB constructs (Fig.IV.7D-F). 
SOCS36E SH2* construct appeared predominantly cytoplasmic (Fig.IV.7G). Both 
truncation and SH2 domain mutation constructs displayed sub-cellular localization 
similar to the full-length protein, which was reminiscent of reports describing the 
endogenous or over-expressed SOCS36E both in vivo and ex vivo (Almudi et al., 2009, 
2010; Herranz et al., 2012).  
 
IV.2.5 N- and C-termini can suppress the JAK/STAT pathway separately 
I next investigated the generated constructs on the functional level, using the 
6x2xDrafLuc reporter of pathway transcriptional activity. Expression of the full-length 
protein as well as the C-terminal truncation construct resulted in a decrease in basal 
pathway activity under steady state conditions (Fig.IV.8A).  In contrast, ablation of the 
N-terminal did not decrease STAT92E transcriptional activity, indicating that the SOCS 
box domain does not modulate the basal activity of the pathway. Interestingly, expression 
of the point mutation in the SH2 domain (SH2*) thought to prevent binding to pY 
substrates caused an increase in pathway activity, potentially due to sequestration of 
unidentified co-factors that would otherwise interact with endogenous SOCS36E, 
however this possibility was not investigated any further (Fig.IV.8A). Taken together, 
these data suggests a role for the N-terminal in suppression of spontaneous firing of the 
JAK/STAT pathway under steady state conditions.  
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Figure.IV.7 SOCS36E constructs. (A) Schematic representation of generated 
SOCS36E constructs. (B) Western blot analysis of constructs shown in A expressed in 
Kc167 cells. (C-G) Images from Confocal microscopy showing sub-cellular localization of 
SOCS36E constructs. Colour legend for panels C-G shown in C. 
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Confirmation of functionality of the N-terminal came from investigation of 
pathway activity following stimulation with Upd2-GFP conditioned media. Both 
truncated versions of SOCS36E were able to suppress pathway activity compared to the 
control cells, however that suppression was not as efficient as that elicited by the full-
length protein (Fig.IV.8B). The SH2* mutant did not affect pathway activity, implying 
that binding to phosphorylated tyrosine residue is required for both activities of 
SOCS36E. These results indicate that both N- and C-termini along with a functional SH2 
domain are required for regulation of the pathway activity following stimulation.  
As truncation of the N-terminal left only the SH2 domain and SOCS box intact, I 
investigated whether the ΔN mutant can affect pathway activity in an ECS independent 
manner. Therefore, I expressed the SOCS36E constructs in cells treated with dsRNA 
targeting Elongins B/C and Cullin 5 and incubated cells with pathway ligand conditioned 
media. Knockdown of Elongins B/C and Cullin 5 increased the pathway activity as 
shown previously (Fig.IV.6). This increase was suppressed by the full-length SOCS36E 
and SOCS36EΔSB constructs. By contrast, the ΔN mutant was unable to decrease the 
pathway activity under these conditions (Fig.IV.8C). Considering that the N-terminal 
truncated construct was able to suppress the pathway in the presence of Elongins B/C and 
Cullin 5, this confirms that SOCS box of SOCS36E is indeed required for formation of 
the putative ECS ubiquitin ligase. Moreover, these results strongly suggest that the N-
terminal of SOCS36E functions as a negative regulator of the pathway via mechanism 
independent of ECS complex formation. 
 
IV.2.6 SOCS box and SH2 domains are required for regulation of Dome levels 
 As an independent approach to examine the separate functions of the N- and C-
terminal of SOCS36E, I next assessed the effect of expressing the SOCS36E constructs 
on Dome levels. I co-transfected constant levels of Dome with increasing dosage of 
SOCS36E constructs and subsequently examined the steady state level of Dome protein. 
The full-length SOCS36E construct negatively affected stability of the receptor even at 
very low expression levels (Fig.IV.9). In contrast, high levels of protein were required to 
obtain the similar effect with the SOCS36EΔN construct. SOCS36EΔSB and SH2* 
constructs had no effect on Dome stability, even at high protein levels. This indicates that  
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Figure.IV.8 N- and C-termini of SOCS36E are required for suppression of the JAK/STAT 
pathway. (A-C) Transcriptional JAK/STAT pathway activity in cells expressing SOCS36E 
constructs was measured by 6x2xDrafLuc reporter. Cells were treated with mock (A) or 
Upd2-GFP conditioned media (B and C) for 4 days prior to quantification. (C) In addition 
to transfection, cells were treated with Control or a combination of ElonginB/C and Cullin 
5 dsRNAs. Total amount of dsRNA was kept constant, as described in materials and 
methods section. All results were normalised to Empty vector transfected cells (treated 
with Control dsRNA in C). Stars above columns reflect statistical significance between 
the Empty vector and indicated sample (in C, ElonginB/C and Cullin5 treated Empty 
vector cells were used to analyse statistical significance against). Statistical significance 
was analysed with ANOVA with Bonferroni’s multiple comparisons test with ***, p<0.005; 
**, p<0.01; *, p<0.05. 
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Figure.IV.9 SOCS box and a functional SH2 domain are required for regulation of Dome 
stability. S2R+ cells co-transfected with constant amount of Dome and increasing 
concentrations of SOCS36E constructs, as indicated.  
 
regulation of Dome stability requires the SOCS box domain of SOCS36E together with 
an intact SH2 domain. 
 
IV.2.7 Interaction of Dome with SOCS36E requires intact SH2 domain and is 
stabilised by the N-terminal domain of SOCS36E 
Mammalian SOCS1 has been shown to interact preferentially with JAKs, while 
the remainder of mammalian SOCS proteins have been reported to have higher affinity 
for the associated receptors or the JAK:receptor complexes (Piganis et al., 2011; Kershaw 
et al., 2013, reviewed in Croker et al., 2008; Yoshimura, 2009). To determine binding 
partners of SOCS36E, I next co-expressed Dome or Hop together with SOCS36E and 
pulled down Dome or Hop. Interaction of SOCS36E with Dome was much stronger than 
that with Hop (Fig.IV.10A). Furthermore, knockdown of Hop did not affect the 
Dome:SOCS36E interaction, implying that this interaction is direct. By contrast, 
SOCS36E interaction with Hop was much less robust and was further weakened by 
Dome knockdown. This indicates that SOCS36E:Hop interaction is at least partially 
dependent on Dome, a phenomenon also observed for mammalian SOCS proteins 
(Fig.IV.10A) (Starr and Hilton, 1998; Yoshimura, 2009). Interestingly, interaction of 
SOCS36E with the receptor or JAK remained unaffected by stimulation of the pathway. 
While I have previously shown that Dome is constitutively tyrosine phosphorylated,  
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Figure.IV.10 The N-terminal and SH2 domains are required for SOCS36E interaction 
with Dome. (A) Kc167 cells co-transfected with SOCS36E-FLAG and Dome-HA, Hop-HA 
or Empty vector were treated with Control (LacZ), Hop or Dome dsRNAs, as indicated, 
for 4 days. Prior to lysis, cells were stimulated for 15min with mock or Upd2-GFP 
conditioned media. Lysates were subjected to anti-HA immunoprcipitation and 
subsequent analysis with SDS-PAGE and western blotting. (B) Kc167 cells transfected 
with Hop-HA were treated for 15min with mock or Upd2-GFP conditioned media and 
lysed with lysis buffer supplemented with phosphatase inhibitors. Lysates were 
subjected to anti-HA immunoprecipitation followed by SDS-PAGE and western blotting. 
(C) S2R+ cells were co-transfected with Dome-HA and FLAG-tagged SOCS36E 
constructs, as indicated. Prior to lysis, cells were incubated with mock or ligand 
conditioned media for 15min. Lysates were subjected to anti-HA immunoprecipitation 
followed by SDS-PAGE and western blot analysis.  
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therefore enabling interaction with SOCS36E via its SH2 domain (Fig.III.3), I also 
investigated Hop phosphorylation levels. I observed that tyrosine phosphorylation of Hop 
under steady state conditions was increased upon pathway stimulation, similar to that 
observed for Dome (Fig.IV.10B, Fig.III.3, respectively).  These results indicate that 
SOCS36E preferentially interacts with the constitutively phosphorylated receptor of the 
pathway. 
 In order to identify the regions necessary for the interaction of SOCS36E with 
Dome I made use of the SOCS36E truncations (Fig.IV.10C). I found that full-length 
SOCS36E as well as the SOCS36EΔSB constructs co-immunoprecipitate with Dome in a 
ligand independent manner. As expected, SOCS36E SH2* did not precipitate with Dome, 
confirming that Dome:SOCS36E interaction is mediated by the SH2 domain.  No 
detectable interaction with SOCS36EΔN implies involvement of the N-terminal region in 
interaction (Fig.IV.10C). This would also explain why high levels of ΔN construct 
expression were required to destabilise the receptor (Fig.IV.9). Taken together, these 
results demonstrate that SOCS36E:Dome interaction requires both an intact SH2 domain 
and the N-terminal region.  
 
IV.2.8 Full-length SOCS36E can suppress phosphorylation of Dome in response to 
ligand-mediated pathway stimulation 
Involvement of the N-terminal region of SOCS36E for interaction with Dome 
does not however explain why the SOCS36EΔSB construct can suppress pathway 
activity (Fig.IV.6). I hypothesised that the N-terminal of SOCS36E may regulate kinase 
activity. As cytokine receptors are substrates of their associated JAK kinases, I analysed 
the pTyr levels of Dome and Hop in SOCS36E RNAi background. Stimulation with 
pathway ligand resulted in increased pTyr levels of both Dome and Hop in control and 
SOCS36E RNAi background (Fig.IV.11A). However, knockdown of SOCS36E caused 
elevated pTyr levels of Dome under steady state as well as stimulated conditions. Hop 
phosphorylation remained unaffected by SOCS36E ablation. This indicates that 
SOCS36E might be involved in the regulation of Dome phosphorylation. 
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In the converse experiment, I co-expressed Hop and Dome with SOCS36E 
constructs and quantified blots of Dome and Hop pTyr levels from three independent 
experiments to identify any trends. Co-expression of full-length SOCS36E prevented 
Dome phosphorylation in response to pathway stimulation (Fig.IV.11B and quantified in 
C). In contrast, SOCS36EΔN and SH2* constructs had no effect on Dome 
phosphorylation, while SOCS36EΔSB mildly increased basal levels of Dome 
phosphorylation. These results indicate that both N- and C-termini as well as the SH2 
domain of SOCS36E are required to suppress Dome phosphorylation upon ligand 
binding. 
 
IV.2.9 SOCS36E constructs do not affect Hop phosphorylation 
Based on previous results, I hypothesised that the N-terminal of SOCS36E might 
be involved in either masking of tyrosine residues on Dome or regulating the catalytic 
activity of Hop. Quantification of Hop tyrosine phosphorylation when co-expressed with 
SOCS36E constructs indicated that both truncations and the SOCS36E SH2* constructs 
lead to a mild elevation of Hop phosphorylation under steady-state conditions 
(Fig.IV.11B and quantified in D). The full-length SOCS36E had no effect on Hop 
phosphorylation and neither of the SOCS36E constructs affected Hop phosphorylation in 
response to ligand-mediated pathway stimulation. To clarify whether SOCS36E 
constructs can affect Hop catalytic activity, I made use of the fact that JAKs undergo 
auto-phosphorylation (Saharinen et al., 2000; Matsuda et al., 2004; Funakoshi-Tago et 
al., 2006). Based on this phenomenon, I established and conducted in vitro kinase activity 
assays, using incorporation of radiolabelled phosphate from 32P γ-ATP as the readout of 
Hop auto-activity. SOCS36E constructs were synthesised de novo to avoid contamination 
with potential co-factors or extracted from cells to ensure correct folding (Fig.IV.12A and 
B, respectively). Irrespective of method used, no change in Hop auto-phosphorylation 
was observed (Fig.IV.12C). While inherently a negative result, this at least suggests that 
SOCS36E does not affect Hop catalytic activity. 
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Figure.IV.11 Full-length SOCS36E regulates Dome phosphorylation. (A) Kc167 cells co-
transfected with Dome-HA and Hop-HA were treated with Control or SOCS36E dsRNAs 
for 4 days. Prior to lysis with lysis buffer supplemented with phosphatase inhibitors, cells 
were incubated for 10min with Upd2-GFP or mock conditioned media. Lysates were 
subjected to anti-HA immunoprecipitation and subsequent SDS-PAGE and western blot 
analysis. Arrow indicates Dome, arrowhead indicates Hop. (B) Kc167 cells co-transfected 
with Dome-HA, Hop-HA and FLAG-tagged indicated SOCS36E construct were treated 
and analysed as described in A. (C, D) Quantifications of Dome (C) or Hop (D) 
phosphorylation levels, determined by ratio of band observed in pTyr blot and HA blot, 
under experimental settings as shown in B, n=3. Error bars indicate SEM. No statistically 
significant difference between mock or Upd2-GFP stimulated cells transfected with the 
same constructs was observed following analysis with two-way ANOVA and Bonferroni’s 
multiple comparisons test.  
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Figure.IV.12 SOCS36E does not affect catalytic activity of Hop. (A, B) S2R+ cells were 
transfected with Hop-HA and lysed. Hop-HA was immunoprecipitated and left on beads 
that were used in in vitro kinase activity assay. Assays were performed using 32P γ-ATP 
and assessed by incorporation of radioactive phosphate onto Hop-HA, as described in 
materials and methods section (II.3.4). (A) Kinase activity assay reaction was 
supplement with SOCS36E constructs obtained by de novo synthesis in E.Coli extracts, 
as described in materials and methods section (II.3.3). Synthesised SOCS36E 
constructs were labelled with 35S-Methionine. (B) SOCS36E constructs used to 
supplement the kinase activity assay reaction were obtained by immunoprecipitation of 
FLAG-tagged SOCS36E constructs from transfected S2R+ cells and subsequent elution 
using 3xFLAG peptide. See materials and methods for details. (C) Amount of 
incorporated 32P into Hop-HA in kinase activity assays performed as shown in A and B 
was quantified using phosphorimager. Quantifications were normalised to Control 
reaction within experiment. Results were pooled irrespective of method used to obtain 
SOCS36E constructs with total n=6. No statistically significant difference was observed 
between samples when analysed with two-way ANOVA followed by Bonferroni’s multiple 
comparisons test. Error bars represent SEM. 
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IV.2.10 SOCS36E suppresses STAT92E phosphorylation 
The ability of full-length SOCS36E to suppress Dome phosphorylation in 
response to ligand stimulation without affecting Hop auto-phosphorylation implies steric 
inhibition of Hop by SOCS36E. As transduction of the signal by the JAK/STAT pathway 
involves phosphorylation of STAT92E by Hop, we 
investigated whether SOCS36E can affect STAT92E phosphorylation. Unfortunately, 
STAT92E pTyr levels in Kc167 cells proved difficult to detect, as no signal was observed 
upon stimulation with pathway ligand in cells treated with control dsRNA (Fig.IV.13A). 
However, ablation of SOCS36E or Ptp61F produced a strong pTyr-STAT92E band that 
was detectable even in cells not stimulated with pathway ligand. Cells deprived of 
SOCS36E showed an increase in STAT92E phosphorylation upon pathway stimulation, 
while knockdown of Ptp61F caused constitutive phosphorylation of STAT92E. This 
indicates that SOCS36E and Ptp61F negatively regulate phosphorylation of pathway 
components.  
 In the converse experiment, I attempted to utilise SOCS36E constructs to 
investigate effects of individual domains of SOCS36E on STAT92E phosphorylation. I 
used S2R+ cells in this experiment as STAT92E pTyr levels appeared much higher in this 
cell-line, leaving head-room for potential suppression from SOCS36E constructs. I 
observed phosphorylation of STAT92E following stimulation with conditioned media, 
however the effect of SOCS36E was variable between experiments (Fig.IV.13B and C). 
The reason for the variability of this assay remains perplexing and no conclusions 
regarding effect of SOCS36E constructs on STAT92E phosphorylation could be drawn.  
 
IV.3. Discussion 
This study provides molecular characterization of the negative regulator of 
Drosophila JAK/STAT signalling pathway, SOCS36E. I showed that SOCS36E is 
involved in regulation of the receptor stability, most likely by formation of ubiquitin 
ligase complexes with Elongins B/C and Cullin 5. Indeed, all components of the ECS 
complex regulate stability of the receptor Domeless, and therefore are negative regulators 
of the ligand-activated JAK/STAT pathway. An intact SOCS36E SH2 domain is required 
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for this process, together with the SOCS box domain. Moreover, SOCS36E is able to 
negatively regulate ligand-induced as well as basal activity of the JAK/STAT pathway in 
a manner independent of SOCS box and Elongins B/C and Cullin 5. This suppression of 
pathway signalling is mediated by the unconserved and undefined N-terminal region of 
SOCS36E. Both, N- and C-termini of SOCS36E are required for suppression of Dome 
phosphorylation in response to ligand-mediated pathway stimulation, however the 
catalytic activity of Hop remains unaffected. The exact molecular mechanism by which 
the N-terminal of SOCS36E operates remains unresolved. Taken together, SOCS36E 
negatively regulates the Drosophila JAK/STAT pathway via two independent 
mechanisms. 
 
IV.3.1 SOCS36E with Elongins B/C and Cullin 5 affect Dome stability 
Mammalian SOCS proteins have been shown to affect internalization and 
endocytosis of cytokine receptors by more than one mechanism. SOCS1 has been shown 
to regulate INF-αR1 receptor stability by sequestration of associated JAK resulting in 
destabilization of the receptor (Piganis et al., 2011). Granulocyte-Colony Stimulating 
Factor Receptor is targeted for degradation via ubiquitination of key residue by Elongin-
Cullin-SOCS3 complex (Hörtner et al., 2002; Zhuang et al., 2005; Wölfler et al., 2009). 
Our data indicates that SOCS36E co-localizes with Dome in vivo (Fig.IV.3) and co-
precipitates in vitro (Fig.IV.10A), strongly suggesting a direct interaction. As changes in 
SOCS36E expression due to RNAi-mediated knockdown (Fig.IV.5) or protein over-
expression (Fig.IV.9) resulted in opposing change in receptor levels, it is plausible that 
SOCS36E targets Domeless for degradation. Numerous reports have indicated that SOCS 
molecules can form E3 ubiquitin ligase complexes in vertebrates, by associating with 
Elongins B/C and Cullin 5 (Babon et al., 2009; Linossi and Nicholson, 2012). Those 
complexes mediate ubiquitination of their substrates, often receptors. As I have observed 
Dome to be ubiquitinated (Fig.III.12), it is very likely that SOCS36E can form ubiquitin 
ligases similarly to its mammalian orthologues and mediate receptor ubiquitination. 
Indeed, I observe that knockdown of Elongins B/C and Cullin 5 resulted in stabilization 
of the receptor (Fig.IV.5). 
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Figure.IV.13 SOCS36E suppresses phosphorylation of STAT92E. (A-C) Cells were 
lysed with lysis buffer supplemented with phosphatase inhibitors and lysates were 
subjected to anti-STAT92E immunoprecipitation followed by SDS-PAGE and western 
blotting. (A) Kc167 cells were treated with indicated dsRNAs for 4 days, treated with mock 
or Upd2-GFP conditioned media for 10min and lysed. (B) Cells were transfected with 
FLAG-tagged SOCS36E constructs, stimulated with mock or Upd2-GFP conditioned 
media for 10min and lysed. (C) Cells treated as described in B, stimulated only with 
Upd2-GFP conditioned media.  
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Interestingly, I observed constitutive degradation of Dome (Fig.III.5) that 
correlated with its poly-ubiquitination (Fig.IV.12). While knockdown of Elongins B/C 
and Cullin 5 did not increase basal activity of the pathway (Fig.IV.4B), it increased the 
stability of the receptor under steady state conditions (Fig.IV.5). The lack of correlation 
between pathway activity and receptor stability can be explained by the fact that only 
ligand-bound receptor can signal. However, the observed increase in receptor levels 
following knockdown of ECS complex components was not as strong as in the case of 
Dor knockdown (Fig.IV.5A), nor knockdown of SOCS36E or Elongin B caused complete 
inhibition of degradation (Fig.IV.5B) as was the case following inhibition of lysosomal 
degradation using Bafilomycin (Fig.III.10). It is possible that ECS complex is involved in 
only partial ubiquitination of the receptor, therefore performing an accessory role in the 
process. In the light of previous reports on the negative regulatory role of endocytosis in 
regulation of the Drosophila JAK/STAT pathway (Devergne et al., 2007; Vidal et al., 
2010), this accessory role of ECS complex becomes essential for fine-tuning pathway 
output. This is particularly important especially following stimulation of the pathway 
with a ligand, which might be evidenced by the second, lower band in MultiDsk 
immunoprecipitation (Fig.III.12). This hypothesis would assume existence of another 
ubiquitin ligase responsible for poly-ubiquitination as well as redundancy. Alternatively, 
it is also possible that ubiquitination might not be required for Dome degradation, but 
rather for modulation of the process. 
 
IV.3.2 SOCS36E regulates JAK/STAT pathway activity via mechanism independent of 
ubiquitin ligase formation 
 Only SOCS1 and 3 have been reported to regulate the JAK/STAT pathway via 
multiple mechanisms, while the remainder of the proteins in the SOCS family depend 
predominantly on formation of the ECS ubiquitin ligase as their mechanism of function 
(reviewed in Croker et al., 2008; Yoshimura, 2009; Linossi et al., 2013). My data implies 
that SOCS36E can suppress the activated JAK/STAT pathway via mechanism 
independent of Elongins B/C and Cullin 5 (Fig.IV.6A and Fig.IV.8B and C). This is 
further supported by the fact that truncation of the SOCS box domain, which in 
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mammalian SOCS proteins is required for association with Elongins B/C and Cullin 5 
(Kamura et al., 1998; Zhang et al., 1999), does not render the construct inactive 
(Fig.IV.8B). Similar results have been reported in vivo, where SOCS box-truncated 
version of SOCS36E was still able to mildly suppress pathway signalling (Callus and 
Mathey-Prevot, 2002). This implies that the SOCS box domain of SOCS36E is required 
for effective suppression of the activated pathway signalling, however it is not the only 
mechanism utilised by SOCS36E.  
 Another line of evidence for secondary mechanism of function of SOCS36E 
comes from previous reports indicating ability of SOCS36E to suppress HopTuml 
signalling in vivo, resulting in decreased tumour index (Bina et al., 2010). This is 
particularly important considering HopTuml independence from Dome in the same assay 
(Nina Bausek and Samira Bina, personal communication), an indication supported by the 
result in Fig.IV.6C indicating additive effect of SOCS36E overexpression and Dome 
knockdown. 
The existence of a SOCS-box-independent mechanism is also supported by 
observations that SOCS36E but not Elongins B/C or Cullin 5 inhibits the basal activity of 
the pathway (Fig.IV.6B and Fig.IV.8A). Consistent with this, truncation of the SOCS box 
domain does not affect suppression of the basal activity of the pathway (Fig.IV.8A). This 
implies that this secondary mechanism is required for suppression of the basal activity of 
the pathway. Recognition of the importance of SOCS36E in regulation of pathway 
signalling in two different states of activation, basal and stimulated, is an important one, 
as SOCS36E was thus far believed to act only as part of a negative feedback loop (ie. 
suppressing activity only after stimulation). In this context, SOCS36E resembles SOCS4 
and 5 that are believed to be constitutively present in cells, while SOCS1-3 and CIS are 
induced upon pathway activation (reviewed in Linossi et al., 2013). However, SOCS36E 
is a strong transcriptional target of the pathway, suggesting a possibility that protein 
levels dictate the balance between two mechanisms of function. 
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IV.3.3 N-terminal of SOCS36E has a role in suppression of the JAK/STAT pathway 
signalling 
Lack of suppression of basal pathway activity (Fig.IV.8A) by construct missing 
the N-terminal domain, implies that this domain is important for SOCS36E function. 
Also in the absence of Elongins B/C and Cullin 5, SOCS36EΔN can not suppress the 
ligand-stimulated pathway (Fig.IV.8C), indicating again that the N-terminal domain is 
required for protein function. Despite numerous studies on mammalian SOCS molecules, 
only a handful of reports have indicated a role for the N-terminal in SOCS4 and 5. A 
report from Seki and colleagues (Seki et al., 2002), indicated N-terminal of SOCS5 to be 
sufficient for interaction with IL-4 receptor in a phosphotyrosine independent fashion. 
Moreover, SOCS5 has been reported to associate with EGFR in N-terminal dependent 
manner (Kario et al., 2005; Nicholson et al., 2005). Although the reported interactions 
between SOCS36E and EGFR signalling pathway was not investigated in this study, it is 
important to note that truncation of the N-terminal domain of SOCS36E also decreased 
interaction with Sevenless, Drosophila EGFR receptor (Almudi et al., 2010). I also 
observed that SOCS36EΔN construct did not co-immunoprecipitate with Dome 
(Fig.IV.10C), which might explain why high expression levels of this construct was 
required to destabilize Dome (Fig.IV.9). This implies that the N-terminal of SOCS36E 
plays a similar role to the N-terminal of SOCS3, which has been characterized to contain 
an N-extended SH2 domain (N-ESS) involved in orientation of interaction with 
phosphorylated tyrosine residue (Sasaki et al., 1999; Yasukawa et al., 1999; Babon et al., 
2006). Interestingly, a recent report from Feng and colleagues (Feng et al., 2011) 
indicated presence of a conserved motif in the N-termini of SOCS4 and 5 that has 
potential role in protein interaction. As SOCS36E is a homologue of mammalian SOCS4 
and 5, my results provide further evidence for the conserved functional role of the long 
N-termini in SOCS molecules.  
I also observed that, similarly to mammalian SOCS molecules, SOCS36E requires 
an intact SH2 domain to interact with its substrates. This conclusion is supported by 
evidence from co-immunoprecipitation with Dome (Fig.IV.10C) as well as functional 
assays (Fig.IV.8, 9 and 11). This is in line with reports of SOCS36E interaction with 
Sevenless being dependant on an intact SH2* domain and SOCS36E substrate tyrosine 
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phosphorylation (Almudi et al., 2010). As phosphorylated tyrosine residues are required 
for interaction with SH2 domain and given that SOCS36E co-immunoprecipitated with 
Dome and Hop irrespective of ligand-mediated stimulation of the pathway, it is plausible 
that Dome and Hop are constitutively phosphorylated on tyrosines that are not essential 
for signal transduction, or STAT92E binding in this case. However, I could not exclude 
the possibility that SOCS36E binds to the same phosphorylated tyrosine residues as 
STAT92E does, which would classify as competitive binding.  
 
IV.3.4 Regulation of phosphorylation of the JAK/STAT pathway components  
Only SOCS1 and 3 have been reported to interact directly with JAK kinases and 
obscure their catalytic activity by steric hindrance (Kershaw et al., 2013). While 
structurally SOCS36E is distinct to SOCS1 or 3, it is involved in regulation of Dome 
phosphorylation in response to pathway stimulation (Fig.IV.11) as well as inhibition of 
STAT92E phosphorylation (Fig.IV.13A). I have considered two possible mechanisms by 
which SOCS36E can regulate phosphorylation of pathway components. Firstly, it could 
affect catalytic activity of Hop. This possibility is less likely to be true, based on the lack 
of change in Hop phosphorylation levels in cells (Fig.IV.11) and in vitro kinase activity 
assays assessing Hop’s ability to auto-phosphorylate (Fig.IV.12). It should be noted 
however, that the stoichiometry of the in vitro reactions was unknown. Therefore, it is 
possible that insufficient amounts of SOCS36E constructs were present in the reaction 
mixture to effectively inhibit activity of Hop. Furthermore, Dome was not present in the 
reaction mixtures in the kinase assay. Considering my observation that SOCS36E 
preferentially binds to Dome, it is possible that Dome is required for SOCS36E to 
position itself in a way that allows for inhibition of Hop’s catalytic activity, similarly to 
SOCS3 (Kershaw et al., 2013). The second possibility regarding SOCS36E mechanism 
of function is that SOCS36E “masks” Tyrosine residues on substrates from the Hop 
kinase, thereby preventing phosphorylation. Investigation of this possibility would 
require crystallographic studies, which might be very interesting but also very 
challenging technically. The fact that SOCS36E suppresses phosphorylation of Dome and 
STAT92E might imply that the first possibility is more likely, however it cannot be 
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excluded that phosphorylation of STAT92E is a consequence of increased 
phosphorylation of Dome (Fig.IV.11). 
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Chapter V Analysis of the catalytic activity of Hopscotch and 
its gain-of-function mutants  
V.1. Introduction 
V.1.1 Mutations in JAK kinases often lead to pathologies 
The JAK/STAT signalling pathway plays a central role in numerous 
developmental processes as well as in the maintenance of homeostasis. Phosphorylation 
of pathway components, mediated by JAK kinases is essential for pathway activity. Not 
surprisingly, mutations affecting catalytic activity of JAKs are often pathological in 
nature. Interestingly, such mutations do not have to arise in the JH1 kinase domain, as 
other domains provide regulatory function, as described previously (Section I.2.5). 
Investigation of the pathological significance of those mutations at molecular level is 
challenging in mammals due to redundancies between receptors, JAKs, STATs and 
negative regulators. Moreover, pathogenicity of mutations in JAKs depends not only on 
the residue affected, but also on the tissue or cell population affected. This is particularly 
important in case of JAK3 mutations, as expression of JAK3 is strongly associated with 
the immune system (Ghoreschi et al., 2009).  
Drosophila does not possess adaptive immune system, therefore it is hard to 
justify using this organism to model effects of JAK mutations on the immune system, 
such as Y100C in JAK3. However, fruit fly is a suitable model organism to study tumour 
development. Two gain-of-function Hop alleles, HopTuml and HopT42, have been reported 
to produce black melanotic masses, phenotypes reminiscent of myeloproliferative 
neoplasias (Harrison et al., 1995; Luo et al., 1997).  
 
V.1.2 Hop as a model to study pathogenic JAK mutations 
Similarly to mammalian JAKs, Hop contains FERM domain located towards the 
N-terminal and JH1 and JH2 domains towards the carboxy terminal (Fig.V.1A). This  
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Figure.V.1 Homology between Hop and mammalian JAK kinases. (A) Schematic 
representation of the Drosophila Hop and mammalian JAK1-3 proteins. Individual 
domains are colour coded and labelled. Numbers at the right indicate amino acid length 
of proteins. Selected single point mutations that are associated with diseases are 
indicated for each protein. Names given to oncogenic Hop alleles are in bold font over 
the mutation indicators. (B) Sequence shared identity with Hop across indicated portions 
of proteins, generated with ClustalW2 sequence alignment analysis tool. Domain 
location and sizes were determined using ExPASy Prosite analysis tool. 
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structural similarity is not reflected in the amino acid sequence, with only 20% shared 
identity between Hop and JAK2, its closest human homologue (Fig.V.1B). Mammalian 
JAKs share much stronger amino acid conservation between them than with Hop. 
Interestingly, also pathogenic mutations seem to be localized to the similar sites in 
Hop. HopTuml mutation is a single amino acid substitution, G341E, located in the FERM 
domain similarly to Y100C mutation in JAK3 or R340Q in JAK2 (Cacalano et al., 1999). 
HopT42 is more reminiscent of a well studied JAK2 V617F pathogenic mutant, which is 
strongly associated with myoploriferative neoplasias. The HopT42 mutation is a single 
point mutation substituting glutamic acid at position 695 to lysine (E695K). Interestingly, 
despite affecting different domains of the kinase, both Tuml and T42 alleles cause the 
same phenotype of blood cell over proliferation leading to the formation of melanised 
tumours (Harrison et al., 1995; Luo et al., 1997). This phenotype was reproduced by 
tissue specific expression of mutated Hop proteins in the lymph gland, Drosophila 
equivalent of mammalian haematopoietic organ. Also strong over-expression of wild-
type Hop resulted in similar phenotype, leading to characterisation of both mutants as 
gain-of-function mutations causing increased pathway activity. However, 
hyperphosphorylation of the kinase and STAT92E has been reported for both T42 and 
Tuml mutants, but not upon over-expression of wild-type Hop (Harrison et al., 1995). 
Similar observations regarding hyperphosphorylation of pathway components were 
reported for mammalian JAK gain-of-function mutants. Studies on how two mutations in 
distant domains of Hop can result in a similar phenotype offers a unique opportunity to 
gain insight into structure-function relationship of Hop and molecular aetiology of its 
mutants. 
 
V.2. Results 
V.2.1 HopT42 and HopTuml activate JAK/STAT pathway more potently than wild-type 
Hop 
Both, HopTuml and HopT42 have been previously shown to elevate transcriptional 
pathway activity in vivo and in vitro, and HopTuml has been used as a dominant genetic 
background in which to conduct genetic screens and screen validation  
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Figure.V.2 Increased activity of GOF Hop mutants is not correlated by their 
autophosphorylation or STAT92E phosphorylation. (A) Transcriptional activity of the 
pathway in Kc167 cells transfected with indicated HA-tagged constructs and treated with 
mock or Upd2-GFP conditioned media for 4 days was measured by luminescence 
assay. Results were normalized to mock treated Empty vector transfected cells. Stars 
above columns indicate statistical significance compared to Empty vector cells within 
mock or Upd2-GFP treated group, determined by two-way ANOVA followed by 
Bonferroni’s multiple comparisons test. Statistical significance between mock and Upd2-
GFP treated cells transfected with one ligand was determined by Student’s t-test. ***, 
p<0.005; **, p<0.01; **, p<0.05. Error bars represent SEM. (B) Kc167 cells transfected 
with indicated Hop constructs were treated with mock or Upd2-GFP conditioned media 
for 10min and lysed. Lysates were used for SDS-PAGE followed by western blot 
analysis. (C) Kc167 cells transfected with indicated HA-tagged Hop constructs were 
treated with mock or Upd2-GFP conditioned media for 10min prior to lysis with lysis 
buffer supplemented with phosphatase inhibitors. Lysates were subjected to HA (top two 
panels) or STAT92E (bottom two panels) immunoprecipitation followed by SDS-PAGE 
and western blot analysis.  
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(Harrison et al., 1995; Luo et al., 1997; Müller et al., 2005; Kallio et al., 2010). As a first 
step to study Hop in a cell based system, and to validate that HA-tagged Hop mutant 
constructs work in my assays, I assessed transcriptional pathway activity in cells 
transfected with these constructs. Additionally, I attempted to generate a kinase dead 
version of Hop by mutating a conserved lysine residue, K926 in the JH1 domain to 
glutamine. This missense change was selected based on sequence homology with JAK2 
and was predicted to be essential for ATP binding by sequence analysis software 
(ExPASy Prosite). This mutant was abbreviated as HopJH1 and used alongside the GOF 
mutants in these experiments, intended as negative control. Expression of exogenous 
wild-type Hop resulted in increased basal and stimulated activity of the pathway, 
however the increase was not as dramatic as in the case of GOF mutants (Fig.V.2A). No 
statistical significance was observed between mock and ligand stimulated conditions in 
cells transfected with Hop constructs, however data indicated a trend in this direction. 
The HopTuml and HopT42 mutations were equally potent in increasing pathway activity. 
Increases compared to endogenous were over three-fold following stimulation with 
pathway ligand and over fifteen-fold under steady state conditions. Surprisingly, the 
HopJH1 mutant also caused an increase in pathway activity to a similar degree as the wild-
type Hop, suggesting that the lysine mutated was most likely not essential for catalytic 
activity. To exclude the possibility of transcriptional differences arising from differences 
in kinase dosage, protein levels of transfected constructs were assessed. (Fig.V.2B). 
Phosphorylation of STATs is commonly used as an indication of pathway activity 
in mammalian system. Previous reports indicated STAT92E to be hyperphosphorylated 
in cells transfected with GOF Hop mutants (Luo et al., 1997). I therefore investigated 
tyrosine phosphorylation of Hop mutants and endogenous STAT92E by 
immunoprecipitation and subsequent western blotting with pY specific antibody. While 
phosphorylation of Hop and its mutants increased in response to stimulation with 
pathway ligand (Fig.V.2C), no clear difference between the various Hop constructs was 
observed. In addition, STAT92E was phosphorylated only in response to pathway 
stimulation, even upon expression of GOF Hop mutants. Interestingly, STAT92E  
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Figure.V.3 Hop and its mutants localize to the cytoplasm. Confocal microscopy images 
of cells transfected with indicated HA-tagged Hop constructs. White arrows point to not 
transfected cells, acting as controls. Left panel: HA staining in greyscale, middle panel: 
composition of DAPI and Ha staining, right: DIC (in grey) with DAPI and HA staining.  
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phosphorlation levels in cells transfected with HopTuml construct appeared to be slightly 
lower. These results indicate that GOF Hop mutants hyperactivate the JAK/STAT 
pathway without hyperphosphorylating STAT92E or themselves.  
The lack of increased phosphorylation levels of STAT92E in cells transfected 
with Hop GOF mutants might be indicative of a non-canonical signalling exerted by 
those mutants, including potential cross-talk with other signalling pathways or 
modulation of epigenetic landscape, among others  (Fig.V.2C). This is particularly 
relevant in case of HopTuml mutant, which exhibited even lower levels of STAT92E 
phosphorylation. Activation of another signalling pathway is only one of the means by 
which GOF kinase mutants have been reported to exert oncogenic effects (Busch et al., 
2009). However, alternative signalling pathways were not analysed in this study. Another 
possibility is nuclear translocation and alteration of epigenetic landscape, as reported in 
case of JAK2 V617F mutant (Dawson et al., 2009). To account for this possibility, I 
inspected subcellular localization of Hop constructs. All of the constructs were evenly 
distributed across the cytoplasm (Fig.V.3). Enrichment at the plasma membrane reported 
for mammalian JAK proteins was not observed with Hop constructs, potentially due to 
expression of exogenous protein (Haan et al., 2006). No clear nuclear localization was 
observed (Fig.V.3), however this method might not be sensitive enough to detect small 
amounts of proteins and cell fractionation might be required. It should be kept in mind 
that nuclear translocation of JAK2 V617F has been both proposed and questioned 
(Dawson et al., 2009; Girodon et al., 2011).  
 
V.2.2 Hop GOF mutants bind to Dome, however they do not depend on it 
Signalling by JAK2 V617F has been shown to depend on cytokine receptor presence, but 
not on ligand binding (Lu et al., 2008). To investigate whether Hop GOF mutants require 
Dome for activity, I measured pathway transcriptional activity in cells transfected with 
Hop mutant constructs and treated with control or Dome RNAi (Fig.V.4A and B). Under 
steady state conditions knockdown of Dome caused decrease in basal pathway activity in 
control cells, indicating that Dome is required for this low level basal activity (Fig.V.4A) 
Alternatively, basal activity might represent activation of the pathway by small amounts 
of pathway ligand that are secreted by Kc167 cells (Wright et al., 2011). No statistically 
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significant difference in transcriptional activity was observed upon Dome knockdown in 
cells transfected with Hop constructs, with exception of HopJH1 transfected cells, 
suggesting that this mutant may have a higher dependence on the receptor than wild-type 
Hop. By contrast, measurement of the ligand-stimulated pathway activity revealed that 
knockdown of Dome decreased firefly luciferase (Fig.V.4B). This can be potentially 
attributed to the endogenous pathway being down-regulated, as is the case in cells 
transfected with the Empty vector.  However, knockdown of Dome in cells expressing 
GOF Hop mutant constructs resulted in 6x2xDrafLuc reporter accumulation to the same 
levels as in the Empty vector cells treated with control dsRNA. This implies that Dome is 
required but not necessary for GOF Hop mutants to activate the pathway. 
In order to confirm the efficiency of Dome knockdown at the protein level, I 
assessed the phosphorylation level of wild-type Hop in RNAi background. I observed 
that cells deprived of Dome had decreased phosphorylation levels of Hop under steady 
state conditions and very mild increase was observed following stimulation with pathway 
ligand, most likely due to incomplete Dome knockdown (Fig.V.4C). Positive and 
negative control knockdowns produced interesting pattern of Hop phosphorylation, as 
knockdown of Ptp61F resulted in only a mild increase in Hop phosphorylation in 
response to pathway stimulation when compared to control cells. This increase was 
expected to be higher considering previous reports regarding the role of Ptp61F as a 
negative regulator of the Drosophila JAK/STAT pathway (Baeg et al., 2005; Müller et 
al., 2005).  Knockdown of STAT92E, which was expected not to produce any change in 
Hop pTyr levels, resulted in elevated Hop phosphorylation independent of ligand 
(Fig.V.4C). While not investigated any further, it is possible that this is an indirect effect 
due to changes in the transcription of negatively acting pathway regulators such as 
SOCS36E (Callus and Mathey-Prevot, 2002, reviewed in Arbouzova and Zeidler, 2006). 
Finally, I investigated the interaction of Hop GOF mutants with Dome by pulling 
down Dome. Dome interaction with HopWT and HopTuml appeared to be stronger 
compared to HopT42 (Fig.V.4D). Dome P925I mutant, previously described to have 
impaired interaction with Hop (Fig.III.4), was used as a negative control. None of the 
Hop constructs used interacted with Dome P925I at a detectable level, indicating that 
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Figure.V.4 Hop GOF mutants display lower dependency on receptor presence. (A, B) 
Transcriptional pathway activity in Kc167 cells transfected with indicated HA-tagged Hop 
constructs and treated with Control of Dome dsRNAs, as indicated, for 4 days was 
measured by 6x2xDraf luminescence assay. Alongside the dsRNA treatment, cells were  
treated with mock (A) or Upd2-GFP conditioned media (B). Statistically significant 
difference is indicated by stars above the bars, as determined by Student’s t-test with 
***, p<0.005; **, p<0.01; *, p<0.05. Results were normalized to Empty vector transfected 
cells treated with control dsRNA. Error bars represent SEM. (C) S2R+ cells batch-
transfected with Hop-HA were treated with indicated dsRNAs for 4 days and stimulated 
with mock or Upd2-GFP conditioned media for 10min prior to lysis with lysis buffer 
supplemented with phosphatase inhibitors. Lysates were used for HA 
immunoprecipitation and analysed with SDS-PAGE followed by western blot. (D) Cells 
co-transfected with Dome-FLAG or Dome P925I-FLAG and indicated HA-tagged Hop 
constructs were treated with mock or Upd2-GFP conditioned media for 10min and lysed. 
Lysates were subjected to immunoprecipitation with anti-FLAG antibody and analysed 
with SDS-PAGE and western blot. 
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each Hop mutant uses the same interaction site. These results indicate that GOF 
mutations in Hop do not stabilize interaction with Dome, while T42 mutation might 
mildly destabilize this interaction. 
 
V.2.3 Hop GOF mutants do not have increased autophosphorylation kinetics 
One of the potential mechanisms by which GOF JAKs hyperactivate the pathway 
is increased efficiency of the catalytic activity, in which more STAT proteins are 
phosphorylated prior to the termination of signalling. To investigate whether this is the 
case with Hop GOF mutants, I developed and conducted in vitro kinase activity assays. 
Due to lack of available substrates, I used Hop autophosphorylation as an indicator of 
catalytic activity (Saharinen et al., 2000). The most striking observation was much lower 
incorporation of 32P by HopJH1 than the remainder of Hop constructs used at 10 and 
30min of reaction (Fig.V.5A). I conducted a time course activity assay over one hour 
period and best fit curves were determined to characterise reaction kinetics (Fig.V.5B-D). 
As expected, HopJH1 mutant kinetics proved to be slower compared to the rest of the 
constructs. The plateau, representing saturation of phosphorylation sites in the population 
of kinases, was not achieved in the duration of the assay as all curves were still climbing 
(Fig.V.5C). For this reason it is impossible to determine whether any of the Hop mutants 
might plateau at a higher level and therefore reveal the possible existence of additional 
phosphorylation sites. The initial kinetics of HopWT, HopTuml and HopT42 were very 
similar to each other. This implies that Hop GOF mutants’ catalytic activities are not 
altered compared to the wild-type Hop, while mutation in the JH1 domain resulted in 
decreased autophosphorylation dynamics. 
 
V.3. Discussion 
In this study I have investigated the differences between wild-type Hop and its 
GOF mutants, HopTuml and HopT42, using ex vivo and in vitro approaches. I introduced a 
single point mutation in the JH1 domain that affected the kinetics of the kinase, but did 
not render it dormant as expected. With exception of lowered kinetics indicated by in 
vitro kinase activity assay, the HopJH1 mutant behaved very similarly to the wild-type  
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Figure.V.5 Autophosphorylation kinetics of Hop GOF mutants are similar. (A-G) 
Indicated HA-tagged Hop constructs were transfected into S2R+ cells and extracted by 
immunoprecipitation, left on beads and subjected to in vitro  kinase activity assay, as 
described in materials and methods for indicated periods of time. (A) Representative 
image of the kinase activity assay, arrow points towards radioactive Hop construct band 
(top band). Bottom band is likely to be unspecific. (B-G) Quantification of 
autophosphorylation kinetics of indicated constructs, with raw quantification (B) and best 
fit curve, according to equation: Y=TOP*[1-exp(K*X)] (C). Constructs are colour coded 
for convenience. (D-G) Raw data and best fit curve of individual constructs. Error bars 
indicate SEM. 
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Hop. Transcriptional hyperactivation of the pathway observed upon expression of two 
GOF Hop mutants was not correlated by phosphorylation of JAKs themselves or 
STAT92E, the only STAT protein in Drosophila. Also the autophosphorylation kinetics 
were not affected by both mutations. Despite both mutants interacting with Dome 
similarly to wild-type Hop, they did not require the receptor to induce pathway activity. 
Taken together, these results indicate GOF mutations in Hop act to hyperactivate the 
pathway via a mechanism that appears to be independent of Dome but which does not 
change the catalytic kinetics of the kinase or increase STAT92E tyrosine 
phosphorylation.  
 
V.3.1 Increased transcriptional pathway activity is not correlated by phosphorylation of 
pathway components  
Gain-of-function mutations in kinases often result in hyperactivation of the 
pathway, a description used to characterise either constitutively active pathway or 
pathway that is overly sensitive to ligand stimulation, leading to numerous malignancies 
(reviewed in Vainchenker and Constantinescu, 2013). Using transcriptional reporter of 
pathway activity I confirmed that activity of STAT92E is elevated in cells transfected 
with Hop GOF mutants (Fig.V.2A). This effect was particularly prominent under steady 
state conditions, with firefly luciferase reporter activity 15-fold higher than empty vector 
transfected cells. It is important to note that expression of wild-type protein produced an 
increase in pathway activity, especially noticeable under steady state conditions. While 
this effect appeared to be statistically insignificant, the trend is relatively clear. This 
implies that at high levels exogenous HopWT can hyperactivate the pathway, a finding 
consistent with previous reports (Luo et al., 1997). One of the mechanisms by which 
GOF Hop constructs can increase transcription of artificial reporter of pathway activity is 
by phosphorylating STAT92E in a manner different than wild-type kinase would, by 
hyper- or differential phosphorylation of additional residues. I did not observe the 
tyrosine hyperphosphorylation of STAT92E by GOF Hop constructs that was reported 
previously (Fig.V.2.B) (Luo et al., 1997). Discrepancies in results might be caused by use 
of different cell lines, expression levels of constructs, technical differences or any 
combination of those reasons. The same reasons might apply to discrepancies in observed 
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phosphorylation levels of Hop and its mutants. Previous reports indicated HopTuml and 
HopT42 to be hyperphosphorylated compared to HopWT, which is not observed in my 
hands (Harrison et al., 1995; Luo et al., 1997).   
In either case, investigation of tyrosine phosphorylation of STAT92E might be 
insufficient and misleading, as serine phosphorylation of mammalian STATs has been 
reported to play a role in transcriptional regulation (Schuringa et al., 2000; Friedbichler et 
al., 2010, 2011; Steen et al., 2013, reviewed in Decker and Kovarik, 2000; Schindler et 
al., 2007). While JAKs are considered to phosphorylate their substrates only on tyrosine 
residues, the JH2 domain of JAK2 has been shown to be a dual specificity kinase domain 
(Ungureanu et al., 2011), suggesting that serine/threonine residues within STAT92E 
might be phosphorylated by Hop. Alternatively, such phosphorylation might be an 
indirect effect elicited by cross-activation of PI3K/Akt/mTor pathway by hyperactive 
JAKs (Levine and Wernig, 2006; Busch et al., 2009).  
 
V.3.2 Interplay between Hop GOF mutants and pathway receptor                 
Investigation of Hop requirements for its receptor revealed that under steady state 
conditions transcriptional pathway activity is not affected by Dome knockdown in a 
background that expresses exogenous Hop (Fig.V.4A). On the other hand, pathway 
activity following ligand-mediated pathway stimulation was decreased by Dome RNAi in 
control cells and in cells transfected with wild type Hop constructs (Fig.V.4B). This 
decline in activity cannot be attributed only to the inability of the endogenous pathway to 
transduce signal, as no difference between steady state and stimulated conditions was 
observed in the absence of dsRNAs in cells expressing GOF Hop mutants (Fig.V.2A). 
However, GOF Hop mutants still elicited elevated levels of pathway activity in the 
absence of Dome. This implies that Dome facilitates HopTuml and HopT42 signalling but is 
not necessary for the process. This result is consistent with in vivo tumour formation 
assay which find that melanotic spot size and number are independent of Dome 
knockdown (Nina Bausek, unpublished data). Direct interaction of Hop with Dome was 
comparable between different Hop constructs, reinforcing the idea that GOF mutations do 
not affect interaction with the receptor. Another possibility worth considering is that in 
the absence of Dome another receptor can potentially interact with Hop. Latran has been 
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shown to function as an inactive receptor for the JAK/STAT pathway in Drosophila that 
can bind Hop (Kallio et al., 2010). Even though Latran has not been shown to interact 
with STAT92E, it is possible that Latran can substitute for Dome as Hop or Hop mutants’ 
binding partner.  
 
V.3.3 JH1 domain and kinetics of autophosphorylation 
When assayed in vitro, JAK2 has a relatively poor catalytic activity compared to 
other members of the mammalian JAK family (Saharinen and Silvennoinen, 2002). Given 
that JAK2 represents the closest Hop homologue, it may not be surprising that Hop also 
displays a relatively low kinetics of catalytic activity. Never the less, the comparison of 
kinetics of auto-phosphorylation of wild-type Hop with its GOF mutants did not reveal 
any significant differences between the constructs (Fig.V.5). However, the HopJH1 mutant 
autophosphorylated itself at a slower rate compared to the other three constructs. This is 
particularly interesting, considering that the construct did not demonstrate decreased 
activity in the functional assays compared to wild-type Hop construct (Fig.V.2). The only 
exception was a decrease in basal pathway activity upon Dome knock down, that was not 
observed with other constructs. This suggests that HopJH1 construct might be more 
dependant on interaction with the receptor, a factor that was not present in the in vitro 
kinase activity assay. It should be noted that the JH2 domain of of HopJH1 construct 
remained intact. A possibility that JH2 domain play another role besides 
autophosphorylation, should be also considered. 
The fact that mutations in the FERM or JH2 domains of Hop did not increase 
activity of Hop is baffling, as similar oncogenic mutations in mammalian JAKs have 
been reported to increase activity of JH1 domain (Yeh et al., 2000; Zhao et al., 2010; 
Ungureanu et al., 2011). Considering homology between mammalian JAKs and Hop, it is 
probable that G341E and E695K mutations introduced structural alterations in the protein 
that did not have any steric but rather allosteric effects. This might relate to structural 
mimicry of activated state, enhanced trans-phosphorylation kinetics or the facilitation of 
interactions with substrates. At the same time, it should be considered that 
autophosphorylation of kinases, especially in the absence of the receptor, might not be the 
most appropriate measurement of kinase activity. While autophosphorylation has been 
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widely reported as a regulatory step, phosphorylation of STATs has direct physiological 
relevance (Saharinen and Silvennoinen, 2002; Mazurkiewicz-Munoz et al., 2006; Yan et 
al., 2012). Studies on JAK2 indicated that V617F mutation does not increase kinetics of 
reaction but rather increases affinity for the substrates (Zhao et al., 2010). While these 
results provide an insight into the molecular mechanisms, more detailed studies will be 
required to dissect the differences and similarities between Hop GOF mutants in vivo. 
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Chapter VI Conclusions and proposed directions  
VI.1. Introduction 
The JAK/STAT signalling pathway plays essential roles in numerous biological 
processes that are vital for correct development and the maintenance of homeostasis. 
Misregulation of the pathway can have serious consequences for the organism, resulting 
in developmental defects as well as diseases, including solid and haematological 
malignancies (O'Sullivan et al., 2007). In Drosophila the JAK/STAT pathway is fully 
conserved with lower redundancy between pathway components and regulators 
(Arbouzova and Zeidler, 2006). Hyperactivation of the pathway results in blood cell 
proliferation defects phenotypically reminiscent of human leukaemia (Crozatier and 
Meister, 2007). This makes Drosophila a suitable model organism to investigate 
molecular aspects of the JAK/STAT pathway activity. 
 
VI.2. Domeless 
VI.2.1 Evolutionary conservation of the JAK/STAT pathway  
Domeless is the only functional JAK/STAT pathway receptor in Drosophila. It 
has been described as similar to mammalian type I cytokine receptors based on its 
structural conservation (Brown et al., 2001; Chen et al., 2002). The Drosophila 
JAK/STAT pathway is strongly implicated in the immune response to wasp 
parasitisation, a process dependent on Dome and regulated on the level of the receptor 
(Crozatier and Meister, 2007; Makki et al., 2010). Formation of lamellocytes represents a 
link between immunity and haematopoiesis in Drosophila, that has parallels to the 
mammalian system (O'Shea et al., 2002). In this context, functional similarities between 
Dome and mammalian type I cytokine receptors are evident. 
Missing structures such as identifiable Box domains in the cytoplasmic domain 
and Immunoglobulin-like domain in the extracellular portion of the receptor as well as 
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only a semi-conserved WSxWS motif in the CBM set Domeless apart from type I 
cytokine receptor family. However, I have shown that Dome interacts with Hop via a 
motif found in type II cytokine receptors, represented mainly by interferon receptors that 
are essential for the immune system and the functional evidence presented here and in 
previous reports suggests that these missing domains are not in fact essential for cytokine 
receptor function.  
In addition, Clathrin-mediated endocytosis of mammalian cytokine receptors is 
predominantly initiated by ligand binding, leading to receptor degradation. Here I have 
shown that Domeless undergoes constitutive degradation irrespective of stimulation with 
exogenous ligand or activation of the downstream pathway components, although a 
similar observation has been made for the Leptin receptor in mammalian cells (Belouzard 
et al., 2004). Interestingly, the human Leptin polypeptide was shown to be sufficient to 
activate Drosophila JAK/STAT pathway via interaction with Dome, indicating a 
functional conservation of the CBM (Rajan and Perrimon, 2012). In the same report, 
strong parallels between Drosophila Upd2 and human Lleptin were suggested at a 
functional level, indicating both molecules are involved in regulation of organismal 
energy balance.  
From an evolutionary perspective, it is striking that in mammalian system JAKs 
and STATs mediate signalling from numerous cell-surface receptors, regulating many 
biological processes, as outlined above. Conversely, multiple similar processes are 
regulated in Drosophila by a single receptor. This suggests that Dome represents an 
ancestor protein that likely gave rise to type I and II cytokine receptors, adipokine 
receptor (Ob-R), erythropoietin-like receptors and growth hormone receptor.  
 
VI.2.2 Dome as a model receptor for regulation of signalling output by endocytosis 
Negative regulatory functions of endocytosis on the JAK/STAT pathway has been 
described previously, however, the conclusions were made in regard to quantitative 
signalling, rather than qualitative differences (Howe and Mobley, 2004; Vidal et al., 
2010; Platta and Stenmark, 2011). Given the presence of a single receptor that undergoes 
constitutive degradation, the Drosophila JAK/STAT pathway represents an attractive 
 140 
model to study the regulation of the JAK/STAT pathway by endocytosis. Such a 
suggestion is supported by numerous factors. Firstly, the lack of redundancy among 
cytokine receptors and receptor complex composition simplifies the pathway. Secondly, 
the receptor undergoes constitutive degradation, even in the absence of pathway 
stimulation. However, my data indicates that subtle differences in internalization and 
degradation kinetics exist when comparing steady state and ligand-stimulated conditions. 
Moreover, the ubiquitination pattern of the receptor changes in response to ligand 
stimulation, suggesting a potential molecular basis for the aforementioned differences in 
kinetics, while Hop binding seems not to play a role in Dome endocytosis – a 
characteristic which would allow for studies on the receptor itself, rather than 
investigation of the whole receptor complex. Despite the failure to identify internalization 
motifs present in Dome, my data indicates that the process of receptor internalization in 
Drosophila is reminiscent of the mammalian system. It would be interesting to identify 
the AP-2 interaction motifs in Dome. Finally, commonly accepted advantages of using 
Drosophila as a model organism for in vivo studies are applicable.  
 
VI.3. Hopscotch 
VI.3.1 Activity of GOF Hop mutants  
Malignancies arising due to mutations in the JAK/STAT pathway are mostly 
associated with the kinase itself, with JAK2 V617F being the best characterised mutation. 
Localised within the JH2 domain, the V617F substitution affects the inhibitory role of the 
JH2 domain on JH1 domain (Vainchenker and Constantinescu, 2013) and causes an 
increase in the affinity of JAK2 for STATs (Zhao et al., 2010). Interestingly, the report 
from Zhou and colleagues also indicated an important role for the JAK2 FERM domain 
in the regulation of kinase activity. Only few mutations in FERM domains have been 
reported to be oncogenic, however the molecular mechanisms involved remain unknown 
(reviewed in Vainchenker and Constantinescu, 2013). 
Homologous to JAK2, Drosophila Hop shares the same domains as the 
mammalian JAKs, with the exception of dysfunctional SH2-like domain present in JAK1 
and 2. Two independent gain-of-function dominant mutations, hopTuml and hopT42, 
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localised to the FERM and JH2 domains respectively, result in a phenotype that has been 
described as being reminiscent of human leukaemia (Harrison et al., 1995; Luo et al., 
1997). Due to the structural differences in the JH2 domain of Hop and mammalian JAKs, 
hopT42 hyperactivates Hop via mechanism that is likely to be different on the structural 
basis than that observed in JAK2 V617F when considering the reports on π-stacking 
phenomenon caused by V617F mutation (Dusa et al., 2010; Gnanasambandan et al., 
2010). Despite the structural differences, the functional outcome might be the same, as 
my data indicates that neither the hopT42 nor hopTuml mutation causes an increase in the 
catalytic activity of the Hop JH1 domain (measured by autophosphorylation) or an 
increase in STAT92E phosphorylation. While this data contradicts previous reports, I did 
observe an increase in transcriptional activity of the pathway. This indicates that 
melanotic tumours observed in flies carrying these mutations arise due to non-STAT 
mediated activity, including non-canonical signalling. Such mechanisms have already 
been reported for JAK2 V617F mutation, which is implicated in alteration of the 
epigenetic landscape as well as activation of other signalling pathways (Dawson et al., 
2009; Vainchenker and Constantinescu, 2013). 
 
VI.3.2 Proposed direction of research on Hop GOF mutations 
One of the major issues encountered during my investigation of HopTuml and 
HopT42 using cell culture approaches was caused by transfection of the exogenous kinase. 
Introduction of additional Hop kinase caused an increase in pathway activity even in the 
case of the wild-type Hop. While this increase was not as dramatic as in the case of GOF 
mutants, detailed analysis of the functions of Hop derived from such an approach may 
therefore be skewed. Therefore, flies carrying the mutations should be used to investigate 
molecular mechanisms of Hop hyperactivation. An alternative to in vivo approach is 
establishment of primary cell lines using cells extracted from HopTuml and HopT42 flies, 
which would allow analysis to be undertaken on proteins expressed at normal 
endogenous levels – although this might be technically challenging. Both approaches, cell 
culture and in vivo, have some advantages and disadvantages, however they might prove 
complementary to each other. As fly lines are readily available, I will briefly outline 
proposed experiments below. 
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The data presented in this thesis did not identify any changes in STAT92E 
tyrosine phosphorylation levels following expression of Hop GOF mutants. This should 
be validated using biochemical techniques in vivo. While technically challenging, 
immunoprecipitation of endogenous STAT92E from tissue expressing Hop or its GOF 
mutants at endogenous levels could prove a powerful tool. Cells residing in the 
Drosophila haemolymph would be a prime tissue for such investigation, however other 
tissues/organs might be suitable for the purpose. This approach is especially relevant 
considering the tissue specific drivers that would allow for exogenous expression or 
RNAi-mediated ablation of pathway regulators. The same biochemical techniques could 
be employed to study other pathways that might be affected by hyperactive kinases, such 
as Akt and Erk pathways reported to be activated by JAK2 V617F, as well as proteins 
implicated in epigenetic regulation. For example, Histone 3 has been reported to be 
phosphorylated by nuclear localised JAK2 V617F. Complementary to protein based 
assays, qPCR of pathway target genes can also be used to determine the activity of the 
pathways investigated. As another example, numerous cancers have been associated with 
silencing of SOCS proteins, it would be interesting to investigate whether expression of 
the pathway target SOCS36E is changed in flies carrying Hop GOF mutations.  
A particularly appealing method to study differences between HopWT, HopT42 and 
HopTuml at the protein level, is high resolution mass spectrometry (Mann et al., 2013). 
Alternative and cheaper approach is a 2D differential in-gel electrophoresis, which, when 
undertaken at sufficient resolution, can identify differences in protein expression level as 
well as protein modifications. Such high throughput methods can provide a complete 
overview of processes affected by oncogenic mutations arising in Hop, which can then be 
followed-up by hypothesis-driven studies. 
 
VI.4. SOCS36E 
The SOCS family of proteins have received a lot of attention due to their roles as 
tumour suppressors (Elliott et al., 2008). In particular, SOCS1 and 3 have been a focus of 
numerous studies because of the unique kinase inhibitory region in their N-terminals 
(Linossi et al., 2013). By contrast, relatively little is known about the long N-terminal 
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domain group of SOCS proteins, namely SOCS4-7. Only a few reports have been 
published which indicate the importance of the N-terminal domain of these molecules for 
protein interactions (Croker et al., 2008). Only recently, computational modelling 
determined the presence of an unstructured motif in the N-terminals of SOCS4 and 5 that 
might mediate protein-proteins interaction (Feng et al., 2011). My results indicate that the 
N-terminal domain of Drosophila SOCS36, a homologue of SOCS4 and 5, is also 
required for the interaction with Dome. Moreover, I have shown that the N-terminal 
domain of SOCS36E also plays a role in the suppression of pathway activity under steady 
state conditions as well as following pathway stimulation. This function is mediated by 
inhibition of Domeless phosphorylation, possibly via the obstruction of kinase function. 
However, autophosphorylation of the kinase was unaffected, therefore it seems unlikely 
that the N-terminal domain of SOCS36E is functioning in a fashion similar to the KIR 
present within SOCS1 and 3. This finding opens new avenues of research into the 
mechanisms of function for long N-terminal domain SOCS proteins. 
I have also investigated the ability of SOCS36E to regulate Dome stability in a 
SOCS box-dependent manner. This is in line with reports indicating that all SOCS 
proteins are able to form ubiquitin ligases (Babon et al., 2009). However, SOCS proteins 
are believed to function in a negative feedback loop, being transcriptional targets of the 
JAK/STAT pathway.  Based on my data, a contrary model is suggested, where SOCS36E 
is constantly present in the cell, suppressing the basal activity of the pathway via its N-
terminal and regulating stability of the receptor. I have shown that Dome is ubiquitinated, 
however it remains to be seen whether SOCS36E is responsible for this modification and 
whether ubiquitination triggers Dome endocytosis. An alternative model should be 
considered, where SOCS36E destabilizes Dome indirectly, by affecting another protein. 
Finally, the fact that flies homozygous for null mutations in the SOC36E locus are 
viable and display only minor defects related to the JAK/STAT pathway is interesting 
(Bellen et al., 2004; Almudi et al., 2009). Firstly, it suggests that degradation of Dome 
can occur in the absence of SOCS36E. Secondly, it indicates that regulators of other 
processes can compensate for the loss of SOCS36E. To provide an example, Ptp61F can 
potentially suppress phosphorylation of Dome under steady state conditions in the 
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absence of SOCS36E. It would be interesting to explore what compensatory mechanisms 
are activated in SOCS36E-null flies. 
 
VI.5. Summary 
In this thesis I describe work characterising molecular mechanisms that regulate the 
Drosophila JAK/STAT pathway. I showed that Domeless interacts with Hop via a motif 
found in interferon receptors and that it undergoes constitutive degradation independent 
of ligand or kinase. However, its stability is regulated by the SOCS-box domain of 
SOCS36E, which is also implicated in regulation of Dome phosphorylation via the N-
terminal domain. This function is novel for the long N-terminal SOCS molecules, which 
have not been investigated in detail in this context. Moreover, I investigated the 
mechanisms by which Hop gain-of-function mutants promote oncogenesis. My results 
indicate that the core  JAK/STAT pathway components are not affected by these mutants, 
contradicting previous reports, however the pathway is hyperactivated. I suggest that an 
alternative approach based on in vivo studies may be worth pursuing. Taken together, this 
work provides good basis for further, more in-depth studies. 
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